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ABSTRACT 
ENGINEERING NANOMATERIALS FOR IMAGING AND THERAPY OF 
BACTERIA AND BIOFILM-ASSOCIATED INFECTIONS 
SEPTEMBER 2019 
AKASH GUPTA 
B.S., IIT (ISM) DHANBAD 
INTEGRATED M.SC., IIT (ISM) DHANBAD 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Vincent M. Rotello 
Infections caused by multidrug-resistant (MDR) bacteria pose a serious global burden of 
mortality, causing thousands of deaths each year. The “superbug” risk is further exacerbated by 
chronic infections generated from antibiotic-resistant biofilms that are highly resistant to 
available treatments. Synthetic macromolecules such as polymers and nanoparticles have 
emerged as promising antimicrobials. Moreover, ability to modulate nanomaterial interaction 
with bacterial cellular systems plays a pivotal role in improving the efficacy of the strategy.  
In the initial studies on engineering nanoparticle surface chemistry, I investigated the role 
played by surface ligands in determining the antimicrobial activity of the nanoparticles. In further 
study, I determined that surface monolayer of hydrophobic ligands facilitated the nanoparticles to 
block bacterial efflux pumps, yielding reduction in antibiotic dosage to treat pathogenic bacteria 
including methicillin-resistant S. aureus (MRSA). Moreover, functionalization of nanoparticle 
surface with pH-responsive ligand was used to develop a general strategy to target and image 
bacterial biofilms for a broad-range of species. In a subsequent study, I have utilized a unique 
approach of integrating synthetic nanomaterials on the surface of natural super carrier-Red Blood 
Cells for selective delivery of nanoparticles to the site of bacterial infection for antimicrobial 
therapy. This strategy shows potential to combat bacterial infections without harming the ecology 
viii 
 
of human microbiome, as well as circumvent the issues associated with non-specific uptake of 
nanoparticles by the reticuloendothelial system.   
In another study, systematic investigation of antimicrobial activity of oxanorbornene-
polymer derivatives generated polymer nanoparticles with unprecedented therapeutic selectivity 
towards MDR bacteria. Additionally, polymeric nanoparticles prevented onset of resistance 
development in bacteria for ~1300 generations and eradicate biofilms on infected mammalian 
cells, a feat unachieved by previous antimicrobial polymers. Amphiphilic polymer derivates 
increased the influx of antibiotics in Gram-negative bacteria and biofilms, resulting in synergistic 
antimicrobial therapy. Subsequently, we utilized engineered polymers to generate nanosponges 
through self-assembly of polymers around essential-oil based cores for topical treatment of 
wound biofilms. Overall, our results show strong potential as an infectious disease therapeutic 
while simultaneously provide a rational approach to design novel antimicrobials for sustainably 
combating bacterial infections. 
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CHAPTER 1 
INTRODUCTION 
1.1 Emergence of multi-drug resistant bacteria 
Over the past-century, antibiotics have been used to combat bacterial infections with high 
potency and cost-effectiveness. However, in the last few decades, widespread overuse of 
antibiotics has resulted in the emergence of multi-drug resistant (MDR) bacteria that are resistant 
to multiple antibiotics simultaneously.1 The rise of “superbugs” resistant to antibiotics, constitutes 
one of the dominant challenges in human health. Antibiotic-resistant bacteria cause more than 2 
million cases of infections every year with more than 23,000 annual deaths in US alone.2 Number 
of annual deaths caused by MDR infections world-wide increases to 700,000 every year. Recent 
projections by World Health Organization (WHO) indicate that bacterial infections will cause 
more than 10 million deaths each year by 2050, more than that caused by cancer presently. 3  In 
recent years, numerous strains such as New Delhi metallo β-lactamase-producing 
Enterobacteriaceae strains have been found to be resistant to almost all antibiotics except 
tigecycline and colistin.4  Furthermore, there have been multiple reports of other “superbug” 
outbreaks where the infection causing strains were resistant to all the clinically available 
antibiotics.  
Most-cases of MDR-infections require prolonged antibiotic therapy with tissue 
debridement (i.e. surgical removal) in some cases, resulting in low-patient compliance and 
excessive healthcare-costs.5 Notably, widespread antibiotic resistance poses an economic burden 
of more than $55 billion per year towards excess healthcare and societal costs in the US. 6 
Moreover, conventional treatment strategies utilizing antibiotics further contributes to increased 
resistance in the surviving bacterial cells. For example, 40% of the S. aureus strains isolated from 
hospitals are resistant to methicillin (methicillin-resistant S. aureus, MRSA) and some even 
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resistant to last-resort antibiotic-vancomycin (vancomycin-resistant S. aureus, VRSA) and 
carbapenems.7,8   
 
Figure 1.1. Three of the main antibiotic resistance strategies used by bacteria. Reproduced by 
permission from Reference 10.   
Antibiotics execute their antibacterial effect by specifically targeting essential surviving 
mechanisms in bacteria, such as inhibiting synthesis of cell wall and interfering in production of 
DNA, RNA and vital proteins.9 ,10  However, with billions of years of evolutionary progress, 
bacteria have developed an intrinsic ability to overcome the threats posed by these traditional 
antibacterials through mutations and transfer of DNA (horizontal gene transfer).11 Single bacterial 
strain can acquire multiple drug-resistance genes from different microbes, resulting in generation 
of multi-drug resistant (MDR) “superbugs”.12 Antibiotic resistance in bacteria will increase and 
the situation will become more dire as the number of MDR strains continues to grow. This 
rapidly escalating threat has contributed to an urgent need to discover novel antibacterials and 
new treatment strategies to combat these highly resistant bacteria. 
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1.2 Bacterial biofilms 
Bacterial cells often adhere to damaged tissues, medical implants or indwelling devices to 
cause persistent infections by forming biofilms as shown in Figure 1.2.13 Biofilms are three-
dimensional microcolonies of bacteria that are embedded inside a slimy matrix of extracellular 
polymeric substance (EPS).14 The EPS matrix possesses complex composition of extracellular 
polysaccharides, proteins, nucleic acids and lipids that plays a significant role in protecting the 
biofilm residing microbes.15,16 Importantly, EPS matrix acts as a barrier that prevents penetration 
of antimicrobials, rendering them ineffective against these refractory infections.17,18  
  
 
 
Figure 1.2. Schematic showing the cycle of biofilm formation, starting from planktonic bacterial 
cells to eventual dispersal of microbes from the matrix. Adapted with permission from Reference 
50. 
  Approximately ~80% of human bacterial infections involve the formation of biofilm on 
the living tissue.19 Multiple nosocomial infections are caused due to adherence of biofilms onto 
the biomaterial surface such as those associated with the use of urinary catheters, central venous 
catheters, orthopedic devices, arthro-prostheses and dental implants.20,21 Biofilm formation on 
diseased or damaged tissues is associated with cystic fibrosis, endocarditis and chronic wounds.22 
Biofilm infections are highly refractory to conventional antibiotics and can evade host immune 
response. 23  Moreover, biofilm infections can frequently result in chronic inflammation of 
surrounding tissue due to invasion of neutrophils and other immune complexes.24,25   
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The main mechanisms for resistance in bacterial biofilms can include limited penetration 
of antibiotics inside the biofilm matrix due to physiochemical characteristics of the EPS as shown 
in Figure 1.1.23,26 In some cases, enzymatic degradation of antibiotics inside the matrix can also 
retard antibiotic penetration.27 Secondly, biofilms have an altered chemical microenvironment 
that plays a crucial role in its resistance against biofilms. For example, biofilms have a very low 
pH due to accumulation of acidic waste products that can antagonize antibiotics such as 
vancomycin.28 Similarly, deep layers of biofilms can have anaerobic microenvironment that can 
also compromise the activity of antibiotics such aminoglycosides.26 Finally, ~1% of biofilm 
microbes phenotypically mutate into persister cells that can continue to survive even after 
exposure to antibiotics.19 
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Figure 1.3.  Schematic representation showing mechanism of resistance in biofilms caused by 
limited penetration of antibiotics, resistant phenotypes and altered microenvironment of EPS. 
Adapted with permission from Reference 23.  
1.3 Current Strategies to combat bacterial infections  
Discovery of antibiotics in mid-20th century revolutionized the treatment of infectious 
diseases facilitating treatment of potentially life-threatening conditions and greatly reducing the 
burden of mortality caused by bacterial infections. Most of the antibiotics discovered in the early 
years of invention were predominantly obtained from screening natural products produced during 
the process of microbial fermentation.29 Recently, researchers have identified antibiotics from 
different ecological systems that exhibit novel mechanisms of actions. Alternatively, medicinal 
chemists have focused on modifying the chemical structures of the existing classes of antibiotics 
to generate new antibacterials. For instance, fourth generation cephalosphorins and β-lactam 
antibiotics exhibit extended spectrum activity against Gram-positive and Gram-negative 
bacteria.30,31 Another actively pursued strategy in the clinic to combat MDR infections involves 
use of antibiotic cocktails that can target multiple pathways to kill bacteria.32,33 These strategies 
have shown improved efficacy; however they involve increased risks of developing antibiotic 
resistance in the patients.34 Moreover, rapid and continuous spread of antibiotic resistance in 
bacteria has contributed to the urgent need of developing alternative antimicrobial therapies.  
Majority of “non-antibiotic” approaches for the treatment of bacterial infections involves 
targeting virulence factors of bacterial pathogens rather than actively killing the microbes.35,36 
Most bacterial pathogens produce virulence factors to evade host-immune response, proliferate 
inside and cause damage to the host cells.37,38 Antivirulence compounds can block the activity of 
these virulence factors, making pathogens susceptible to the host-immune response or adjunct 
antibiotics. For example, monoclonal antibodies and small molecules binding with bacterial 
toxins have shown to be effective in treatment of bacterial infections, with some studies even 
being pursued in clinical trials.39,40 Similarly, therapeutics that target quorum-sensing pathways 
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(bacterial cell communication) have demonstrated ability to prevent infections caused by 
formation of biofilms.41 , 42  Some of the other actively pursued antibacterial strategies utilize 
engineering bacteriophages (virus eating bacteria) and manipulating the microbiome, however 
they are still in their preliminary stages.43,44     
Antimicrobial peptides (AMPs) have emerged as promising therapeutics that actively 
target and kill bacterial cells. AMPs are host-defense molecules that demonstrate broad-spectrum 
activity and reduced resistance acquisition.45,46 These favorable characteristics can be attributed to 
the unique amphiphilic topology of peptides, featuring polycationic headgroups, enabling them to 
disrupt microbial membranes.47 AMPs exhibit low hemolytic activity and minimal toxicity to 
mammalian cells, rendering them highly effective in antimicrobial therapies. However, AMPs are 
susceptible to proteolytic degradation compromising their antimicrobial efficacy in physiological 
environment.48,49      
Building on the structural advantages of both antibiotics and AMPs, nanomaterials 
provide another potential solution for antimicrobial therapies. For example, nanomaterials can 
simultaneously disrupt the bacterial membrane and target intracellular components to impede 
proper functioning of the cellular machinery. 50 , 51 , 52  The distinct physio-chemical traits of 
nanomaterials make them promising candidates to achieve enhanced therapeutic efficacy against 
resilient MDR infections.53,54 Nanomaterials can execute multiple bactericidal pathways, making 
it difficult for bacteria to adapt against these therapeutics.55 These pathways are dependent upon 
the inherent core material, shape, size and surface chemistry of nanomaterial scaffolds.56,57,58 
Moreover, high therapeutic loading coupled with the enhanced ability to penetrate biological 
membranes make nanomaterials excellent candidates for the transport of drugs at the site of 
infection.59,60,61 Finally, the ability to modulate nanomaterial interaction with bacterial cellular 
systems plays a pivotal role in improving the therapeutic efficacy of the treatment.62  
 7 
 
1.4 Interaction of nanomaterials with bacteria 
Nanomaterial-bacteria interactions depend upon multiple factors such as electrostatic 
attraction, hydrophobic and receptor–ligand interaction and van der Waals forces.50 A 
fundamental study of the interactions between nanomaterials and bacteria provides crucial insight 
for designing novel antimicrobial agents. 
Bacteria are mainly classified into Gram-negative and Gram-positive depending upon the 
structure of their cell wall (Fig. 1a). 63  The cell wall of Gram-positive bacteria has a thick 
peptidoglycan layer (15–100 nm) with polymeric techoic acids and a cytoplasmic membrane 
underneath.52 The phosphates present in the techoic acid polymeric chains are responsible for the 
bacterial negative charge and serve as binding sites for the divalent cations in the solution. On the 
other hand, Gram-negative bacteria consists of a cytoplasmic membrane followed by a thin 
peptidoglycan layer (20–50 nm), which is further protected by a hydrophobic lipid bilayer 
consisting of lipopolysaccharides. This additional lipid layer greatly reduces the penetration 
ability of numerous hydrophobic antibacterial agents such as detergents.63 
The bacterial membrane is negatively charged primarily due to the presence of 
phosphates and carboxylates as components of lipopolysaccharides present on Gram-negative 
bacteria. The structure of the bacterial cell wall plays a crucial role in determining the interaction 
of NPs with the microbes. In early studies of nanoparticle–microbe interactions, Murphy and 
coworkers have demonstrated that CTAB coated gold nanorods or nanospheres were 
homogenously distributed on Gram-positive B. cereus. This phenomenon was attributed to the 
electrostatic interaction between the positively charged nanomaterial and the negatively charged 
techoic acid moieties on the bacteria.64 Alternatively, mannose substituted gold nanoparticles bind 
with the pili on Gram-negative E. coli. Pili are hair like structures emanating from bacterial 
surfaces that are rich in lectin (sugar-binding proteins) and hence preferentially binding to the 
mannose coated NPs.65 Building on these observations, Rotello and coworkers demonstrated that 
cationic NPs exhibited toxicity against bacteria.66  In subsequent studies, the subtle interplay 
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between NP coverage and membrane structure indicated that the positively charged hydrophobic 
AuNPs formed spatial aggregates on the bacterial membrane. Gold nanoparticles (AuNP) of 2 nm 
core diameter exhibited low toxicity against E. coli (Gram-negative) but rapidly lysed B. subtilis 
(Gram-positive) bacteria.67 The interaction between the specific NP functionality and membrane 
structure can result in blebbing, tubule formation or other membrane defects. 
As we have previously studied in section 1.2, the complex architecture, dynamics, and 
composition of extracellular polymeric substances (EPS) in the matrix are profoundly responsible 
for the low penetration of therapeutic agents. Diffusion of therapeutics inside the biofilm can be 
affected by several genetic and physiological heterogeneities such as the hydrophobicity of 
bacterial cell walls.68  Hence, fundamentally understanding the interactions between NPs and 
complex biofilm matrices is crucial in designing materials for biofilm treatment. 
The penetration and deposition of NPs within the biofilms are key components for the 
design of biofilm therapeutics. Peulen and Wilkinson reported that the penetration ability of NPs 
decreased inversely to their size due to small pore sizes within biofilms. 69  Furthermore, NP 
deposition inside the biofilms is largely dependent upon the electrostatic interaction as well as the 
homogeneity of the charges across the biofilm surface. In a related study, Rotello and co-workers 
provided further insight on the penetration ability of the NPs inside the biofilms. They 
demonstrated that the neutral and anionic quantum dots (QDs) did not show any penetration 
inside the biofilms, while cationic QDs were widely distributed throughout the biofilm. 
Furthermore, cationic QDs with hydrophobic terminal groups were found inside the bacterial 
cells, whereas their hydrophilic counterparts remained in the EPS matrix of the biofilm (Figure 
2).70 
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Figure 1.4. Surface design controls penetration ability of nanoparticles. a. Quantum dots used in 
study. b. Micrographs of microtomed slices of the biofilm showing no penetration by anionic and 
neutral particles and efficient infiltration by cationic quantum dots. Adapted from reference 70. 
1.5 Antimicrobial mechanism of NPs 
The therapeutic activity of many antibiotics originates from their ability to inhibit cell 
wall synthesis, interfering with the expression of essential proteins and disrupting the DNA 
replication machinery. However, bacteria have developed the ability to resist each of these 
mechanisms of action. One fundamental mechanism of bacterial resistance is the alteration of the 
target of the antibiotic.71 For example, modification of cell wall components confers resistance to 
vancomycin, whereas altered structures of ribosomes resist tetracycline.72 Similarly, bacteria can 
overexpress enzymes such as β-lactamases and aminoglycosides to degrade antibiotics. 
Additionally, overexpression of efflux pumps enables bacteria to evade multiple antibiotics 
simultaneously. Finally, many pathogens such as Chlamydophila pneumonia reside inside the 
 10 
 
cellular compartments of the host cells to escape from the antibiotics that are mostly confined to 
extracellular space.73 
 
 
Figure 1.5. Schematic diagram showing a. cell wall structures of Gram-positive and Gram-
negative bacteria and b. antimicrobial mechanism of NPs: (A) disruption of cell membrane 
resulting in cytoplasmic leakage; (B) binding and disruption of intracellular components; (C) 
disruption of electron transport causing electrolyte imbalance and (D) generation of reactive 
oxygen species (ROS). 
Nanomaterials can overcome the antibiotic-resistance mechanisms owing to their unique 
physio-chemical properties, enabling nanomaterials to execute multiple novel bactericidal 
pathways to achieve antimicrobial activity. Nanomaterials can bind and disrupt bacterial 
membranes, causing leakage of cytoplasmic components.54 Upon membrane permeation, 
nanomaterials can also bind to intracellular components such as DNA, ribosomes and enzymes to 
disrupt the normal cellular machinery (Fig. 1.5b). Disruption in the cellular machinery can lead to 
oxidative stress, electrolyte imbalance and enzyme inhibition, resulting in cell death.52 The 
bactericidal pathways followed by nanomaterials are inherently dependent upon their core 
material, shape, size and surface functionalization. In early studies on nanomaterial-based 
antimicrobials, researchers varied the inherent core materials to generate nanomaterials with 
different mechanisms of action. For example, silver nanoparticle-based antimicrobials utilize free 
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Ag+ ions as active agents. The silver ions disrupt the bacterial membrane and electron transport 
while simultaneously causing DNA damage.74 Similarly, free Cu2+ ions from copper NPs can 
generate reactive oxygen species (ROS) that disrupt amino acid synthesis and DNA in bacterial 
cells. On the other hand, ZnO and TiO2 based nanomaterials cause cell membrane damage and 
generate ROS to kill bacteria.75,76 Different nanomaterial cores can offer a range of antibacterial 
mechanisms to combat drug-resistant superbugs. However, these non-functionalized 
nanomaterials often exhibit narrow-spectrum activity against bacterial species. Moreover, they 
display low therapeutic indices (i.e. selectivity) against healthy mammalian cells, limiting their 
widespread use in biomedical applications. The surface chemistry of nanomaterials is critical to 
modulate their interaction with bacteria, improving their broad-spectrum activity while 
simultaneously reducing their toxicity against mammalian cells. 
Nanomaterials based antimicrobials have demonstrated their efficacy against both 
planktonic (free floating bacteria) and biofilm (bacterial community) infections. In the following 
sections, we have briefly discussed some of the nanomaterial-based strategies for combating 
MDR bacterial and biofilm infections. 
1.6 Nanomaterials as self-therapeutic antimicrobial agents 
NPs provide multiple attributes that facilitate the development of unique antimicrobial 
strategies.77,78 NPs can interact with and penetrate bacterial cells with unique bacteriostatic and 
bactericidal mechanisms.79 For example, possessing slightly larger diameters than drug efflux 
pumps, NPs can potentially reduce efflux-mediated extrusion.80,81 Exploiting these characteristic 
properties, several NP-based systems have been employed for antimicrobial applications. 
Xu and co-workers demonstrated enhanced in vitro antibacterial activities of 
vancomycin-capped AuNPs (Au-Van) against vancomycin-resistant enterococci and E. coli 
strains (Figure 1.6). 82  Similarly, Feldheim and co-workers demonstrated that antimicrobial 
activity of NPs functionalized with non-antibiotic molecules depended upon their composition on 
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the surface.83 These studies indicate that modulating NP surfaces exhibits great potential for 
antimicrobial therapy. However, further studies on how NP surface functionality modulates 
antimicrobial activity can provide valuable information for future NP-based antimicrobial agents. 
 
Figure 1.6. Schematic diagram showing the binding of vancomycin capped gold nanoparticles 
with vancomycin-resistant enterococci. Adapted from reference 82. 
The antibacterial activity of silver has been well established. High surface area and 
concomitant increase in dissolution rate are key to its use in silver-based antimicrobials, where 
free Ag+ ions are the active agents.84 However, they face certain shortcomings, such as high 
toxicity to mammalian cells and limited penetration in biofilm matrices.85,86 Recent studies have 
focused on countering these issues by using inherent NP properties and surface functionalization 
as their toolkit. For example, Mahmoudi and co-workers developed silver ring-coated 
superparamagnetic iron oxide NPs (SPIONS) with ligand gaps that demonstrated high 
antimicrobial activity and remarkable compatibility with healthy cells. Additionally, these NPs 
exhibited enhanced activity against biofilm infections due to deeper penetration under an external 
magnetic field.87 
Graphene NPs,88 AuNPs,89 and carbon nanotubes90 possess photothermal properties that 
can be utilized to design therapeutic agents. These nanomaterials absorb light (700–1100 nm) and 
release heat. Ling and co-workers designed graphene-based photothermal NPs that captured and 
killed Staphylococcus aureus and E. coli bacteria upon near-infrared (NIR) laser irradiation. In 
this approach, graphene oxide was reduced and functionalized with magnetic NPs (MRGO). 
These NPs were functionalized with glutaraldehyde (GA) to induce excellent crosslinking 
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properties with Gram-positive and Gram-negative bacteria (Figure 1.7). Rapid and effective 
killing of 99% of both bacterial species was achieved upon NIR irradiation.91 
 
Figure 1.7. Schematic representation of antibacterial photothermal treatment by mildly reduced 
graphene oxide functionalized with glutaraldehyde. 
1.7 Nanomaterials as delivery vehicles for antimicrobial therapy 
The antimicrobial efficacy of therapeutics can be increased by using delivery vehicles to 
successfully transport them to the infection site.59,60 Nanoparticle-based drug delivery systems can 
provide increased drug retention time in blood and reduced nonspecific distribution and targeted 
delivery of drugs at the site of infection. The surface chemistry of the NP plays a crucial role in 
ensuring the solubility of the NP in the blood stream and in providing a ‘‘stealth’’ invisibility 
against the body’s natural defense system. The mononuclear phagocytic system can eliminate 
these nanovehicles from the blood stream unless the vehicles are engineered to escape 
recognition.92,93 Another important biological barrier to nanoparticle-based drug delivery is the 
process of opsonization. Opsonin proteins in blood rapidly adhere to nanoparticles, allowing the 
macrophages from the mononuclear phagocytic system (MPS) to bind and remove NPs from 
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circulation.94 , 95  Numerous strategies have been used to hide nanoparticles from the MPS to 
address these limitations.96 Of these methods, the most preferred is the adsorption or grafting of 
hydrophilic polymers such as PEG97 on the surface of nanoparticles. These coatings create a 
‘cloud’ of uncharged hydrophilic moieties on the particle’s surface that repel plasma proteins and 
increase the circulation and retention time in the circulatory system of the body. 
Bacterial infections are able to evade antibiotic treatment through reduced bactericidal 
concentration or reduced antimicrobial activity of therapeutic agents at the site of infection.98 
Localized delivery of the drugs/antimicrobials can increase their therapeutic efficacy. Therefore, 
NPs can serve as promising drug delivery vehicles owing to their tunable surface functionality, 
biocompatibility, and high drug loading capacity.99 
NPs such as mesoporous silica possess a uniquely large surface area and tunable pore size 
that make them promising candidates for designing drug delivery vehicles. 100  For example, 
Schoenfisch and co-workers designed amine-functionalized silica NPs that were able to readily 
penetrate and eradicate pathogenic biofilms through rapid nitric oxide release.101 Similarly, silica 
NPs have been fabricated as scaffolds for silver NP (AgNP) release.102 Using NPs for controlled 
antimicrobial release can markedly improve their biocompatibility with mammalian cells and 
mitigate their hazardous environmental impact.103,104,105 In one such study, biodegradable lignin-
core NPs (EbNPs) infused with silver ions were proposed as greener alternatives to AgNPs. 
EbNPs were coated with cationic polyelectrolytes and loaded with Ag+ ions. These NPs exhibited 
broad-spectrum biocidal action against Gram-positive and Gram-negative bacteria at lower Ag+ 
ion concentrations than conventional AgNPs. 106 Therapeutic selectivity is critical when designing 
effective drug delivery vehicles. Triggered release of antimicrobials from these nanocarriers can 
be an alternative strategy to diminish their undesirable side effects. In one particular study, 
Langer and co-workers designed PLGA-PLH-PEG NPs as a carrier to deliver vancomycin to 
bacterial cells, exploiting their localized acidity. PLGA-PLH-PEG NPs demonstrated high 
binding affinity to bacterial cells at pH 6.0 as compared to 7.4. Vancomycin-encapsulated NPs 
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exhibited a 1.3-fold increase in the MIC against S. aureus as compared to 2.0-fold and 2.3-fold 
for free and PLGA-PEG encapsulated vancomycin, respectively. 107  In a similar study, pH-
responsive NPs were used to deliver hydrophobic drugs to biofilm moieties. Polymeric NPs used 
in this study consisted of a cationic outer shell to bind with the EPS matrix and a pH-responsive 
hydrophobic inner shell to release encapsulated farnesol molecules on demand. These scaffolds 
resulted in a 2-fold increase in efficacy in the treatment of biofilms as compared to the drug 
alone.108 
Apart from acidic microenvironments, NPs can be designed to trigger antibiotic release 
upon exposure to bacterial toxins. For example, Zhang and co-workers designed AuNP-stabilized 
phospholipid liposomes (AuChi-liposomes) that respond to bacterial toxins. Chitosan-
functionalized AuNPs were adsorbed on the liposomal surfaces to provide stability and prevent 
undesirable antibiotic leakage. In the presence of α-toxin-secreting S. aureus bacteria, AuChi-
liposomes released vancomycin that effectively inhibited their growth.109  
Cationic NPs exhibit excellent penetration ability in biofilms. Moreover, they can self-
assemble at the oil-water interfaces to generate nanocapsules. 110  Combining these two 
characteristic features, Rotello and co-workers generated a highly effective therapeutic system for 
the treatment of bacterial biofilm infections. Peppermint oil and cinnamaldehyde were chosen as 
the therapeutic oil template, owing to their inherent antimicrobial nature, in combination with 
amine-functionalized cationic silica NPs that stabilized the oil-water interface to generate 
nanocapsules (CP-caps) (Figure 1.8). These capsules were further stabilized by the formation of 
hydrophobic Schiff bases upon reacting with cinnamaldehyde. The cationic NPs enabled the 
capsules to readily penetrate the biofilms and release the antimicrobial oils to eradicate the 
biofilm infections. Moreover, the therapeutic selectivity of CP-caps was tested on a biofilm-
fibroblast cell co-culture model. These studies showed effective biofilm infection eradication with 
simultaneous growth enhancement of fibroblast cells.111 
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Figure 1.8. Nanoparticle-stabilized capsules for treatment of biofilm infections. a. Fabrication of 
capsules. b. Toxicity of CP-Cap against Escherichia coli cells while enhancing fibroblast viability. 
1.8 Dissertation overview 
Nanomaterials have emerged as new tools that can be used to combat deadly bacterial 
infections and overcome the barriers faced by traditional antimicrobials such antibiotic resistance. 
The surface engineering of nanomaterials dictates their interaction with bacterial cellular system 
and plays a pivotal role in determining the ability of nanoparticles to combat bacterial infections. 
In this thesis, we have focused on tuning the surface chemistry of nanomaterials for imaging and 
therapy of bacterial infections. We have demonstrated that tailoring of surface functionalities can 
enable unique mechanism of actions to combat multi-drug resistant bacteria as well as increase 
the selectivity of the therapy while showing minimal toxicity to the host cells.  
In the Chapter 2 of this thesis, I have investigated the structure-activity relationship 
between the surface chemistry and the antimicrobial activity of the gold nanoparticles. This study 
demonstrates high potential of engineered gold nanoparticles as antimicrobials as well as provides 
a basis for developing novel nanoparticle-based antimicrobials. Building on these studies, In 
Chapter 3 I further explored the ability of these engineered nanoparticles in combination with 
existing antibiotics to treat MDR bacteria. These nanoparticles showed unique mechanisms of 
action to combat resistant bacteria, suggesting their potential as next-generation therapeutics.  
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In Chapter 4, I have fabricated nanoparticles with pH-responsive ligands for selectively 
targeting acidic microenvironment of the biofilms. Further these engineered nanoparticles were 
embedded with transition metal catalysts for bioorthogonal imaging of biofilms. This study 
illustrates an example for increasing the selectivity of nanomaterials by tailoring nanomaterial 
surface chemistry. In Chapter 5, I have used an alternative strategy to improve the selectivity of 
the bioorthogonal nanoparticles (nanozymes) to target bacterial biofilms. These nanozymes were 
electrostatically adsorbed on carrier Red Blood Cells, enabling them to selectively accumulate at 
the site of bacterial infection while avoiding non-specific uptake in macrophages. This study 
shows that interactions at nano-bio interface can play a crucial role in integration of synthetic 
materials with naturally occurring systems, resulting in novel antimicrobial therapies.             
Synthetic polymers show structural conformations reminiscent of host-defense 
antimicrobial peptides. In Chapter 6, I have explored the structure-activity relationship by varying 
the polymer structure and screening their antimicrobial and hemolytic activity. These studies 
provide a deeper insight about tuning the polymer structures to generate polymer nanoparticles 
with high therapeutic indices against MDR bacteria. In the subsequent Chapter 7, I have utilized 
engineered polymer nanoparticles for synergistic antimicrobial therapy showing novel 
mechanisms to address bacterial and biofilm infections. These studies further corroborate the 
importance of surface chemistry in antimicrobial therapies. In Chapter 8, we have utilized 
functionalized polymers to fabricate nanosponges through self-assembly of polymers around 
essential-oil based cores for topical treatment of wound biofilms.  
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CHAPTER 2 
ENGINEERING SURFACE FUNCTIONALITY OF GOLD NANOPARTICLES 
TO COMBAT MULTI-DRUG RESISTANT BACTERIA 
2.1 Introduction 
The emergence of multi-drug resistant (MDR) bacteria has become a severe threat to 
public health.1According to a report published by the U.S. Centers for Disease Control and 
Prevention, antibiotic resistant bacteria cause millions of infections and thousands of deaths every 
year in the U.S.2 Additionally, the significant and continuous decrease in the number of approved 
antibiotics in the past decade has contributed to the increasingly threatening situation3 that has 
resulted in an urgent need for the discovery of novel antibacterials and treatment strategies.4 
There are a number of actively pursued strategies, including searching for new antimicrobials 
from natural products, modification of existing antibiotic classes, and the development of 
antimicrobial peptides.5  
Nanoparticles (NPs) provide versatile platforms for therapeutic applications based on 
their physical properties.6,7,8 For example, NP size range is commensurate with biomolecular and 
bacterial cellular systems, providing additional interactions to small molecule antibiotics.9,10 The 
high surface to volume ratio allows incorporation of abundant functional ligands, enabling 
multivalency on NP surface to enhance interactions to target bacteria. Utilizing these 
characteristic features, NPs have been conjugated with known antibiotics to combat MDR 
bacteria. The antibiotic molecules can be infused with NPs via noncovalent interactions11,12 or 
incorporated on NPs via covalent bonds.13,14 Both methods have been reported for enhanced 
activity against bacteria, showing decreased minimum inhibitory concentration (MIC) in 
comparison with use of free antibiotics.15,16,17 The improved performance is proposed to result 
from polyvalent effect of concentrated antibiotics on the NP surface as well as enhanced 
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internalization of antibiotics by NPs. 18  Yet the dependence on existing antibiotics in these 
approaches may not be able to delay the onset of acquired resistance. 
The functional ligands on NP surface can provide direct multivalent interactions to 
biological molecules, allowing NPs to be exploited as self-therapeutic agents.19,20,21 This strategy 
can circumvent the employment and the potential limitation of existing antibiotics in nanocarrier 
systems.22 For assembly of such self-therapeutic NPs, the essentially inert and nontoxic nature of 
gold makes it an attractive core material.23 To this end, we synthesized a series of self-therapeutic 
gold nanoparticles (AuNPs) as an antimicrobial agent. The structure-activity relationship of the 
functional ligands on 2 nm core AuNP revealed that AuNP antimicrobial properties can be 
tailored through surface hydrophobicity, providing a new aspect to design antimicrobial 
nanomaterials. 
On the basis of these studies, we focused on the most potent AuNP candidate and tested 
this particle with clinically isolated uropathogens. The result showed inhibited growth of multiple 
strains of uropathogens, including many MDR strains and methicillin-resistant Staphylococcus 
aureus (MRSA). Significantly, this AuNP did not induce bacterial resistance even after 20 
generations. These particles are also compatible with mammalian cells: the maximum hemolytic 
index of this AuNP is >50, and at the MIC against MRSA, the C10-AuNP treated mammalian 
cells maintained >80% viability. 
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Figure 2.1. Molecular structures of functional ligands on AuNPs. 
2.2 Results and Discussions 
We recently reported that 2 nm core cationic monolayer-protected AuNPs can interact 
with cell membrane of Gram-positive and Gram-negative bacteria, resulting in formation of 
distinct aggregation patterns and lysis of bacterial cell.24 Similarly, Jiang and co-workers also 
demonstrated that blebbing caused by cationic AuNPs induced bacterial membrane damage.20 
These results suggested that 2 nm AuNPs with cationic surface properties could be used as 
antimicrobial agents. To systematically investigate the role of surface chemistry in NP 
antimicrobial efficacy, AuNPs were synthesized with a range of different cationic functionalities 
featuring different chain length, nonaromatic, and aromatic characteristics (Figure 2.1). All 
AuNPs were highly soluble in water; including NP 3 with the most hydrophobic end group (stock 
solution concentration was 56 μM). 
We first evaluated the functional AuNP antimicrobial activities on a laboratory strain 
(Escherichia coli DH5α), using broth dilution methods to determine the minimal inhibitory 
concentrations (MICs).25 AuNPs were incubated with 5 ×105 cfu/mL of E. coli overnight. All 
AuNPs were able to completely inhibit the proliferation of E. coli at nanomolar concentrations; 
the MICs of different AuNPs, however, varied by the R group. To correlate antimicrobial activity 
with AuNP surface functionality, we plotted the MICs against the calculated AuNP end group log 
P values that quantitatively represent the relative NP surface hydrophobicity (Figure 2.2).26 A 
marked structure-activity relationship was observed, with hydrophobic NPs being more effective 
against E. coli growth. The most hydrophobic AuNP tested, NP 3 that carried an n-decane end 
group was capable of inhibiting E. coli proliferation at only 32 nM. 
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Figure 2.2. MIC values (nM) of AuNPs bearing different hydrophobic surface ligands against E. 
coli DH5α. Log P represents the calculated hydrophobic values of the end groups. 
We next tested the antimicrobial activities of the most potent antimicrobial (NP 3) on 
uropathogenic E. coli clinical isolates (Table 2.1). Five isolates with differing resistance to 
clinically used antibiotics. (resistant to 1-17 drugs, depending on strain) were used for this study. 
NP 3 suppressed the growth of all five uropathogenic strains of E. coli, including three MDR at a 
concentration of 16 nM, lower 27  or similar to20 reported antibiotic capped AuNPs. The 
comparable MIC values of MDR and laboratory strains suggest that C10-AuNP could potentially 
address the common mechanisms of bacterial resistance. 
Next, NP 3 was further tested with more species/ strains of uropathogenic clinical isolates, 
including Gram-negative Enterobacter cloacae complex and Pseudomonas aeruginosa and 
Gram-positive S. aureus and methicillin-resistant S. aureus (MRSA) (Table 2.1). Among these 
isolates, P. aeruginosa has intrinsic resistance to a variety of antibiotics due to their exceptionally 
low outer-membrane permeability and multidrug efflux pumps.28 Likewise, S. aureus has been a 
stumbling block for antimicrobial treatment, overcoming most of the therapeutic chemo-agents 
developed in the past five decades.29 Particularly, MRSA has emerged as “superbug”, resistant to 
most antibiotics commonly used for the staph infections.30 NP 3 was effective in treating each of 
these pathogens, with MICs of 8-64 nM. 
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Table 2.1. MIC values of C10-AuNP against uropathogenic clinical isolates. 
Strain Species MIC (nM) # of resistant drugs MDR 
CD-2 E. coli 16 1 No 
CD-496 E. coli 16 2 Yes 
CD-3 E. coli 16 3 Yes 
CD-19 E. coli 16 4 Yes 
CD-549 E. coli 16 17 Yes 
CD-866 E. cloacae complex 16 2 Yes 
CD-1412 E. cloacae complex 8 4 Yes 
CD-1545 E. cloacae complex 16 7 Yes 
CD-1006 P. aeruginosa 16 1 No 
CD-23 P. aeruginosa 32 13 Yes 
CD-1578 S. aureus 64 4 Yes 
CD-489 S. aureus - MRSA 32 10 Yes 
 
On the basis of the enhanced toxicity of NP 3, we hypothesized that the cationic 
hydrophobic AuNPs are particularly effective at compromising the integrity of bacterial 
membrane, causing toxicity to bacterial cells.24 To support this hypothesis, we employed a 
propidium iodide (PI) staining assay. PI can only penetrate bacterial cells with compromised 
membrane and binds nucleic acids, with a concomitant enhancement of red fluorescence.31,32 
Uropathogens, E. coli CD-2 and S. aureus CD-489, were chosen as representative Gram-negative 
and Gram-positive strains. Bacteria (1×108 cfu/mL) were incubated with NP 3 at a final 
concentration of 500 nM for 3 h at 37 °C and then stained with PI before imaging. Confocal laser 
scanning microscopy (CLSM) images in Figure 2.3 showed NP induced membrane damage in 
both bacteria. 
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Figure 2.3. PI staining showing NP 3 (C10-AuNP)-induced bacterial cell membrane damage. 
Scale bar is 5 μm. 
To study the development of bacterial resistance to NP 3, E. coli CD-2 was exposed to 
sub-MIC (66% of MIC) of NP 3, with the obtained bacterial cell population defined as the first 
generation. After harvesting the first generation, the MIC was tested, and a second generation was 
generated by exposing the first generation at its sub-MIC (66%). After 20 generations, E. coli 
remained susceptible to the original MIC of 16 nM. Compared to literature reported rate at which 
E. coli acquires resistance to conventional antibiotics,20 NP 3 significantly delayed evolution of 
resistance. This lack of bacterial adaptation provides a means of potentially controlling and 
preventing the drug resistance.33,34 
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Figure 2.4. Hemolytic activity of NP 3 at different concentrations. HC50 was estimated to be 
∼400 nM (as denoted by the red cross in figure). 
To assess the biocompatibility of our antimicrobial NP 3, we performed hemolysis assay 
on human red blood cells as well as viability assays on mammalian cells. At all the MIC 
concentrations tested (in the range of 4 nM to 128 nM), NP 3 showed modest hemolytic activity 
as shown in Figure 2.4. HC50, which is the concentration to lyse 50% of human red blood cells,35 
was ∼400 nM for NP 3. The hemolytic index (HC50/MIC) was used to assess NP 3 selectivity 
against eukaryotic cells; therefore, the maximum hemolytic index of NP 3 was 50 (400 nM/8 nM). 
The observed AuNP cell selectivity could be explained by the fact that the surface of bacterial 
cells are more negatively charged than mammalian cells,36 therefore accounting for the better 
affinity toward multi cations in bacteria. Also, the presence of cholesterol in mammalian cell 
membranes helps to stabilize the membranes, making them less sensitive to destruction by 
antimicrobial AuNPs.37 It should be noted that the mammalian cell culture model used in this 
study may not fully reflect the in vivo toxicity profile. 
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2.3 Conclusions 
We report here an antimicrobial strategy using self-therapeutic AuNPs to combat MDR 
bacteria. Cationic and hydrophobic functionalized AuNPs effectively suppressed growth of 11 
clinical MDR isolates, including both Gram-negative and Gram-positive bacteria. The NP ligand 
structure-activity relationship revealed that surface chemistry played an important role in AuNP 
antimicrobial properties, providing a design element for prediction and rational design of new 
antibiotic NPs. Considering the efficient antimicrobial effect on MDR bacteria, the high 
biocompatibility, and the slow development of resistance, cationic hydrophobic nanoparticles 
such as NP 3 offer a promising strategy for the long-term combating of (MDR) bacteria, a key 
issue in healthcare. 
2.4 Experimental methods 
2.4.1 Synthesis of AuNPs 
2 nm diameter gold nanoparticles were synthetized by the Brust-Schiffrin two-phase 
methodology1 using pentanethiol as the stabilizer; these clusters were purified with successive 
extractions with ethanol and acetone. A Murray place exchange reaction2 was carried out in dry 
DCM to functionalize the nanoparticles with each ligand. 38 , 39  The monolayer-protected 
nanoparticles were redispersed in water and the excesses of ligand/pentanethiol were removed by 
dialysis using a 10,000 MWCO snake-skin membrane. The final concentration was measured by 
UV spectroscopy on a Molecular Devices SpectraMax M2 at 506nm according to the reported 
methodology. 
2.4.2 Determination of antimicrobial activities of cationic gold nanoparticles  
Bacteria were cultured in LB medium at 37 °C and 275 rpm until stationary phase. The cultures 
were then harvested by centrifugation and washed with 0.85% sodium chloride solution for three 
times. Concentrations of resuspended bacterial solution were determined by optical density 
 31 
 
measured at 600 nm. M9 medium was used to make dilutions of bacterial solution to a 
concentration of 1×106 cfu/mL. A volume of 50 μL of these solutions was added into a 96-well 
plate and mixed with 50 μL of NP solutions in M9, giving a final bacterial concentration of 5×105 
cfu/mL. NPs concentration varied in half fold according to a standard protocol, ranging from 125 
to 3.9 nM. A growth control group without NPs and a sterile control group with only growth 
medium were carried out at the same time. Cultures were performed in triplicates, and at least two 
independent experiments were repeated on different days. The MIC is defined as the lowest 
concentration of AuNP that inhibits visible growth as observed with the unaided eye. 
2.4.3 Propidium Iodide staining assay  
E. coli CD-2 and MRSA CD-489 (1×108 cfu/mL) were incubated with 500 nM C10-AuNP in M9 
at 37 °C and 275 rpm for 3 h. The bacteria solutions were then mixed with PI (2 μM) and 
incubated for 30 min in dark. Five microliters of the samples were placed on a glass slide with a 
glass coverslip and observed with a confocal laser scanning microscopy, Zeiss 510 (Carl Zeiss, 
Jena, Germany) using a 543 nm excitation wavelength.  
2.4.4 Resistance development 
E. coli CD-2 was inoculated in M9 medium with 10.4 nM (2/3 of 15.6 nM, MIC) at 37 °C and 
275 rpm for 16 h. The culture was then harvested and tested for MIC as describe above. E. coli 
CD-2 was cultured without NP as well every time as a control for comparison of MICs.  
Hemolysis assay. Hemolysis assay was performed on human red blood cells as we described in a 
previous study. 40  Briefly, citrate stabilized human whole blood (pooled, mixed gender) was 
purchased from Bioreclamation LLC, Westbury, NY. The red blood cells were purified and 
resuspended in 10 mL of phosphate buffered saline as soon as received. A total of 0.1 mL of RBC 
solution was added to 0.4 mL of NP solution in PBS in 1.5 mL centrifuge tube the mixture was 
incubated at 37 °C, 150 rpm for 30 min followed by centrifugation at 4000 rpm for 5 min. The 
absorbance value of the supernatant was measured at 570 nm with absorbance at 655 nm as a 
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reference. RBCs incubated with PBS as well as water were used as negative and positive control, 
respectively. All samples were prepared in triplicate.  
2.4.5 Mammalian cell viability assay  
A total of 20 000 NIH 3T3 (ATCC CRL-1658) cells were cultured in Dulbecco's modified Eagle 
medium (DMEM; ATCC 30-2002) with 10% bovine calf serum and 1% antibiotics at 37 °C in a 
humidified atmosphere of 5% CO2 for 48 h. Old media was removed and cells were washed one 
time with phosphate-buffered saline (PBS) before addition of NPs in the prewarmed 10% serum 
containing media. Cells were incubated for 24 h at 37 °C under a humidified atmosphere of 5% 
CO2. Cell viability was determined using Alamar blue assay according to the manufacturer's 
protocol (Invitrogen Biosource). After a wash step with PBS three times, cells were treated with 
220 μL of 10% alamar blue in serum containing media and incubated at 37 °C under a humidified 
atmosphere of 5% CO2 for 3 h. After incubation, 200 μL of solution from each well was 
transferred in a 96-well black microplate. Red fluorescence, resulting from the reduction of 
Alamar blue solution, was quantified (excitation/emission: 560 nm/590 nm) on a SpectroMax M5 
microplate reader (Molecular Device) to determine the cellular viability. Cells without any NPs 
were considered as 100% viable. Each experiment was performed in triplicate. 
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CHAPTER 3 
SYNERGISTIC ANTIMICROBIAL THERAPY USING ENGINEERED 
NANOPARTICLES FOR THE TREATMENT OF MULTI-DRUG RESISTANT 
BACTERIAL INFECTIONS 
3.1 Introduction 
Increasing antibiotic resistance in bacterial strains is a serious and growing threat to 
human health,1,2 as multi-drug resistant (MDR) bacteria cause millions of infections each year. 
For instance, more than 40% of Staphylococcus aureus strains collected from hospitals are 
resistant to methicillin (methicillin-resistant S. aureus, MRSA) and in some cases even resistant 
to broad-spectrum antibiotics such as carbapenems and vancomycin.3,4,5 Most cases of MDR 
infections require prolonged antibiotic treatment that are associated with extensive health-care 
costs and further contribute to increase in antibiotic tolerance in surviving bacterial cells.6 Recent 
projections suggest that annual global deaths caused by MDR infections will reach 10 million by 
2050.7 Immunity to traditional antibiotics will continue to increase, and the situation will become 
more dire as the number of strains of MDR bacteria increases.8,9 
There have been considerable efforts to develop new antimicrobials by screening natural 
products, modifying existing antibiotics, and synthesizing antimicrobial peptides. 10  Synthetic 
macromolecules such as polymers that mimic host-defense peptides are frequently used as 
biocidal agents.11,12 More recently, nanoparticles (NPs) have emerged as promising weapons in 
our antimicrobial arsenal. Their antimicrobial efficacy is attributable to their large surface area 
enabling high synergy arising from multivalent interactions.13,14 For example, NPs functionalized 
with small molecule ligands exhibit broad-spectrum activity against bacteria.15,16 Additionally, 
NPs can address common antibiotic resistance mechanisms such as efflux pump mediated 
expulsion. 17 , 18  Recently, Feldheim and coworkers showed that appropriate surface 
functionalization of AuNPs with small molecule ligands can regulate the expression of genes 
responsible for multiple antibiotic resistance in bacteria.16 
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One strategy to enhance the efficacy of NPs against bacterial cells is to functionalize 
them with antibiotics. For example, NPs “capped” with vancomycin and aminoglycoside exhibit 
enhanced antibacterial activities against resistant strains as compared to antibiotics and NPs 
alone.19,20 However, an alternative strategy is to use NPs in combination with existing antibiotics 
to combat MDR bacterial infections. 21 , 22  We hypothesized that fine-tuning of NP surface 
chemistry could exhibit synergistic effect with antibiotics in combating MDR bacteria. We 
investigated the role of the surface chemistry of NPs in combination therapy by screening NPs 
with different functional groups in combination with antibiotics against resistant bacteria. 
Assessment of the structure activity relationship revealed that hydrophobic functionalized C10 
and C12-AuNPs lowered the minimum inhibitory concentration (MIC) of fluoroquinolone 
antibiotics against MDR bacteria by 8 to 16 times. The synergy of this combination therapy was 
attributed to the ability of functionalized NPs to act as efflux pump inhibitors,22 confirmed by 
accumulation of ethidium bromide (EtBr) inside bacterial cells upon incubation with NPs. We 
also investigated the outer-membrane proteins (OMPs) of bacterial cells, which serve as their first 
line of defense.33 Combination of NPs with antibiotics provides a complementary approach to 
target MDR bacteria while helping to avoid the regulatory issues associated with other 
bioconjugate systems, further improving current therapeutic strategies. 
3.2 Results and discussion 
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Figure 3.1. Molecular structures of functional ligands on AuNPs. Log P represents the calculated 
hydrophobic values of the end groups. Minimum inhibitory concentrations (MICs) of the NPs 
against E. coli (CD-549) are shown. 
We have previously reported that positively charged 2 nm AuNPs bind to the surface of 
bacterial membranes, forming distinct aggregation patterns and causing cellular lysis.23 Further 
modification of the NP surface monolayer with hydrophobic ligands elicited broad-spectrum 
activity against clinical MDR isolates.24 These studies suggest that tuning NP surface chemistry 
can regulate their interactions with bacteria, in-turn affecting their efficacy in antimicrobial 
combination therapies. We screened a library of NPs with varying hydrophobicity of ligands to 
evaluate their efficacy in combination with antibiotics (levofloxacin and ciprofloxacin) using a 
checkerboard titration method.  
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Table 3.1. Table showing lowest FICI (fractional inhibitory concentration 
index) indices obtained for the combination of NPs and antibiotics. 
 
We first evaluated the antimicrobial activity of different functional NPs by determining 
their minimum inhibitory concentration (MIC) against uropathogenic E. coli (Escherichia coli, 
CD-549) as a model strain. MIC was determined using broth dilution method where 5×105 cfu/ml 
of bacterial cells were incubated with different concentration of AuNPs overnight.25 The MIC for 
different NPs are listed in Figure 3.1. The MIC of antibiotics (levofloxacin and ciprofloxacin) 
against E. coli (CD-549) was determined to be 512 mg/ L. 
 
Combination FICI  Effect Fold increase in Antibiotic efficacy 
TTMA – levofloxacin 0.56  Additive 2 
TTMA –ciprofloxacin 1  Additive 2 
C6 – levofloxacin 0.625  Additive 8 
C6 – ciprofloxacin 0.75  Additive 2 
C10 – levofloxacin 0.25  Synergistic 8 
C10 – ciprofloxacin 0.25  Synergistic 8 
C12 – levofloxacin 0.375  Synergistic 8 
C12 – ciprofloxacin 0.375  Synergistic 8 
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Figure 3.2. Graphs showing synergistic and additive interactions between nanoparticles and 
antibiotics (ciprofloxacin and levofloxacin) tested in pairs. Data are the fractional inhibitory 
concentrations (FICs) of the two factors in combination. TTMA and C6 shows additive 
interactions with antibiotics; C10 and C12 NPs show synergistic response (concave curve).  
To determine the potency of the combination of AuNPs and antibiotics, we performed 
checkerboard titration and calculated the fractional inhibitory concentration index (FICI) for both 
NPs and antibiotics (Table 3.1).26,27 The FICI values corresponding to TTMA and C6-AuNPs (≥ 
0.5 and <4.0) indicate an additive response, whereas the FICI values for C10 and C12-AuNPs 
indicate a synergistic response (< 0.5) with the antibiotics. Additionally, the concave curve 
obtained with microdilution checkerboard method in case of C10 and C12 AuNPs indicate 
synergistic response (Figure 3.2).28 The MIC of antibiotics was decreased 8-fold (64 mg/L) in 
presence of C-10 and C-12 AuNPs at sub-MIC NP dosages (4 nM, 8 nM respectively).  
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Figure 3.3. Graphs showing synergistic and additive interactions between C10 and C12 
nanoparticles and antibiotics (ciprofloxacin and levofloxacin) tested in pairs against a. and b. 
methicillin resistant S. aureus and c. and d. uropathogenic P. aeruginosa. 
After determining the most effective NPs for combination therapy, NP-antibiotic 
cocktails were further tested against uropathogenic clinical isolates of Pseudomonas aeruginosa 
(CD-23) and methicillin-resistant Staphylococcus aureus (MRSA, CD-489). C10 and C12 AuNPs 
showed synergistic effect in combination with fluoroquinolone antibiotics resulting in upto 16-
fold reduction in the MIC of antibiotics (Figure 3.3). These results indicate the ability of 
functionalized NPs to antibiotic efficacy against both Gram positive (S. aureus) and Gram 
negative (E. coli, P. aeruginosa) strains. More information regarding the checkerboard 
combinations is provided in the Table 3.2, 3.3.  
Table 3.2. FIC indexes of NP-antibiotic combinations against CD-489 (MRSA) 
Table 3.3. FIC indexes of NP-antibiotic combinations against CD-23 (P. aeruginosa) 
 
Combination NP Conc.  
(nM) 
Antibiotic Conc.  
 (mg/L) 
FICI = FICNP + FICAb Effect Fold increase in 
Antibiotic efficacy 
C10 – levofloxacin 8 16 0.5 = 0.25 + 0.25 Additive 4 
C10 – ciprofloxacin 8 8 0.375 = 0.25 + 0.125 Synergistic 8 
C12 – levofloxacin 8 8 0.375 = 0.25 + 0.125 Synergistic 8 
C12 – ciprofloxacin 8 8 0.375 = 0.25 + 0.125 Synergistic 8 
Combination NP Conc. 
 (nM) 
Antibiotic Conc.  
 (mg/L) 
FICI = FICNP + FICAb Effect Fold increase in 
Antibiotic efficacy 
C10 – levofloxacin 8 64 0.375 = 0.25 + 0.125 Synergistic 8 
C10 – ciprofloxacin 8 64 0.375 = 0.25 + 0.125 Synergistic 8 
C12 – levofloxacin 4 32 0.313 = 0.25 + 0.062 Synergistic 16 
C12 – ciprofloxacin 4 32 0.313 = 0.25 + 0.062 Synergistic 16 
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After establishing synergy obtained from the combination of NPs and antibiotics, we 
probed the effect of different AuNPs on MDR bacteria that could be relevant in establishing 
synergy with antibiotics. We investigated the ability of NPs to act as efflux pump inhibitors, as 
expulsion of antibiotics via efflux pumps is a major contributor to drug resistance in bacteria.29,30 
We used ethidium bromide (EtBr), which is widely used as a substrate for efflux pumps in cells, 
to determine the ability of NPs to act as efflux pump inhibitors.31 We first conducted kinetics 
study using Carbonyl cyanide m-chlorophenyl hydrazine (CCCP) to determine influx and efflux 
of EtBr in bacteria. We observed that at sub-MIC dosages (0.5 × MIC) of CCCP (efflux pump 
inhibitor), accumulation of EtBr inside bacterial cells was significantly increased, as shown by 
the increase in fluorescence in Figure 3.4 a. Subsequently, ability of NPs to accumulate EtBr 
inside cells the bacterial cells was also tested. NPs at sub-MIC concentrations (0.5 × MIC) were 
added to bacterial cells followed by addition of EtBr (4 µg/mL) and the fluorescence kinetics (Ex: 
530 nm and Em: 585 nm) was studied after 30 minutes’ incubation. Carbonyl cyanide m-
chlorophenyl hydrazine (CCCP), a widely-used efflux pump inhibitor, was used as a positive 
control, and untreated cells were used as negative control.32 We observed that hydrophobic NPs 
(C10 and C12) enhanced accumulation of EtBr inside cells similar to that of CCCP (Figure 3.4 b, 
c, d). Whereas, untreated cells showed high efflux of EtBr corresponding to their low 
fluorescence. Notably, less hydrophobic TTMA NPs also showed accumulation of EtBr inside 
cells but it was comparatively lesser than CCCP. Importantly, synergistic interaction of 
hydrophobic NPs as compared to additive interaction of TTMA NPs can be explained due to 
higher ability of hydrophobic NPs to inhibit efflux mediated exclusion in bacterial cells. 
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Figure 3.4. a. Fluorescence kinetics showing influx and efflux of EtBr before and after the 
addition of CCCP (efflux pump inhibitor) in bacteria. Fluorometric kinetics of bacterial cells after 
addition of NPs and CCCP showing increase in fluorescence due to accumulation of ethidium 
bromide inside the cells upon addition of NPs in b. E. coli c. methicillin-resistant S. aureus and d. 
P. aeruginosa. Only bacterial cells are used as negative controls. 
We next investigated the proteomic profiles of the bacterial membrane to further 
understand the effect of NPs on bacteria, since the bacterial membrane acts as the first line of 
defense against foreign attack.33 We used E. coli as model strain for our proteomic studies, due to 
their high relevance in clinical studies. We extracted bacterial membrane protein from untreated 
bacterial cells and cells treated with C-10 and C-12 AuNPs using sarkosyl method, and further 
analyzed them by mass spectrometry.34,35 
We identified two distinct mechanisms underlying the synergy achieved by the addition 
of engineered NPs – (i) deregulation of major efflux pump protein and (ii) downregulation of 
proteins responsible for regulating important cellular processes. The Tolc-AcrAB efflux pumps 
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are major contributors to antibiotic resistance in E. coli species. 36  Upon incubation with 
hydrophobic AuNPs, the expression of tolC is downregulated indicating suppression of efflux 
pumps. Furthermore bamA, bamD, and bamE proteins, crucial for assembly of tolC at bacterial 
outer membrane proteins are strongly deregulated, compromising the detoxification of the cell.37  
 
 
Figure 3.5. a. Proteomic profiles of outer membrane protein expression after treatment with C12 
AuNPs. b. Cell viability of 3T3 fibroblast cells after treatment with C10 and C12 NPs. 
Secondly, we concluded that hydrophobic NPs also interact with multiple proteins to 
disrupt crucial cell-survival processes that can also contribute to enhancing the efficacy of 
antibiotics.  For example, proteins such as kpsD and rfaQ, responsible for export of 
polysaccharides through the outer membrane and biosynthesis of lipopolysaccharides 
(respectively) were downregulated (Figure 3.5 a). 38 , 39  Additionally, Lam B, transporter of 
carbohydrates into cells was downregulated along with Tsx, a nucleoside transporter protein.40 
Furthermore, downregulated proteins such as LamB, OmpC, Tsx, OmpW, and NlpB were 
previously confirmed to contribute to antibiotic resistance in E. coli species.41 
We next investigated the biocompatibility of hydrophobic NPs by performing viability 
assays on mammalian cells. NIH-3T3 fibroblast cells were cultured and treated with AuNPs using 
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previously reported protocols.24 C10 AuNPs showed an IC50 of 560 nM, while more hydrophobic 
C12 AuNP had an IC50 of 300 nM. Additionally, after treatment with 100 nM of AuNPs (C10 and 
C12), NIH-3T3 fibroblast cells showed 80% (for C12) and 90% (for C10) cell viability, 
indicating the low toxicity of these NPs against mammalian cells. The observed specificity of 
NPs for bacterial cells can be attributed to more negatively charged bacterial membrane as 
compared to mammalian cells. Moreover, the cholesterol present on mammalian cells helps 
stabilize the membrane and prevents toxicity from cationic AuNPs.24 
3.3 Conclusions 
We have reported a strategy to use nanoparticles in combination with current antibiotics 
to combat MDR bacteria. We concluded that NP surface chemistry plays a vital role in regulating 
the nature of the interactions possessed by NP-antibiotic combinations for treatment of these 
pathogens. Combining NPs with antibiotics is a new modular approach to the existing 
therapeutics, which could assist in “recycling” currently ineffective antibiotics while 
circumventing the regulatory issues associated with other bioconjugate systems. Additionally, 
further studies by fine-tuning NP surface chemistry and using their combinations with “no more 
effective” antibiotics can unveil to us, novel pathways that have been unexplored in the fight 
against these resistant microbes.   
3.4 Experimental methods 
3.4.1 Ligand synthesis  
Previous synthesis of our thiol-terminated ligands (TTMA, C6 and C10) can be found here.42 
Synthesis of the C-12 quaternary ammonium ligands starts with Trit-C11-Teg-OMs. The 
procedure is the following. 
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Compound X: To a round bottom flask equipped with a stirbar and capable of being pressurized, 
Trit-C11-Teg-OMs (0.6 g, 0.86 mmol) and N, N-dimethyldodecylamine (1.0 g, 4.68 mmol, 5.4 eq) 
were dissolved in tetrahydrofuran (THF, 5 mL) and stirred at reflux . Crude product was checked 
by TLC and THF was evaporated at reduced pressure. The residue was purified by successive 
hexane (4 times) and diethylether:hexane (1:1, 4 times) washings with support of sonication and 
then dried in a high vacuum system. The product formation was quantified, and their structure 
was confirmed by NMR. 
Compound Y: To a round bottom flask equipped with a stirbar, Compound X (0.4 g, 0.44 mmol) 
was dissolved in dry dichloromethane (DCM, 5 mL) and an excess of trifluoroacetic acid (TFA, 
20 equivalents, 1.0 g, 0.67 mL, 8.8 mmol) was added. The color of the solution was turned to 
yellow upon addition of TFA. Then, triisopropylsilane (TIPS, 0.105 g, 0.14 mL, 0.66 mmol, 1.5 
eq) was added to the reaction mixture. The reaction mixture was stirred for 2 hours under N2 at 
room temperature. The solvent and most of the TFA/TIPS were evaporated under reduced 
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pressure. The residue was purified by hexane washings (5 times) and dried in a high vacuum 
system. The product formation was quantitative, and their structure was confirmed by NMR.  
3.4.2 Nanoparticles synthesis 
2 nm diameter gold nanoparticles were synthetized by the Brust-Schiffrin two-phase 
methodology43 using pentanethiol as the stabilizer; these clusters were purified with successive 
extractions with ethanol and acetone. A Murray place exchange reaction44 was carried out in dry 
DCM to functionalize the nanoparticles with each ligand. 45 , 46  The monolayer-protected 
nanoparticles were redispersed in water and the excesses of ligand/pentanethiol were removed by 
dialysis using a 10,000 MWCO snake-skin membrane. The final concentration was measured by 
UV spectroscopy on a Molecular Devices SpectraMax M2 at 506 nm according to the reported 
methodology.47  
3.4.3 Determination of minimum inhibitory concentrations  
MIC is the minimum concentration of an antimicrobial agent that inhibits visible growth of 
bacteria overnight. The MIC of fluoroquinolone antibiotics (ciprofloxacin and levofloxacin), 
CCCP (EPI), and AuNPs for MDR E. coli was determined using a broth microdilution method as 
recommended by the Clinical and Laboratory Standards Institute. E. coli CD-549 was cultured in 
lysogeny broth (LB) medium at 37°C and 275 rpm to stationary phase. The cultured bacteria were 
then harvested by washing and centrifuging cycles with 0.85% sodium chloride solution three 
times. The concentration of bacteria was determined by measuring the optical density at 600 nm. 
Bacterial solution (100 μl) was mixed with 100 μl serially diluted concentrations of antimicrobial 
agent (antibiotics or NPs) in a 96-well plate, yielding a final bacterial concentration of 5×105 
cfu/ml. The bacterial solution without antimicrobial agent was used as a growth control, whereas 
medium alone was used as a sterile control. All the assays were performed in triplicate, and at 
least two independent experiments were repeated on different days.  
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3.4.4 Checkerboard titrations for synergy testing  
To assess possible synergy between antibiotics and NPs, we performed two-dimensional 
checkerboard titrations using a micro-dilution method. In 96-well plates, 2-fold dilutions of 
antibiotics against a range of 2-fold dilutions of NPs were used to determine the MIC of the 
combinations. Antibiotic-NP interaction was determined by calculating the fractional inhibitory 
concentration of antibiotics (FIC Ab) and NPs (FIC NP): 
FICAb = (𝑀𝐼𝐶 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 𝑎𝑛𝑑 𝑁𝑃 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛) ÷ (𝑀𝐼𝐶 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 𝑎𝑙𝑜𝑛𝑒)  
FICNP = (𝑀𝐼𝐶 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑖𝑜𝑡𝑖𝑐 𝑎𝑛𝑑 𝑁𝑃 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛) ÷ (𝑀𝐼𝐶 𝑜𝑓 𝑁𝑃 𝑎𝑙𝑜𝑛𝑒)  
FICIcombination = FICAb + FICNP 
FICAb was plotted against FICNP. A concave curve indicates synergy, whereas a convex 
curve indicates antagonism. Synergy was defined as FICI values ≤0.5, antagonism by FICI 
values >4.0, and additive interaction by FICI values between >0.5 and 4.0.  
3.4.5 Ethidium bromide accumulation assay  
To determine the ability of NPs to act as efflux pump inhibitors, we used a previously reported 
procedure. The E. coli CD-549 strain was grown in LB medium until mid-log phase (OD600 = 0.6). 
Next, bacteria were centrifuged at 16,000 g for 5 min and washed with PBS. OD600 of bacteria 
was adjusted to 0.3. Subsequently, EtBr was added to the final sample at a concentration of 4 
µg/ml followed by addition of CCCP/NPs at ½ MIC concentrations and incubated for 30 minutes. 
Kinetics study of fluorescence obtained was measured using UV/Vis spectrophotometer at 
excitation and emission wavelength of 530 nm and 585 nm (respectively) at 25 °C for 30 minutes. 
Extraction of bacterial outer-membrane proteins. E. coli was grown with ½ MIC of engineered 
NPs in M9 medium for 18 h at 37 ºC. Outer membrane proteins of MDR E. coli were extracted 
following previously reported protocols.34 Briefly, overnight bacterial cultures were centrifuged 
at 10,000 g at 4 º C for 15 min. The bacterial pellet was suspended in 20 ml ice-cold 30 mM Tris 
HCl (pH 7.2) and the suspension was again centrifuged at 10,000 g at 4 º C for 15 min. The pellet 
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was resuspended again in 10 ml ice-cold 30 mM Tris HCl (pH 7.2). The suspended cells were 
disrupted by sonication in ice using a Soniprep sonicator (Misonix S-4000, USA) for 45 seconds 
with intermittent cooling every 45 seconds for a total of 2.5 min. The lysate was centrifuged for 
15 min at 10,000 g at 4 ºC. The membranes were collected by ultracentrifuge (OptimaTM L-
100XP, Beckman, USA) at 50,000 g for 1h at 4 ºC. The obtained OM pellet was suspended in a 
small amount of 30 mM Tris HCl (pH 7.2) and stored at -20 ºC. The concentration of OMPs was 
determined by BCA assay.  
3.4.6. Tryptic digestion and 1D LC-MS/MS analysis  
30 μg of total proteins in 150 μl of 8M urea in 50 mM ammonium bicarbonate were reduced and 
alkylated by adding 2 μl of 0.5M Tris(2-carboxyethyl) phosphine (TCEP) and incubating at 30 °C 
for 60 min. The reaction was cooled to room temperature before alkylation by adding 4 μl of 
0.5M iodoacetamide at room temperature in the dark for 30 min. To dilute the 8M urea to 1M 
before digestion, 430 μl of 50 mM Ammonium Bicarbonate was added. Mass spectrometry-grade 
LysC/Trypsin (Promega) was added (1:20 ratio) for overnight digestion at 30 °C using an 
Eppendorf Thermomixer at 700 rpm. Formic acid was added to the peptide solution (2%), 
followed by desalting by C18 TopTip (Item# TT200C18.96, PolyLC) and finally drying on a 
SpeedVac. Tryptic peptides were re-suspended in 150 μl of 2% Acetonitrile in % 0.1 formic acid 
to bring the concentration to [0.2 μg/μl]. 10 μl of total tryptic peptides (2 μg total) was utilized for 
1D LC-MSMS analysis in triplicate runs by on-line analysis of peptides by high-resolution, high-
accuracy LC-MS/MS, consisting of an EASY-nLC 1000 HPLC Acclaim PepMap peptide trap, a 
50 cm- 2μm Easy-Spray C18 column, Easy Spray Source, and a Q Exactive Plus mass 
spectrometer (all from Thermo Fisher Scientific). A 230-min gradient consisting of 5–16%B (100% 
acetonitrile) in 140 min, 16-28% in 70 min, 28-38% in 10 min, and 38-85% in 10 min was used to 
separate the peptides. The total LC time was 250 min. The Q Exactive Plus is set to scan 
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precursors at 70,000 resolution followed by data-dependent MS/MS at 17,500 resolution of the 
top 12 precursors.  
3.4.7. 2D LC-MS/MS analysis  
Twenty µg total desalted protein digests were reconstituted in 1.5% acetonitrile in 100 mM 
ammonium formate pH ~10. A total of 2.5 μg was then loaded onto a first-dimension column, 
XBridge BEH130 C18 NanoEase (300 μm x 50 mm, 5 μm), using a 2D nanoACQUITY Ultra 
Performance Liquid Chromatography (UPLC) system (Waters corp., Milford, MA) equilibrated 
with solvent A (20 mM ammonium formate pH 10, first dimension pump) at 2 μL/min. The first 
fraction was eluted from the first-dimension column at 17.5% of solvent B (100% acetonitrile) for 
4 min and transferred to the second-dimension Symmetry C18 trap column 0.180 x 20 mm 
(Waters corp., Milford, MA) using a 1:10 dilution with 99.9% second-dimensional pump solvent 
A (0.1% formic acid in water) at 20 μL/min. Peptides were then eluted from the trap column and 
resolved on the analytical C18 BEH130 PicoChip column 0.075 x 100 mm, 1.7 μm particles 
(NewObjective, MA) at low pH by increasing the composition of solvent B (100% acetonitrile) 
from 1 to 6% in 2 min, then to 16% in 80 min, to 26% in 12 min, and finally to 38% in 2 min, all 
at 400 nL/min. Subsequent fractions were carried with increasing concentrations of solvent B. 
The following four first-dimension fractions were eluted at 20, 23, 27, and 60% solvent B. The 
analytical column outlet was directly coupled to an Orbitrap Velos Pro mass spectrometer 
(Thermo Fisher Scientific) operated in positive data-dependent acquisition mode. MS1 spectra 
were measured with a resolution of 60,000, an AGC target of 1e6, and a mass range from 350 to 
1400 m/z. Up to 5 MS2 spectra per duty cycle were triggered, fragmented by collision-induced 
dissociation, and acquired in the ion trap with an AGC target of 1e4, an isolation window of 2.0 
m/z, and a normalized collision energy of 35. Dynamic exclusion was enabled with duration of 20 
sec. 
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3.4.8. Protein Identification and data analysis  
The LC-MSMS raw data were submitted to Integrated Proteomics Pipelines (IP2) Version IP2 v.3 
(Integrated Proteomics Applications, Inc.) with ProLucid algorithm as the search program48 for 
peptide/protein identification. ProLucid search parameters were set up to search the UniProt 
ECOLI.CFT073.ATCC700928.UPEC (vs. October 2015) protein fasta database including 
reversed protein sequences using trypsin for enzyme with the allowance of up to two missed 
cleavages, Semi Tryptic search with fixed modification of 57 Da for cysteines to account for 
carboxyamidomethylation and precursor mass tolerance of 50 ppm. Differential search includes 
16 Da for-methionine oxidation. The search results were viewed, sorted, filtered, and statically 
analyzed using DTASelect for proteins with protein FDR rates ≤2.5.49 Differential label-free 
proteomics data analysis was performed using IP2-Census, Protein Identification STAT 
COMPARE50 with 1D LC-MS/MS in three technical replicates and one technical replicate of 2D 
LC-MS/MS dataset to discover lower-abundance proteins. The result was a label-free 
quantification analysis, with t-test and DAVID Bioinformatics Resources Functional Annotation 
6.7.51 
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CHAPTER 4 
CHARGE-SWITCHABLE NANOZYMES FOR BIOORTHOGONAL IMAGING 
OF BIOFILM-ASSOCIATED INFECTIONS  
4.1 Introduction 
Bacterial infections are serious threat to public health, causing > 2 million cases of 
illnesses and >23,000 deaths each year in U.S.1 The majority of human bacterial infections (~80%) 
are associated with biofilm formation on living tissues.2 Biofilms are three-dimensional bacterial 
communities where microbes reside in an extracellular polymeric substance (EPS) matrix, and are 
highly protected from exogenous agents. Biofilm-associated infections are responsible for a range 
of chronic diseases including endocarditis, osteomyelitis and implant dysfunction, and are key co-
morbity threats for other diseases such as cystic fibrosis.3,4  Currently, biofilm infections are 
typically diagnosed only after they have become systemic or have caused significant anatomical 
damage,5,6 highlighting the need for effective imaging tools. 
Current techniques for imaging bacteria use probes such as autologous white blood cells7, 
maltodextrin8 and dipicolylamine zinc (II).9 Although these systems are effective for imaging 
planktonic (dispersed) bacterial infections, only limited studies have been conducted on imaging 
of biofilm-associated infections. 10 , 11 , 12  Other imaging modalities such as 67Ga-citrate and 
radiolabeled autologous white blood cells lack the spatial resolution required for surgical 
procedures such as debridement of infected tissue.6, 13  Most high resolution optical imaging 
approaches rely on fluorescent dyes conjugated to a biorecognition element, generating highly 
specific imaging probes that are susceptible to false responses due to phenotypic mutations of 
biofilm residing microbes. 14 , 15  Moreover, physical heterogeneity and complex biofilm 
architecture further complicates imaging of these highly refractory infections.16 In particular, the 
dense and amphiphilic nature of EPS matrix prevents the penetration of imaging agents.17,18 
Synthetic macromolecules such as nanoparticles (NPs) have shown potential to penetrate 
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biofilms 19 , however they currently lack the ability to intrinsically target these resilient 
infections.20,21 
Biofilms have inherently acidic microenvironments (pH 4.5-6.5) as a by-product of sugar 
fermentation caused by bacteria.22 For instance, pH in human dental biofilms often reaches below 
4.5 causing acidic dissolution of tooth enamel. 23  Similarly, cystic fibrosis (CF) pulmonary 
infections are associated with acidification of airways in CF patients.24 We hypothesized that pH-
responsive sulfonamide-functionalized gold nanoparticles (AuNPs)25 could be used to target this 
acidic environment. In this system, targeting of the biofilm is achieved through charge-switchable 
NPs that transition from zwitterionic (non-adhesive) to cationic (adhesive) at the pH values 
typically found in biofilms, providing a broad-spectrum recognition platform for bacteria with 
selectivity towards biofilms compared to healthy mammalian cells. Imaging of the biofilms is 
achieved by the embedded transition metal catalysts (TMCs) that activate the pro-fluorophores in 
situ inside the biofilms. These bioorthogonal ‘nanozymes’ provide an effective imaging system 
that selectively targets bacterial biofilms and provides amplified fluorescence signal output using 
bioorthogonal catalysis. This nanozyme platform was used to effectively image biofilms of 
different bacterial species with complete EPS matrix penetration, and to image biofilms in a 
complex mammalian cell - biofilm co-culture model.  
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Figure 4.1. a. Molecular structures of pH-switchable and control ligands on gold nanoparticles 
(AuNPs). b. Schematic representation showing selective targeting of biofilm infections using pH-
responsive nanoparticles and intrabiofilm fluorogenesis of profluorophores by transition metal 
catalysts (TMCs) embedded in the nanoparticle monolayers. 
4.2 Results and discussion 
Sensing was performed with 2nm AuNPs featuring terminal groups with distinct pKa 
values to selectively target the acidic microenvironment of biofilms.25 Alkoxyphenyl 
acylsulfonamide-functionalized NP1 features groups that are protonated under weakly acidic 
conditions (pKa ~ 6.5), consistent with normal biofilm pH. Acylsulfonamide-functionalized  NP2 
has slightly lower pKa (~4.5) than its aryl analog, providing a tool for measuring the lower 
extremes of biofilm pH.Error! Bookmark not defined.  Finally, NP3 features a sulfobetaine t
ermini, providing a stable zwitterionic control for our studies (pKa < 1) (Figure 4.1 a).26,27 These 
particles were synthesized from pentane-thiol capped 2nm core AuNPs using a place exchange 
reaction.   
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The nanozymes were generated through encapsulation of a ruthenium-based catalyst-
[Cp*Ru(cod)Cl] (Cp* = pentamethylcyclopentadienyl, cod = 1,5-cyclooctadiene) into the ligand 
monolayer of NP1-3 to generate the respective nanozymes (NZ1-3).28  Transmission electron 
microscopy (TEM) images and dynamic light scattering data of NPs before and after 
encapsulation of catalysts show no signs of aggregation. Further size distribution studies for NZs 
were conducted at a range of pH (3.5-7.4) using DLS, demonstrating their stability even in the 
acidic conditions (Figure 4.5, Figure 4.6). The quantification of catalysts encapsulated was done 
using inductively coupled plasma mass spectrometry (ICP-MS), indicating that 24 ± 2 catalyst 
molecules were encapsulated per AuNP for NZ1-3. The catalysts encapsulated per AuNP were 
similar at different pH ranges (3.5-7.4), as validated using ICP-MS (Figure 4.7).   
 
Figure 4.2. a. Catalysis of nanozymes with different chemical headgroups in neutral pH for 2 h at 
37 °C. b. ζ-Potential of NZ1−3 (1 μM) measured in the pH range of 3.5−7.4 is plotted against 
different pH values. Error bars represent standard deviations based on three independent 
measurements per pH value. c. Nanoparticle and catalyst diffusion into P. aeruginosa (CD-1006) 
biofilms after incubation for 1 hr in pH 7.4 media with NZ1−3 (400 nM), as measured by ICP-MS. 
d. Confocal images of biofilm incubated with nanozymes (1 h, 400 nM) followed by incubation 
with alloc-Rho (1 h, 100 μM); biofilm control is the negative control in the absence of nanozyme. 
e. Quantitative analysis of fluorescence intensity generated upon addition of different nanozymes. 
The catalytic activities of NZ1-3 were assessed in solution by deallylation of bis-N, N’-
allyloxycarbonyl rhodamine 110 (alloc-Rho, Figure 4.1) at pH = 7.4.29 The rate of increase in 
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fluorescence was similar (Figure 4.2a) for the NZ1-3 complexes, indicating similar catalytic 
activity for all NZs at physiological pH. Further, we tested the catalytic activity of NZ1 with 
varying pH (3.5-7.4), indicating no significant difference in the catalysis rate for the nanozyme 
(Figure 4.8).  
After establishing their catalytic activity in solution, we determined the pH dependence 
of the NZ’s surface charge by measuring their zeta potential. The surface charge of all three NZs 
(1-3) were close to neutral at physiological pH (7.4), consistent with their zwitterionic structures. 
NZ (1-2) exhibited a sharp transition from neutral to overall positive charge at pH 6.5 and pH 4.5 
respectively, consistent with their respective pKa’s. As expected, NZ3 possessed near neutral 
charge even at highly acidic pH values as seen in Figure 4.2b and Figure 4.6. Next, we performed 
NZ diffusion studies in biofilms using ICP-MS to investigate their ability to penetrate and 
accumulate inside biofilms. We observed that switchable NZ1 showed the highest diffusion into 
biofilms based on Au, with lesser amounts observed with NZ2 and NZ3 respectively (Figure 
4.2c). This trend is mirrored in the Ru signal from the catalyst. This overall change to cationic 
surface charge of the pH-responsive NZs can play a crucial role in their ability to intrinsically 
target biofilms over the mammalian cells (Figure 4.9). 
We then investigated the ability of NZs to image biofilms using confocal microscopy. We 
chose uropathogenic clinical isolate of P. aeruginosa (CD-1006) as a model strain for imaging 
studies due to their high prevalence in clinical biofilms.30,31 Imaging studies of biofilms were 
based on generation of fluorophore (Rhodamine 110) through deallylation of a non-fluorescent 
precursor as shown in Figure 4.1b. Catalytic activity of the NZs was probed inside the biofilms by 
incubating the NZs with biofilms for 1 h, followed by multiple washings to remove absorbed 
particles. Fresh media containing substrate was added following 1 h incubation and subsequent 
washings. Confocal images of biofilms treated with switchable NZ1 exhibited bright fluorescence, 
with only localized fluorescence observed with NZ2, and little or no fluorescence beyond auto 
fluorescence observed with NZ3, results mirrored in the quantified intensities (Figure 4.2 d, e). 
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These results suggest that pH responsive zwitterionic nanozyme NZ1 can be used to target the 
biofilms for imaging applications. 
 
Figure 4.3. a. Confocal microscopy images of DS Red exp E. coli and activated Rhodamine 110 
fluorophore in the presence of NZ1. Composite images show homogeneous colocalization of 
biofilm and activated fluorophores. The panels are projections at 0, 45, and 90° angle turning 
along the Y-axis. The scale bars are 20 μm. b. Integrated intensity of Rhodamine 110 and DS Red 
biofilm after 1 h incubation with NZ1. The x-axis is the depth of penetration of biofilms, where 0 
μm represents the top layer and ∼5.6 μm the bottom layer. The y-axis, normalized fluorescence, 
is normalized intensity of red and green channels at the top layer to compare their localization. c. 
Cell viability of 3T3 fibroblast cells after 24 h incubation with NZ1−3 (0.1−2 μM). The data are 
average of triplicates, and the error bars indicate standard deviations. 
Z-stack confocal imaging was used to determine the localization of activated 
fluorophores inside DS Red (red fluorescent protein) expressing E. coli biofilms (Figure 4.3a). 
The penetration profile of NZ1 was quantified by using NIS element analysis software.32 The 
intensity of green and red channel represents the intensity of Rhodamine-110 and biofilms 
respectively. The integrated intensities were normalized at the top layer of biofilm to compare 
their co-localization with varying biofilm depth (0-5.6 µm). As shown in Figure 4.3b, the 
activated fluorophore (Rhodamine 110) was distributed throughout the biofilm. Biofilms 
incubated without NZ1 were used as negative control. The ability of switchable NZ1 to image 
bacterial biofilms was further validated against three bacterial strains of clinical isolates - 
Enterobacter cloacae (CD-1412), methicillin-resistant Staphylococcus aureus (CD-489) and 
Escherichia coli (CD-2), demonstrating effective imaging of biofilms formed by both Gram 
positive (S. aureus) and Gram negative (E. coli, P. aeruginosa, E. cloacae) (Figure 4.10) species. 
Further, we tested the cytotoxicity of these NZs against NIH 3T3 Fibroblast-cells that maintain 
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high cell viability at 2 µM NZ incubation (Figure 4.3c). These studies indicate the 
biocompatibility of our zwitterionic nanozymes with mammalian cells. 
 
Figure 4.4. Confocal images of a fibroblast-DS Red E. coli biofilm coculture model incubated 
with switchable nanozyme NZ1 (400 nM) and alloc-rhodamine (nonfluorescent, 100 μM) for 1 h. 
a. DS Red, b. Rhodamine 110, and c. merged channels. d. Quantitative analysis of fluorescence 
intensity observed in the images of noninfected cells (cells only) and cells infected with biofilm 
(coculture). Scale bar is 20 μm. 
Imaging of biofilms on biomedical surfaces such as medical implants and indwelling 
devices is a critical capability. However, tracking biofilm-associated infections on human tissues 
and organs is even more challenging and relevant for medical applications. In most cases of 
bacterial infections, microbes are embedded in human tissues inside resilient biofilms comprised 
of EPS.33 Having established that pH responsive NZ1 exhibits the highest selectivity towards 
biofilms and are non-toxic to fibroblast cells, we next investigated their ability to track biofilms, 
using fibroblast-biofilm co-culture as a model. We chose DS Red (red fluorescent protein) 
expressing E. coli as representative strain to generate co-culture model using previously 
established protocols.34,35,36 Co-cultures were then incubated with NZ1 for 1 hour, followed by 
multiple washings to remove non-adhering NZs. Subsequently, substrate alloc-Rho was added in 
fresh media for 1 hour, followed by multiple washing to remove excess substrate. The co-culture 
models were examined using confocal microscopy, exhibiting strong co-localization of 
Rhodamine and DS Red (from biofilm) and minimal fluorescence around mammalian cells 
(Figure 4.4, procedure to analyze image intensity is described in section 4.5, Figure 4.11). The 
co-cultures incubated with alloc-Rho in absence of NZ1 was used as negative control. This high 
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level of selectivity demonstrates the potential of switchable NZs to image bacterial biofilms in 
physiologically relevant conditions. Their ability to selectively target the biofilms can be 
attributed to the overall change in their surface charge (from neutral to cationic) at acidic 
conditions. The positively charged NZ1 shows high accumulation inside the biofilm, whereas the 
neutral charged NZ1 exhibits minimal uptake in fibroblast cells. Hence, the pro-fluorophore gets 
selectively activated in the biofilm, already inhabited by the charge switchable nanozyme.   
4.3 Conclusions 
In conclusion, we have developed a strategy for rapid and effective imaging of biofilms 
that was effective in a complex co-culture model.  The pH-responsive NPs penetrate and 
accumulate inside the acidic microenvironment of biofilms, with bioorthogonal catalysis 
providing a sensitive readout mechanism. This bioorthogonal activation of imaging agents is a 
promising approach to detect biofilm-associated infections, and to locate infected sites during 
critical debridement surgeries. These pH responsive nanozymes offer a broad-spectrum strategy 
for imaging biofilms arising from different and/or mixed bacteria species, circumventing the need 
for designing microbe-specific probes. Considering their enhanced ability to penetrate the biofilm 
matrix, nanozymes hold a strong advantage against currently used imaging probes. In a broader 
context, this study demonstrates the utility of bioorthogonal catalysis for bioimaging. 
4.4 Experimental methods 
4.4.1 Synthesis of gold nanoparticles  
Ligands were synthesized using previously reported procedure.25,37 AuNPs was prepared through 
place-exchange reaction of 1-pentanethiolprotected 2 nm gold nanoparticle (Au-C5) according to 
previously reported procedure.38 Briefly, to the solution of Au-C5 (10 mg) in CH2Cl2 (1 mL) was 
added the solution of ligand 1 (30 mg) in CH2Cl2: MeOH (4:1, 3 mL). After being stirred at rt for 
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24 h, the solvent was evaporated in vacuo. After nanoparticle residue was washed with EtOAc 
(10 mL × 3), the nanoparticle was immediately dissolved in MilliQ water and the aqueous 
solution of the nanoparticle was purified by dialysis with distilled water using SnakeSkinTM 
Dialysis Tubing (Thermo Scientific, 10,000 MWCO). 
4.4.2 Catalyst encapsulation in AuNP monolayer  
The catalyst, [Cp*Ru(cod)Cl]  (3.0 mg) was dissolved in 1 ml acetone and the AuNP (20 µM, 0.5 
mL) were diluted to a final concentration of 5 µM with DI water (1 ml). Then, the catalyst and the 
AuNP solutions were mixed together and acetone was slowly removed by evaporation. During 
the evaporation, hydrophobic catalyst was encapsulated in the particle monolayer to yield to 
NP_Ru. Excess catalysts which precipitated in water were removed by filtration (Millex-GP filter; 
25 mm PES, pore Size: 0.22 µm) and dialysis (Snake Skin® dialysis tubing, 10K) against water (5 
L) for 24 h. Further purifications were followed by multiple filtrations (five times, Amicon® ultra 
4, 10K) to remove free catalysts. The amount of encapsulated catalysts was measured by ICP-MS 
by tracking 101Ru relative to 197Au for NP_Ru. 
4.4.3 Nanozyme kinetics in solution  
Allylcarbamate protected Rhodamine 110 (alloc-Rho) was used as a substrate to test the catalytic 
activity of the nanozymes. A solution containing 100 nM nanozyme and 1 µM substrate was 
prepared in a 96-well plate. 400 nM nanozyme solution and 100 nM substrate solutions alone 
were used as negative controls. The kinetic study was done by tracking the fluorescence intensity 
(Ex: 488 nm, Em: 521 nm, Cutoff: 515 nm) using a Molecular Devices SpectraMax M2 
microplate reader. 
4.4.4 Biofilm culture  
Bacteria were inoculated in LB broth at 37°C until stationary phase. The cultures were then 
harvested by centrifugation and washed with 0.85% sodium chloride solution three times. 
Concentrations of resuspended bacterial solution were determined by optical density measured at 
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600 nm. Seeding solutions were then made in minimal media, M9 broth to reach OD600 of 0.1. 
500 µL of the seeding solutions were added to each well of the 24-well microplate. M9 medium 
without bacteria was used as a negative control. The plates were covered and incubated at room 
temperature under static conditions for a desired period of 24 hours. Planktonic bacteria were 
removed by washing with PB saline three times.  
4.4.5 Diffusion of nanozymes inside biofilms  
After plating bacterial cells in a 24-well plate. On the following day, planktonic bacteria were 
removed by washing with PBS three times. and incubated with NZ 1, NZ 2 and NZ 3 (400 nM 
each) in minimal M-9 media (pH 7.4) for 3 h at 37 °C. After incubation, biofilms were washed 
three times with PBS and lysis buffer was added to each well. All lysed samples were then further 
processed for ICP-MS analysis (vide infra) to determine the intracellular amount of gold and 
ruthenium. Diffusion experiments were performed independently at least two times and each 
experiment was comprised of three replicates.  
4.4.6 Confocal imaging of biofilms  
108 bacterial cells/ml were seeded (2 ml in M9 media) in a confocal dish and were allowed to 
grow, old media was replaced every 24 hours. After 3 days media was replaced by 400 nM of the 
NZ 1, NZ 2 and NZ 3 and biofilms were incubated for 1 h, biofilm samples incubated with only 
M9 media were used as control. After 1 h, biofilms were washed with PBS three times and were 
incubated with 100 µM of the substrates for 1 h. The cells were then washed with PBS three 
times. Confocal microscopy images were obtained on a Zeiss LSM 510 Meta microscope by 
using a 60× objective. The settings of the confocal microscope were as follows: green channel: 
λex=488 nm and λem=BP 505-530 nm; red channel: λex=543 nm and λem=LP 650 nm. Emission 
filters: BP=band pass, LP=high pass. 
4.4.7 Mammalian cell viability studies  
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These experiments were done using previously reported protocol.39 Briefly, 20,000 NIH 3T3 
fibroblast cells (ATCC CRL-1658) were cultured in DMEM medium in presence of 10% bovine 
calf serum and 1% antibiotic solution. The cells were cultured at 37 °C in a humidified 
atmosphere of 5% CO2 for 48 h. Next, the cells were washed with phosphate-buffered saline 
(PBS) and different concentration of NZs (1-3) in 10% serum containing media were incubated 
with the cells for 3 h at 37 °C. After the incubation period, cells were washed with PBS (3 times) 
and cell viability was then determined using Alamar blue assays according to manufacturer’s 
protocol (Invitrogen Biosource). Washed cells were incubated with 220 μl of 10% Alamar Blue 
solution in 10% serum containing media. The solution was incubated at 37 °C under a humidified 
atmosphere of 5% CO2 for 3 h. Subsequently, 200 μl solution from the wells was transferred in a 
96-well black-microplate. The fluorescence reading was measured using a UV/vis 
spectrophotometer with excitation and emission at 560 and 590 nm respectively. Cell incubated 
without NPs were treated as 100% viable cells and the cell viability was calculated accordingly. 
These experiments were performed in triplicates. 
4.4.8 Imaging of co-culture models  
Fibroblast-3T3 co-culture was performed using a previously reported protocol.36 A total of 20,000 
NIH 3T3 (ATCC CRL-1658) cells were cultured in Dulbecco's modified Eagle medium (DMEM; 
ATCC 30-2002) with 10% bovine calf serum and 1% antibiotics at 37°C in a humidified 
atmosphere of 5% CO2. Cells were kept for 24 hours to reach a confluent monolayer in a confocal 
dish. Bacteria (P. aeruginosa) were inoculated and harvested as mentioned above. Afterwards, 
seeding solutions 108 cells/ml were inoculated in buffered DMEM supplemented with glucose. 
Old media was removed from 3T3 cells followed by addition of 2 mL of seeding solution. The 
co-cultures were then stored in a box humidified with damp paper towels at 37°C overnight 
without shaking. The co-cultures were treated with NZs and substrates using similar procedure 
used for biofilm models. 
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4.5 Supplementary information 
4.5.1. Stability of NZs at different pH values  
Hydrodynamic diameter of the NZs at different pH were measured by dynamic light scattering 
(DLS) in 5mM Phosphate buffer (pH 5.5-7.4) and 5mM Citrate buffer (pH 3.5-4.5) using a 
Malvern Zetasizer Nano ZS instrument. The NZs (1 µM) were incubated in the respective buffers 
for 3 hours before each measurement. No significant changes in the NZ size were observed. The 
size distribution by number are presented in the Figure 4.5. 
  
Figure 4.5. DLS measurements of NZs after 3-hour incubation in buffers with varying pH (3.5-
7.4) indicate that NZ size remains same even at acidic conditions. 
4.5.2. Zeta potential of NZs at different pH values  
Zeta potential of the NZs at different pH were measured by dynamic light scattering (DLS) in 
5mM Phosphate buffer (pH 5.5-7.4) and 5mM Citrate buffer (pH 3.5-4.5) using a Malvern 
Zetasizer Nano ZS instrument. The NZs (1 µM) were incubated in the respective buffers for 3 
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hours before each measurement. The zeta potential measured at different pH are presented below 
in the Figure 4.6. 
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Figure 4.6. Zeta potential of NZs at different pH values, indicating overall change in surface 
charge of NZ1 and NZ2 at pH 6.5 and 4.5 respectively. NZ3 remains neutral in charge throughout 
the pH range. 
4.5.3. Quantification of Au and Ru using ICP-MS characterization  
ICP-MS analyses were performed on a Perkin-Elmer NexION 300X ICP mass spectrometer to 
quanify 197Au and 101Ru. Operating conditions are listed as below: nebulizer flow rate: 0.95 L/min; 
rf power: 1600 W; plasma Ar flow rate: 18 L/min; dwell time: 50 ms. A series of solutions with 
gold and ruthenium (concentration: 0, 0.2, 0.5, 1, 2, 5, 10, and 20 ppb) were prepared for 
calibration. Nanozyme solutions were diluted in water to 200 nM. 10 μL sample solution was 
transferred to 15 mL centrifuge tubes. 0.5 mL of fresh aqua regia was added to each sample 
including the standard samples and was diluted to 10 mL with de-ionized water.  
Sample Preparation: was added to the 10 μL sample solution and then the sample was 
diluted to 10 mL with de-ionized water. 
 
Figure 4.7. Ruthenium amount in the nanozymes using ICP-MS measurement. The Catalyst/NP 
represents number of Ruthenium catalysts encapsulated per gold nanoparticle. 
4.5.4. Nanozyme catalysis in solution at different pH  
Allylcarbamate protected Rhodamine 110 (alloc-Rho) was used as a substrate to test the catalytic 
activity of the nanozymes. A solution containing 400 nM nanozyme and 100 µM substrate was 
prepared in a 96-well plate using buffers with varying pH (3.5-7.4). 400 nM nanozyme solution 
and 100 µM substrate solutions alone were used as negative controls. The kinetic study was done 
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by tracking the fluorescence intensity (Ex: 488 nm, Em: 521 nm, Cutoff: 515 nm) using a 
Molecular Devices SpectraMax M2 microplate reader as shown in Figure 4.8. 5 mM Phosphate 
buffer were used for pH range (5.5-7.5) and 5mM Citrate buffer for pH range (3.5-4.5). 
 
Figure 4.8. Catalysis of NZ1 at different pH for 2 hours at 37 ºC. 
4.5.5. Cellular uptake of NZs in 3T3 Fibroblast cells  
The cellular uptake experiments were done using previously approved protocols. 30K Fibrobast 
cell/well were plated in a 24-well plate prior to the experiment. Next day, the cells were washed 
with PBS and incubated with NZ1 (1 μM) in 10% serum-containing media for 3h at 37 °C. 
Subsequently, the cells were washed with PBS (3 times) and then subjected to lysis buffer. The 
lysed cells were then further processed for ICP-MS analysis as shown in Figure 4.9. These 
experiments were performed independently two times and each experiment was comprised of 3 
replicates.  
4.5.6. Sample preparation for ICP-MS and ICP-MS instrumentation  
Samples were prepared using previously reported protocols. The cells were lysed by a lysis buffer 
and were transferred to 15 mL centrifuge tubes. A series of standard solutions of gold and 
ruthenium (0, 0.2, 0.5, 1, 2, 5, 10, and 20 ppb) were prepared for calibration. 0.5 mL of fresh 
aqua regia were added to each sample including the standard samples and were diluted to 10 mL 
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with de-ionized water. 197Au and 101Ru quantification were done on a Perkin-Elmer NexION 
300X ICP mass spectrometer under standard mode. Operating conditions are listed as below: 
nebulizer flow rate: 0.95-1 L/min; rf power: 1600 W; plasma Ar flow rate: 18 L/min; dwell time: 
50 ms. 
 
              
Figure 4.9. Nanoparticle and catalyst uptake in P. aeruginosa (CD-1006) biofilms and NIH-3T3 
Fibroblast cells after incubation for 1 hour in pH 7.4 (cell culture media with 10% serum) with 
NZ1 (400 nM), as measured by ICP-MS. 
4.5.7. Confocal imaging of 4 different strains  
We used the same procedure for imaging biofilms as described in the materials and methods 
section of the manuscript in Figure 4.10.  
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Figure 4.10. Confocal microscopy images of a. CD-489 (S. aureus, a methicillin resistant strain), 
b. CD-1006 (P. aeruginosa), c. CD-2 (E. coli) and d. CD-1412 (En. cloacae) treated with 
nanozymes (NZ1) and pro-rhodamine. The panels are projections at 0º and 90º angle turning 
along Y-axis. The scale bars are 20 µm. e) Integrated intensity of Rhodamine 110 after 1-hour 
incubation with NZ1. The x-axis is the depth of penetration of biofilms, where 0 µm represents 
the top layer. The y-axis is the integrated intensity of the fluorescence resulted from the 
deprotection of Alloc-Rho. 
4.5.8. Data analysis of confocal images  
The data analysis of the confocal images was done using the previously reported procedure.40,41 
Briefly, confocal images obtained were analyzed using ImageJ software. After opening the file in 
ImageJ, the site of interest was selected using drawing selection tool (rectangle). Next, from the 
analyze menu, “set measurements” was selected for determining Area, Integrated density and 
mean grey value. To obtain final cell/biofilm fluorescence, the following formula was used -:  
CTCF = Integrated Density – (Area of selected location × Mean fluorescence of 
background readings)  
An example for the data points obtained for image analysis can be explained using Figure 
S7. Box 1 represents the background, box 2 represents the site for cells only and box 3 represents 
biofilm-mammalian cell coculture in Figure 4.11. The fluorescence calculated for cells only and 
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biofilms was done by selecting 50 similar data points and averaging the results obtained for all 
them.  
 
Figure 4.11. Image showing an example of sites used for image analysis of biofilm-mammalian 
cell co-culture models. Box 1, 2, 3 represents background, cells only and biofilm-cells 
respectively. 
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CHAPTER 5 
RBC-MEDIATED DELIVERY OF BIOORTHOGONAL NANOZYMES FOR 
SELECTIVE TARGETING OF BACTERIAL INFECTIONS 
5.1 Introduction 
Bioorthogonal catalysis offers a strategy for chemical transformations complementary to 
bioprocesses and has proven to be a powerful tool in biochemistry and medical sciences.1, 2 
Nanoparticles embedded with transition metal catalysts (nanozymes) have demonstrated excellent 
ability to catalyze reactions beyond the capabilities of biological systems.3,4 Nanozymes can 
implement bioorthogonal approach to chemically transform a biologically inert substrate to its 
active form at the site of interest. 5  Localization of bio-orthogonal nanozymes at targeted 
biological site is central in maximizing the efficacy of the strategy.6,7 For example, selective 
activation of pro-antimicrobials at the infected tissue can kill disease-causing pathogens while 
causing minimal harm to the beneficial human microbiome. 
   One approach to control spatiotemporal localization of biorthogonal catalysts 
utilizes tuning the size of carrier.8,9 Alternatively, biorthogonal catalysts can be functionalized 
with different ligands, peptides or biomolecules to target the diseased physiological site.10,11,12 
However, these synthetic carrier-based approaches are susceptible to non-specific uptake and 
potential degradation of vehicles in macrophages, compromising the efficacy of therapy.13 
 Red blood cells (RBCs) have been used as cell-based drug delivery systems 
owing to their biocompatibility, long circulation time and low immunogenicity.14,15 RBCs are 
significantly hemolyzed by bacterial toxins, providing these RBC carriers with intrinsic targeting 
ability towards pathogenic bacteria.16,17 Moreover, high surface to volume ratio of RBCs provides 
an ideal surface for hitchhiking of nanoparticles through supramolecular interactions with RBC 
cell surface.18  Recent studies have demonstrated that RBC-hitchhiking of NPs enhanced the 
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delivery efficacy to the target organs with minimal non-specific uptake by the reticuloendothelial 
system.19,20  
 Notably, maintaining the stability of RBC membranes is critical in retaining the 
biocompatibility and immune-evading ability of NP-hitchhiked RBCs.21 Surface functionality of 
NPs dictates their interaction with RBCs and is key to generate RBC “super-carriers” as effective 
drug delivery systems.22 For example, cationic NPs can bind to the anionic glycocalyx on RBC 
cell surface. Whereas, NPs can also bind to hydrophobic domains present on RBC’s plasma 
membranes irrespective of NP surface charge.23 Moreover, tuning hydrophilic and hydrophobic 
moieties on NP-surface can significantly impact the hemolysis caused by NPs.   
We hypothesized that integration of “super-carrier” RBCs with bioorthogonal nanozymes 
would offer a novel route to combat bacterial infections while minimizing the possible off-target 
effects. Here, we have designed a series of nanozymes that feature diverse functional groups with 
different binding ability to RBCs. The structure-activity studies revealed that hydrophilic cationic 
NZs can effectively hitchhike onto RBC surface without compromising the stability of RBC 
plasma membrane. Subsequently, these NZs can detach from RBCs upon hemolysis by bacterial 
toxins and accumulate at the site of bacterial infection. These NZs could activate protected-
antibiotic molecules and effectively eradicate biofilms formed by uropathogenic bacteria, 
whereas minimal toxicity was observed against non-virulent bacterial strains. Moreover, RBC-
NZs showed minimal uptake in macrophage cells as opposed to free nanozymes, suggesting that 
nanozyme hitchhiking does not compromise the immune-evading ability of RBCs. Overall, we 
have generated RBC-hitchhiked nanozymes illustrating the ability of passively targeting bacterial 
infections triggered by bacterial toxins while minimizing non-selective killing of bacteria. This 
strategy can be further explored to activate multiple therapeutic molecules at the targeted site to 
combat complex infections and promote healing of the surrounding tissue simultaneously. 
 76 
 
5.2 Results and discussion 
 
Figure 5.1. a. Molecular structures of the ligand structures used on nanozymes used in the RBC-
adsorption study. b.  Structures of the substrates Resorufin and moxicillin derivative (Pro-Res, 
Pro-Mox) and products (Resorufin, Moxifloxacin) after cleavage by TMC c. Schematic 
representation showing hitchhiking of NZs on Red Blood Cells, selective targeting of biofilms 
infections due to lysis of RBCs in presence of bacterial toxins and intrabiofilm generation of 
antibiotics by transition metal catalysts (TMCs) embedded in the nanoparticle monolayers.   
AuNPs with ~ 2 nm core diameter were functionalized with ligands featuring three main 
components: (1) a hydrophobic alkyl chain interior enabling encapsulation of hydrophobic 
catalysts, (2) tetra ethylene glycol spacer providing biocompatibility and (3) terminal groups 
dictating NP-binding with Red Blood Cells.3,22 Nanozymes (NZs) were generated by 
encapsulation of iron (III) tetraphenyl porphyrin (FeTPP) catalyst in the surface monolayer of 
AuNPs. The chemical functionality of NZ-surface ligands plays a critical role in determining their 
compatibility with RBCs, in-turn dictating ability of NZs to hitchhike on RBC surface.23 We 
synthesized a family of NZs with varying surface charge, hydrophobicity and aromatic properties 
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and studied their compatibility and binding with RBCs. NPs (1-9) were synthesized by ligand 
place exchange reactions with pentanethiol-capped 2 nm Au core. Next, these NPs were 
encapsulated with FeTTP catalysts to generate NZ (1-9) (Figure 5.1).          
Our initial focus was to adsorb NZs on RBCs without compromising the stability of cell 
membrane, hence we screened the library of NZs for hemolytic activity against RBCs. NZs (1-9) 
were incubated with RBCs for 30 minutes and the absorbance of released hemoglobin was 
measured at 570 nm.24 We observed that cationic hydrophilic NZs (NZ 1-2) showed minimal 
hemolysis as compared to their hydrophobic counterparts. Similarly, anionic and zwitterionic 
NZs (NZ 7-9) showed minimal hemolysis of RBCs (Figure 5.2 a), consistent with previously 
reported studies. Next, we studied the adsorption of non-hemolytic NZs (NZ1-2, NZ7-9) on 
RBCs to determine their suitability for RBC-hitchhiking. NZs were incubated with RBCs for 30 
minutes and washed to remove excess NZs. The harvested RBCs were then analyzed using 
inductively coupled mass spectrometry (ICP-MS) to quantify gold content on the cells. Cationic 
NZs showed significant adsorption on RBCs as compared to the anionic and zwitterionic NZs 
(Figure 5.2 b), attributing to electrostatic interaction between NZs and RBCs. 
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Figure 5.2. a. Dose-dependent hemolytic activity of NZ 1–NZ 9 in the absence of plasma 
proteins. % hemolysis was calculated using water as the positive control. Error bars represent 
standard deviations (n = 3). Amount of NZ adsorption on Red Blood Cells after b. incubation for 
30 minutes c. after multiple cycles of centrifugation, at a concentration of 500 nM, as measured 
using ICP-MS. Dose dependent d. hemolytic activity of NZ 1 for 107 Red Blood Cell/mL, e. NZ 
adsorption for NZ 1 for 107 Red Blood Cell/mL. f. Catalysis of free nanozymes and RBC-NZs in 
PBS for 1 h at 37 °C. 
Nanoparticles can frequently detach from RBCs due to shear force and are subsequently 
recognized by the reticuloendothelial system.18 Hence, we further investigated the stability of 
NZs hitchhiked on RBCs (RBC-NZ) by subjecting these RBC-NZs to multiple washing and 
centrifuging cycles. No significant difference in Au content was observed even after 5 
centrifuging cycles, indicating that NZs remain attached to RBCs (Figure 5.2c). Hemolysis and 
adsorption studies of TTMA with RBCs were further studied at reduced incubation time of 30 
minutes (Figure 5.2 d,e).                
   The catalytic activity of RBC-NZs was assessed by fluorometric measurement of 
resorufin molecule fragmented from the non-fluorescent pro-Res (Figure 5.1 b) due to azide 
reduction by FeTTP catalyst. Linear increase in the fluorescence indicate that NZs retain their 
catalytic activity even after adsorption on RBCs (Figure 5.2 f). However, the rate of fluorescence 
increase was higher for free NZs as compared to RBC-NZs that can be attributed to 
conformational restrictions of NZs adsorbed on RBCs. 
Infections caused by bacteria often involve secretion of pore-forming toxins (PFTs) as a 
virulence mechanism. 25  These toxins disrupt the host-cell membrane for pathogenesis, in 
particular causing high hemolysis of RBCs.26  Next, we investigated the hemolysis of RBCs 
caused by uropathogenic clinical isolates (E. coli, methicillin-resistant S. aureus (MRSA)) and 
non-pathogenic laboratory strains (P. aeruginosa, B. sub). We observed that uropathogenic 
strains caused complete hemolysis of the RBCs within 30 minutes of incubation with RBCs, 
whereas the non-pathogenic strains caused minimal hemolysis of RBCs even after incubation 
(Figure 5.3a). Having established that cationic hydrophilic NZs can hitchhike onto RBCs and 
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these RBCs were hemolyzed in presence of bacterial infections. We set out to determine whether 
hemolysis of RBCs could result in detachment of NZs from RBC-surface and enhance the 
accumulation of NZs at the site of bacterial infection.27 We evaluated the amount of Au on the 
surface of hemolyzed RBCs and non-hemolyzed RBCs using ICP-MS. It was determined that 
NZs were subsequently released into the solution upon hemolysis of RBCs, whereas NZs 
remained attached to cell-surface in case of non-hemolyzed RBCs (Figure 5.3 b). This 
phenomenon could be attributed to compromised electrostatic interaction between NZs and RBCs 
upon lysis of cells. Next, we tested the accumulation of NZs using ICP-MS in uropathogenic and 
non-pathogenic biofilms. We observed that RBC-NZs showed high accumulation in toxin-
secreting uropathogenic bacterial biofilms based on Au, whereas minimal amount of Au was 
observed in non-virulent bacterial biofilms (Figure 5.3 c). Similarly, only NZs (bare-NZ) showed 
high uptake in macrophages whereas RBC-NZs showed minimal uptake as quantified by ICP-MS. 
These results indicate that hitchhiking of RBCs can play a crucial role in selectively targeting 
pathogenic infections over docile bacteria as well avoid non-specific uptake in macrophages. 
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Figure 5.3. a. Hemolysis of Red Blood Cells by bacterial biofilms. b. Quantification of Au 
(ng/well) on RBCs-nanozymes incubated in PBS and Triton-X. c. Nanozyme diffusion of Au 
(ng/well) in different bacterial biofilms including pathogenic (methicillin-resistant S. aureus, 
MRSA and E. coli) and non-virulent (P. aeruginosa ATCC 17660, B. Sub FD6b) biofilms after 
incubation for 1 day with RBC-NZ (107 cell/mL, 100 nM NZ), as measured by ICP-MS. Cellular 
uptake of Au (ng/well) in macrophage (RAW 264.7) (20,000 cells/well) after incubation for 1 day 
with RBC-NZ (107 cell/mL, 100 nM NZ), as measured by ICP-MS. d. Confocal images of 
biofilms incubated with RBC-NZs (1 h) followed by incubation with Pro-Res (1 h, 10 μM). 
We further corroborated the selectivity of RBC-NZs towards virulent biofilms through 
imaging studies using confocal microscopy. Studied for imaging biofilms were based on 
generation of fluorophore (Resorufin) through aryl-reduction of non-fluorescent precursor (Pro-
Res) as shown in Figure 5.1 b. RBC-NZs were incubated with toxin-secreting uropathogenic (E. 
coli, MRSA) and non-virulent (B. sub, P. aeruginosa) bacterial biofilms for 24 hours. Biofilms 
were then washed multiple times, followed by 1-hour incubation with substrate and subsequent 
washings. Uropathogenic biofilms showed bright red fluorescence when observed under confocal, 
with minimal fluorescence observed in non-pathogenic biofilms (Figure 5.3 d). Additionally, 
macrophages incubated with RBC-NZs exhibited minimal fluorescence after 24 hours incubation. 
These results further suggest that RBC-hitchhiking can be used to selectively target pathogenic 
biofilms while avoiding non-specific uptake by macrophages. 
Conventional antibiotic-based strategies to combat bacterial infections often disrupt the 
ecology of human microbiome by killing helpful bacteria species inhabiting the host.28,29 After 
establishing the localization of NZs at the site of pathogenic bacteria, we investigated their ability 
to selectively activate antibiotic-precursor to eradicate virulent bacterial biofilms. For this study, 
aryl azide protected moxifloxacin (pro-Mox) was chosen as a model pro-antibiotic due to the high 
clinical relevance of moxifloxacin in the treatment of MDR infections.30 The synthetic protection 
of secondary amine group on moxifloxacin inhibits them to bind with target bacterial enzymes, 
inhibiting their antimicrobial activity prior to activation. Alamar Blue assays were performed on 
biofilms treated with RBC-NZs and pro-Mox determine biofilm viability.   
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Figure 5.4. Deprotection of antimicrobials in biofilms using RBC-hitchhiked nanozymes. RBC-
NZ was used for selective activation of antibiotic prodrugs that decrease biofilms viability. a. E. 
coli (toxin producing) biofilms and b. B. sub (non-virulent) biofilms treated with pro-Mox and 
RBC-NZ (red bars) at 37 oC. Biofilms treated only with pro-Mox (blue bars) or with Mox (grey 
bars) were used in all experiments as negative and positive controls, respectively. Each 
experiment was replicated five times. Error bars represent standard deviations of these 
measurements. 
For biofilm viability studies, virulent uropathogenic (E. coli, MRSA) and non-pathogenic 
bacterial strains (B. sub) were incubated with RBC-NZs (107 cells/ml, 500 nM-NZ) for 24 hours, 
washed and subsequently incubated with different concentrations of pro-Mox for 24 hours. Cells 
incubated with only pro-Mox and Moxifloxacin antibiotics were used as negative and positive 
controls respectively. It was observed that pro-Mox did not reduce biofilm viability against both 
pathogenic and non-pathogenic biofilms. However, pro-Mox incubated with RBC-NZs showed 
reduced biofilm viability of pathogenic biofilms while no significant antimicrobial activity was 
observed against non-pathogenic biofilms. These results indicate that selective accumulation of 
NZs in pathogenic biofilms enabled catalytic activation of pro-antibiotics thereby increasing the 
specificity of the therapy. Moreover, moxifloxacin reduced bacterial viability of both pathogenic 
and non-pathogenic species, indicating the non-selective bacteria killing caused by antibiotic 
treatment. 
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5.3 Conclusions 
In this chapter, I have investigated a strategy utilizing hitchhiking of functionalized 
bioorthogonal nanozymes on Red Blood Cells. These RBCs are hemolyzed in presence of toxins 
secreted by pathogenic bacteria resulting in selective accumulation of nanozymes at the site of 
bacterial infection. These accumulated nanozymes can subsequently activate antibiotics at the site 
and eradicate pre-formed biofilms, without harming non-virulent bacterial species. Moreover, 
RBC-hitchhiked nanozymes show minimal uptake in macrophages. This strategy can be utilized 
to increase the specificity of nanomaterial-based strategies while minimizing the off target effects 
of the current antimicrobial therapies.    
5.4 Experimental methods 
5.4.1. NP synthesis  
2nm diameter gold nanoparticles were synthetized by the Brust-Schiffrin two-phase methodology 
using pentanethiol as the stabilizer; these clusters were purified with successive extractions with 
ethanol and acetone. A Murray place exchange reaction was carried out in dry DCM to 
functionalize the nanoparticles with each ligand.31,32 The monolayer-protected nanoparticles were 
redispersed in water and the excesses of ligand/pentanethiol were removed by dialysis using a 
10,000 MWCO snake-skin membrane. The final concentration was measured by UV 
spectroscopy on a Molecular Devices SpectraMax M2 at 506 nm according to the reported 
methodology.33 
5.4.2. Hemolysis assay  
Hemolysis assay was performed on human red blood cells as we described in previous study.34 
Briefly, citrate-stabilized human whole blood (pooled, mixed gender) was purchased from 
Bioreclamation LLC, NY. The red blood cells were purified and re-suspended in 10 mL 
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phosphate buffered saline as soon as received. 0.1 mL of RBC solution was added to 0.4 mL of 
NP solution in PBS in 1.5 mL centrifuge tube.  
The mixture was incubated at 37 ˚C, 150 rpm for 30 minutes followed by centrifugation 
at 4000 rpm for 5 minutes. The absorbance value of the supernatant was measured at 570 nm with 
absorbance at 655 nm as a reference. RBCs incubated with PBS as well as water were used as 
negative and positive control, respectively. All samples were prepared in triplicate. The percent 
hemolysis was calculated using the following formula:  
% Hemolysis = ((sample absorbance-negative control absorbance)) / ((positive control 
absorbance-negative control absorbance)) × 100. 
5.4.3. Biofilm culture  
Bacteria were inoculated in LB broth at 37 °C until stationary phase. The cultures were then 
harvested by centrifugation and washed with 0.85% sodium chloride solution three times. 
Concentrations of resuspended bacterial solution were determined by optical density measured at 
600 nm. Seeding solutions were then made in minimal media, M9 broth to reach OD600 of 0.1. 
Then, 500 μL of the seeding solutions was added to each well of the 24-well microplate. M9 
medium without bacteria was used as a negative control. The plates were covered and incubated 
at room temperature under static conditions for a desired period of 24 h. Planktonic bacteria were 
removed by washing with phosphate-buffered saline (PBS) three times. 
5.4.4. Nanozyme accumulation in biofilms  
After plating bacterial cells in a 24-well plate. On the following day, planktonic bacteria were 
removed by washing with PBS three times and incubated with RBC-NZ, Bare-NZ (107 RBC/ml, 
500 nM respectively) in minimal M-9 media (pH 7.4) for 1 h at 37 °C. After incubation, biofilms 
were washed three times with PBS, and lysis buffer was added to each well. All lysed samples 
were then further processed for ICP-MS analysis (vide inf ra) to determine the intracellular 
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amount of gold and ruthenium. Diffusion experiments were performed independently at least two 
times, and each experiment comprised three replicates. 
5.4.5. Confocal Imaging of Bacteria  
A total of 108 bacterial cells/mL was seeded (2 mL in M9 media) in a confocal dish and allowed 
to grow; old medium was replaced every 24 h. After 3 days, medium was replaced by RBC-NZ 
and biofilms were incubated for 1 h; biofilm samples incubated with only M9 media were used as 
the control. After 1 h, biofilms were washed with PBS three times and were incubated with 10 
μM of the substrates for 1 h. The cells were then washed with PBS three times. Confocal 
microscopy images were obtained on a Zeiss LSM 510 Meta microscope by using a 60× objective. 
The settings of the confocal microscope were as follows: green channel, λex = 488 nm and λem = 
BP 505−530 nm; red channel, λex = 543 nm and λem = LP 650 nm. Emission filters: BP =band 
pass, LP = high pass. 
5.4.6. Prodrug activation  
Biofilms were cultured as mentioned in the above section. Biofilms were washed off and 
incubated with RBC-NZ (500 nM) in minimal M9 media. After 24 h, biofilms were washed with 
PBS buffer three times and treated with pro-Mox at a concentration of 2.5, 5, 10 M for 24 h. The 
cells were then completely washed off and 10% alamar blue in minimal media was added to each 
well (220 l) and incubated further at 37°C for 2 h. Biofilm viability was then determined by 
measuring the fluorescence intensity at 570 nm using a SpectraMax M5 microplate 
spectrophotometer.  
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CHAPTER 6 
ENGINEERED POLYMERIC NANOPARTICLES WITH UNPRECEDENTED 
ANTIMICROBIAL EFFICACY AND THERAPEUTIC INDICES AGAINST 
MULTI-DRUG RESISTANT BACTERIA AND BIOFILMS  
6.1 Introduction 
Indiscriminate use of antibiotics in agricultural1 and medical fields2 has created multi-
drug resistant (MDR) “superbugs” such as methicillin-resistant Staphylococcus aureus (MRSA) 
along with particularly refractory Gram-negative species that pose a serious threat to global 
health. Planktonic bacteria cause acute infections resulting in sepsis, with the threat further 
intensified by chronic infections from biofilms.3,4 Biofilm-associated infections frequently occur 
on medical implants and indwelling devices such as catheters, prosthesis and dental implants.5 
Biofilm infections can also occur on or around dead tissues leading to endocarditis and chronic 
wound infections.6 These intractable infections are challenging due to the high resistance of these 
infections towards both host immune response and traditional antimicrobial therapies.7 Current 
biofilm treatment techniques require aggressive antibiotic therapy coupled with debridement of 
infected tissue.8 However, this standard regimen incurs high treatment costs and low patient 
compliance due to the invasive nature of the treatment.9 The therapeutic challenge is exacerbated 
by the increasing number of antibiotic-resistant bacterial strains, further impairing the therapeutic 
effectiveness of existing antibiotics.10 
 Antimicrobial peptides (AMPs) have emerged as an alternative to conventional 
antibiotic therapy, exhibiting broad spectrum activity against antibiotic-resistant bacteria.11 , 12 
AMPs have demonstrated high therapeutic indices (TI, selectivity towards bacterial cells 
calculated as HC50 (Hemolytic activity)/MIC) of ~900 and ~3,30013 against planktonic bacteria, 
however these α-helical peptides are susceptible to proteolytic degradation, reducing their 
efficacy.14,15 Host-defense peptide mimicking synthetic polymers have recently been developed, 
demonstrating broad spectrum activity against microbes. 16- 20  However, high toxicity towards 
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mammalian cells and red blood cells, resulting in low therapeutic indices (ranging from ~1-
10)16,18-20 have impaired their practical applications in clinical settings. Low toxicity to m
ammalian cells, in particular red blood cells is critical for effective application of antimicrobials 
in or on patients.29,36 Limited studies have demonstrated synthetic polymers with improved 
therapeutic indices (~150-550)21-24, exhibiting their ability to kill bacteria while causing minimal 
hemolysis of red blood cells.  However, these polymers have focused on the treatment of 
planktonic microbes, overlooking the more drug-resistant biofilm counterparts. To the best of our 
knowledge, synthetic polymers exhibiting high biofilm efficacy while maintaining low toxicity 
towards mammalian cells have not been reported.  
 We report here engineered polymers that effectively eradicate pre-formed 
biofilms while maintaining high therapeutic indices (>1000) against red blood cells (RBCs). In 
the design of these materials we hypothesized that the therapeutic window of cationic polymers 
could be regulated by varying hydrophobic moieties, similar to the hydrophobic residues present 
in the active sites of antimicrobial peptides.25 To this end we synthesized a library of quaternary 
ammonium poly(oxanorborneneimides) possessing different degrees of hydrophobicity (Figure 
6.1) and screened their antimicrobial and hemolytic activities. These polymers form 10-15 nm 
nanoparticles in aqueous solution, increasing their overall cationic charge and molecular mass. 
We observed that longer hydrophobic alkyl chains that bridge the cationic head group and 
polymer backbone greatly enhances toxicity against planktonic bacteria while maintaining low 
hemolytic activity towards RBCs (TI 1250-2500). These nanoparticles readily penetrate biofilms 
and eradicate pre-formed biofilms while still maintaining high TI (60-165). Polymeric NPs (PNPs) 
demonstrated a 6-fold log reduction in bacterial colonies with no mammalian cell toxicity when 
tested in a biofilm-mammalian cell coculture model. Notably, we observed that bacteria did not 
develop any resistance against PNPs even after 20 serial passages, in stark contrast to 
conventional antibiotics.  Overall, our engineered polymeric nanoparticle platform shows strong 
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potential as an infectious disease therapeutic and simultaneously provides a rational approach to 
design novel antimicrobials for sustainably combating bacterial infections. 
 
Figure 6.1. Molecular structures of a. oxanorbornene polymer derivatives. b. MIC values of 
polymer derivatives with different hydrophobic chain lengths. Log P represents the calculated 
hydrophobic values of each monomer c. Schematic representation depicting self-assembly of P5-
homopolymers. Characterization of P5 PNPs using TEM imaging and DLS measurement. d. 
Graph for FRET experiments between P5-Rhodamine Green and P5-TRITC indicating formation 
of polymeric NPs.  
6.2 Results and discussion 
Norbornene/oxanorbornene-based polymers feature conformational restrictions 
reminiscent of peptides, and amphiphilic cationic polymers with this backbone have shown 
promising antimicrobial properties.24,26  Additionally, the synthetic scalability provides a key 
advantage over antimicrobial peptides. 27 , 28  The distribution of hydrophobic moieties on 
antimicrobial macromolecules plays a pivotal role in determining their bactericidal activity.25,29 
In particular, careful consideration of “Amphiphilic balance”,  i.e. distribution of cationic charge 
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and hydrophobic moieties on the polymer are critical to ensure antimicrobial selectivity towards 
bacteria over mammalian cells. 30  We explored this design space through a library of 
oxanorbornene polymers (Figure 6.1 a, 6.2 a) with varying unbranched alkyl chains both bridging 
the cationic head group and the polymer backbone itself, allowing systematic determination of 
structure-antimicrobial efficacy relationships. We found that polymers containing a bridged C11 
alkyl chain spontaneously self-assemble into cationic PNPs (~13 nm) in aqueous solutions as 
confirmed by transmission electron microscopy (TEM, Figure 6.1 c), dynamic light scattering 
(DLS, Figure 6.1 c) and Förster resonance energy transfer (FRET) experiments (Figure 6.1 d, 
Structural details of dye-tagged polymer are in experimental methods section 6.4). These micellar 
structures formed at low polymer concentrations: dilution experiments of encapsulated Nile Red 
within P5 PNPs indicated a critical micelle concentration of < 2.5 µM (Figure 6.6, Section 6.5).31 
The PNP library was screened for antimicrobial activity against an uropathogenic strain 
of Escherichia coli (CD-2), using broth dilution methods to evaluate their minimal inhibitory 
concentrations (MICs). 32  We observed a 1000-fold increase in the antimicrobial activity of 
polymeric nanoparticles upon increasing the hydrophobicity of the alkyl chain bridging the 
backbone and cationic headgroup (Figure 6.1 b). Polymers with shorter internal alkyl chains (P1-
P4) displayed MICs of 64 µM, while analogs with more hydrophobic C11 chains (P5, P6) 
inhibited bacteria growth at 0.064 µM. We further extended the hydrophobicity on the cationic 
headgroup of the polymers and monitored the change in antimicrobial activity. We determined 
that the MICs of PNPs did not change significantly upon increasing the hydrophobicity at the 
cationic headgroup (Figure 6.2 a). This result indicates that careful placement of local 
hydrophobic domains on polymer structure plays a crucial role in determining the antimicrobial 
activity of the polymer. Similar behavior has also been reported in antimicrobial peptides where 
the location of hydrophobic residues determines antimicrobial activity.33,34  
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Figure 6.2. a. Graph showing minimum inhibitory concentrations (MIC) and structure details of 
oxanorbornene derivatives with different hydrophobicity of the cationic headgroups. Log P 
represents the calculated hydrophobic values of each monomer. b. Graph showing toxicity of P5-
P9 polymers against 3T3 Fibroblast cells indicating increase in cytotoxicity with increased 
hydrophobicity of the cationic headgroup. Selectivity towards bacteria as compared to 
mammalian cells is calculated as (IC50/MIC). c. Hemolytic activity of PNPs at different 
concentrations indicates their non-hemolytic behavior at relevant therapeutic concentrations. d. 
TNF-α secretion of Raw 264.7 cells in the presence of PNPs. Lipopolysaccharide (LPS) was used 
as a positive control. 
After establishing antimicrobial efficacy, we performed cell toxicity assays on human 
fibroblast cell lines to determine the IC50 (half-maximal inhibitory concentration) of the most 
hydrophobic polymers (P5-P9) and evaluate their therapeutic selectivity.35 Therapeutic selectivity 
is defined as IC50/MIC that determines the ability of polymers to kill bacteria while causing 
minimal toxicity to mammalian cells. It was observed that polymer cytotoxicity towards 
fibroblasts increased with increasing hydrophobicity of the alkyl chain at cationic headgroup 
(Figure 6.2 b). Least hydrophobic P5 showed IC50 of 20.5 µM, yielding therapeutic selectivity of 
~320. On the contrary, its most hydrophobic counterparts (P6, P8 and P9) showed therapeutic 
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selectivity as low as 78, 23 and 8 respectively. These results further indicate that careful 
placement of hydrophobic domains on polymer can regulate their toxicity towards mammalian 
cells. Similar study has previously reported that co-localization of the charge and hydrophobic 
domains reduced the antibacterial effect, however dramatically reduced the chance of red blood 
cell hemolysis, thereby improving the overall selectivity of the system.30 Hence, we concluded 
that P5 polymer with internally hydrophobic alkyl chains demonstrated highest antimicrobial 
activity with least cytotoxicity.  
Next, we performed hemolysis assays on human RBCs with our most potent polymer P5 
and calculated their HC50 (concentration that causes 50% lysis of RBCs) to determine their 
biocompatibility.36,37  MIC and HC50 values were used to calculate a therapeutic index (TI = 
HC50/MIC) of PNPs against planktonic bacteria. PNPs P5 with undecyl-bridging alkyl chains 
showed minimal hemolytic character (Figure 6.2 c). The highest antimicrobial efficiency was 
observed with P5 PNPs, with an MIC of 64 nM (1.8 µg.ml-1) against E. coli. P5 PNPs showed 
little hemolytic character (HC50 >160 µM, 4700 µg.ml-1) providing an unprecedented therapeutic 
index of > 2500, 5-fold higher than previous polymer-based antimicrobials. Having established 
P5 PNPs are non-acutely toxic, we next investigated their chronic effects in relation to 
inflammatory cytokine responses from macrophage RAW 264.7 cells (Figure 6.7). P5 PNP 
concentrations up to 2 µM showed no significant toxicity or tumor necrosis factor alpha (TNF-α) 
cytokine expression (Figure 6.2 d), suggesting in vitro immunocompatibility with mammalian 
immune cells.38 
We next tested P5 PNPs against multiple uropathogenic clinical isolates (Table 6.1) to 
establish their broad-spectrum activity. P5 PNPs suppressed bacterial proliferation at 
concentrations ranging from 64-128 nM (1.8 µg.ml-1 – 3.6 µg.ml-1), once again similar or lower to 
previously reported antimicrobial polymers. These polymers showed similar antimicrobial 
activity against 5 clinical isolates of E. coli with different susceptibilities to clinical antibiotics 
(resistant to 1-17 drugs), indicating their ability to evade common mechanisms of bacterial 
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resistance. Notably, engineered polymers were effective against clinical isolates of Gram-
negative P. aeruginosa and E. cloacae complex. Similarly, Gram-positive strains of S. aureus 
were susceptible to P5 PNPs including the highly virulent strain of methicillin-resistant S. aureus 
(MRSA). 
Table 6.1. Minimum inhibitory concentrations and therapeutic indices of P5 PNPs against 
multiple uropathogenic clinical isolate bacterial strains.  
Strain Species MIC (nM) TI (HC50/MIC) 
CD-23 P. aeruginosa 64 ~2500 
CD-1006 P. aeruginosa 128 ~1250 
CD-489 S. aureus- MRSA 64 ~2500 
CD-2 E. coli 128 ~2500 
CD-3 E. coli 64 ~2500 
CD-19 E. coli 64 ~2500 
CD-549 E. coli 128 ~1250 
CD-496 E. coli 128 ~1250 
CD-866 E. cloacae complex 128 ~1250 
CD-1412 E. cloacae complex 128 ~1250 
CD-1545 E. cloacae complex 128 ~1250 
 
Due to the highly cationic and hydrophobic nature of our PNPs, we hypothesized their 
activity arose from the disruption of bacterial cell membranes.39,40 This expectation was supported 
through staining with membrane-impermeable propidium iodide (PI) where only cells with 
compromised membranes generate red fluorescence.41,42 Pathogenic E. coli (CD-2), S. aureus 
(CD-489) and non-pathogenic P. aeruginosa (ATCC 19660) were treated with 1 µM of P5 PNPs 
for 3 hours at 37 °C and subsequently stained with PI before imaging. The confocal images 
(Figure 6.3 b) clearly show that the PNPs generate substantial bacterial membrane disruption in 
all three species, regardless of membrane composition or pathogenicity.   
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Figure 6.3. a. Representative 3D projection of confocal image stacks of E2-Crimson (Red 
Fluorescent Protein) expressing E. coli DH5α biofilm after 1 h treatment with P5-Rhodamine 
Green at 1 µM concentration. The panels are projection at 0°, 60° and 90° angle turning along X 
axis. Scale bars are 30 μm. b. Confocal images of E. coli (CD-2), S. aureus (MRSA, CD-489) and 
P. aeruginosa (ATCC 19660) stained with Propidium Iodide (PI) after treatment with PNPs. 
Scale bars are 30 µm. 
After establishing the efficacy of our NPs against bacterial “superbugs”, we tested their 
efficacy against the even more refractory bacterial biofilms. Bacteria in biofilms produce 
extracellular polymeric substance that provides a potent barrier against therapeutics. 8 Penetration 
and accumulation of therapeutics inside biofilms is crucial for effective therapy of these 
infections, 43 , 44  so the ability of PNPs to penetrate biofilms was determined using confocal 
microscopy. We treated biofilms formed by E. coli expressing E2-Crimson (a red fluorescent 
protein) with P5 PNPs functionalized with Rhodamine-Green fluorescent dyes. As shown in 
Figure 6.3a, fluorescently labeled nanoparticles readily penetrated and dispersed throughout the 
biofilms (Figure 6.8), suggesting their ability to be an effective anti-biofilm agent. 
Having established biofilm penetration, the therapeutic ability of P5 PNPs against pre-
formed bacterial biofilms was quantified. We chose a laboratory strain of P. aeruginosa (ATCC 
19660) and 3 uropathogenic clinical isolates, P. aeruginosa (CD-1006), En. cloacae complex 
(CD-1412) and S. aureus (CD-489, a methicillin-resistant strain). As shown in Figure 6.4, P5 
PNPs demonstrate minimum concentrations to eradicate 90% of biofilms (MBEC90) ranging from 
1-3 µM, providing unprecedented therapeutic indices ranging from 60-165 for biofilms (TI = 
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HC50/MBEC90, Figure 6.9). Nanoparticles could treat both Gram-negative (P. aeruginosa, and En. 
cloacae complex) and Gram-positive (S. aureus) bacterial strains, further highlighting their 
broad-spectrum activity against biofilms. Notably, P5 PNPs demonstrated similar efficacy in 
treating MDR (CD-489, CD-1412) and non-resistant strains (CD-1006, ATCC 19660), suggesting 
their value as a therapeutic alternative to traditional antibiotics. 
 
Figure 6.4. Viability of 1-day-old a. P. aeruginosa (ATCC-19660), b. P. aeruginosa (CD-1006), 
c. S. aureus (CD-489), and d. En. cloacae complex (CD-1412) biofilms after 3 h treatment with 
P5 PNPs. The data are average of triplicates, and the error bars indicate the standard deviations. 
TI is the therapeutic index relative to MBEC90 and hemolysis against red blood cells (HC50). 
The ability to eradicate biofilms on biomedical surfaces such as medical implants and 
indwelling devices is a critical capability. However, treating biofilm infections on human tissues 
or organs is more challenging and relevant to medical settings.45 Biofilm infections on wounds 
significantly impair the healing process regulated by fibroblast skin cells.46  
First, we investigated P5 PNPs compatibility with mammalian NIH 3T3 fibroblast cells at 
concentrations used to eradicate pre-formed biofilms, with no significant toxicity observed 
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(Figure 6.7). We next used an in vitro coculture model comprised of mammalian fibroblast cells 
with bacterial biofilm overgrowth.47 , 48  In practice, P. aeruginosa bacteria were seeded on a 
confluent monolayer of NIH 3T3-fibroblast cells overnight to generate biofilms prior to treatment. 
The cocultures were treated with P5 PNPs for 3 hours, washed, and the viabilities of both bacteria 
and fibroblasts were determined. As shown in Figure 6.5a, a 4-6-fold log reduction (99.5%-
99.99%) in bacterial colonies occurred at concentrations ranging from 7.5-15 µM, while no 
substantial loss of fibroblast viability was observed in this concentration range. 
Bacteria rapidly acquire resistance towards antibiotics and other antimicrobials, limiting 
their long-term efficacy. Given the membrane disruption mechanism used by the PNPs, 
development of resistance in bacteria would require dramatic changes in the bacterial 
phenotype.43,45 The ability of PNPs to evade resistance was tested by subjection of uropathogenic 
E. coli (CD-2) to multiple serial passages of sub-MIC (66% of MIC) concentrations of P5 PNPs. 
The resulting bacterial population was harvested, and its MIC was evaluated. As shown in Figure 
6.5 b, even at the 20th serial passage (~1,300 bacterial generations) of CD-2, there was no change 
in MIC. Similar experiments were conducted on ciprofloxacin (quinolone), ceftazidime (β-lactam) 
and tetracycline, clinically relevant antibiotics. Respectively, there was a 33,000, 4,200 and 256-
fold increase in the MICs of antibiotics against CD-2 E. coli after only a few passages. Our 
polymeric nanoparticles evade resistance towards bacteria longer than previously reported 
polymer-based nanomaterials 49  (~600 generations – A. baumannii FADDI-AB156) and 
comparable to a recently discovered novel antibiotic, teixobactin (~1,300 generations – S. aureus 
ATCC 29213).50 
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Figure 6.5. a. Viability of 3T3 fibroblast cells and E. coli biofilms in the co-culture model after 3 
h treatment with P5 PNPs. Scatters and lines represent 3T3 fibroblast cell viability. Bars represent 
log10 of colony forming units in biofilms. The data are average of triplicates and the error bars 
indicate the standard deviations. b. Resistance development during serial passaging in the 
presence of sub-MIC levels of antimicrobials. The y axis is the highest concentration the cells 
grew in during passaging. The figure is representative of 3 independent experiments. 
6.3 Conclusions 
We have designed and fabricated an effective polymer nanoparticle-based therapeutic 
platform to combat MDR bacterial and biofilm infections. Our research demonstrates the ability 
of these PNPs to modulate antimicrobial activity and therapeutic efficacy by structure-specific 
incorporation of hydrophobic and cationic moieties. These amphiphilic cationic PNPs 
demonstrate excellent efficiency in combating planktonic superbugs as well as their more drug-
resistant biofilm counterparts. Their ability to penetrate and eradicate biofilms provides the 
foundation for a therapeutic strategy against biofilm infections that does not require debridement 
and extensive antimicrobial regimens. These PNPs function through a membrane disruption 
mechanism that strongly attenuates generation of tolerance or resistance. Taken together, PNP-
based antimicrobial therapy has the potential to provide an effective platform to combat bacterial 
infections while circumventing standard antibiotic resistance pathways. 
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6.4 Experimental methods 
6.4.1. Polymer synthesis 
Generation of C2 and C6-bridged polyoxanorbornene polymers can be successfully made using 
the same procedures used to generate C11-bridged polymers however replacing 11-
bromoundecanol with bromoethanol or 6-bromohexanol, respectively. 
 
Synthesis of 1. In a pressure tube, furan (4.5ml, 61.7mmol, 1.5eq) and maleimide (4.0g, 
41.1mmol, 1.0eq) were added in addition to 5ml of diethyl ether. The tube was sealed and heated 
at 100 °C overnight. Afterwards, the pressure tube was cooled to r.t. and the formed solid was 
removed, filtered, and washed with copious amounts of diethyl ether to isolate 1 as a white solid 
(95% yield) and was used without further purification. 1H NMR (400MHz, MeOD) 11.14 (s, 1H), 
6.52 (s, 2H), 5.12 (s, 2H), 2.85 (s, 2H). 
Synthesis of 2. To a 250 ml round bottom flask equipped with a stir bar was added 60 ml of DMF. 
Next, 1 (3.76g, 22.7mmol, 1.0eq) was added along with potassium carbonate (12.59g, 91.1mmol, 
4.0eq). The reaction mixture was heated at 50 °C for five minutes. Finally, potassium iodide 
(0.68g, 4.5mmol, 0.2eq) and 11-bromoundecanol (6.00g, 23.90mmol, 1.05eq) were added and 
stirred at 50 °C overnight. Afterwards, the reaction mixture was cooled to room temperature, 
diluted to 150 ml with ethyl acetate and washed with water (7x, 50ml) and brine (1x, 50ml). The 
organic layer was dried with sodium sulfate, filtered, and rotovaped to yield 2.2 was purified by 
sonication of the rotovaped solid in hexanes and filtered (82% yield). 1H NMR (400MHz, CDCl3) 
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6.44 (s, 2H), 5.19 (s, 2H), 3.55, (t, 2H), 3.49 (t, 2H), 2.79 (s, 2H), 1.9 (s, 1H), 1.39 (m, 4H), 1.2 
(m, 14H). 
Synthesis of 3. To a 250ml round bottom flask equipped with a stir bar was added 2 (2.64g, 
7.87mmol, 1.0eq). Next, DCM (100ml) was added along with tetrabromomethane (3.13g, 
9.44mmol, 1.2eq). The reaction was cooled to 0 °C using an ice bath. Finally, triphenylphosphine 
was added in portions (2.47g, 9.44mmol, 1.2eq) and allowed to stir for three hours. Afterwards, 
the reaction mixture was rotovaped and ethyl ether was added (200 ml) and placed in the freezer 
for 2 hours to precipitate out triphenylphosphine oxide. The reaction mixture was filtered, and the 
filtrate was rotovaped. Column chromatography was performed to yield 3, a white solid (79% 
yield). 1H NMR (400MHz, CDCl3) 6.51 (s, 2H), 5.27 (s, 2H), 3.45 (t, 2H), 3.41 (t, 2H), 2.83 (s, 
2H), 1.85 (q, 2H), 1.55 (q, 2H), 1.41 (q, 2H), 1.29 (m, 12H). 
Oxanorbornene Polymer Synthesis. Synthesis of 4. To a 10 ml pear-shaped air-free flask 
equipped with a stir bar was added 3 (800mg, 2.0mmol, 1.0eq) and 4ml of DCM. In a separate 
10ml pear-shaped air-free flask was added Grubbs 3rd generation catalyst51 (35.4mg, 0.04mmol, 
0.02eq) and 1ml DCM. Both flasks were sealed with septa and attached to a schlenk 
nitrogen/vaccum line. Both flasks were freeze-pump-thawed three times. After thawing, Grubbs 
3rd generation catalyst was syringed out and quickly added to the flask containing 3 and allowed 
to react for 10 min. After the allotted time, ethyl vinyl ether (200 µL) was added and allowed to 
stir for 15 minutes. Afterwards, the reaction was diluted to two times the volume and precipitated 
into a heavily stirred solution of hexane (300 ml). The precipitated polymer was filtered and 
dissolved into tetrahydrofuran (THF). The polymer was precipitated again into hexane and 
filtered to yield 4. MW = 25,698, PDI = 1.04 (determined by THF-GPC using a Polystyrene 
calibration curve) 1H NMR (400MHz, CDCl3) 6.0 (br, 1H), 5.7 (br, 1H), 4.95 (br, 1H), 4.4 (br, 
1H), 3.4 (br, 2H), 3.25 (br, 2H), 1.79 (q, 2H), 1.5 (br, 2H), 1.34 (br, 2H), 1.2 (br, 14H). 
Synthesis of 5 Quaternary Ammonium Polymers. To generate the library of quaternary 
ammonium poly(oxanorborneneimides), 4 (50 mg) was added to 20 ml vials equipped with a stir 
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bar. Next, excess of the necessary tertiary amines was added (10ml of a 1M trimethylamine 
solution in THF, all other amines were 200mg) to the vial and purged with nitrogen. First stage of 
the reactions involved stirring for 30 minutes at 80 °C. The polymers precipitated during this time. 
Half of the THF was evaporated and replaced with methanol which re-dissolved the polymers. 
The reaction was allowed to proceed overnight at 50 °C. Afterwards, the solvent was completely 
evaporated, washed with hexane 2 times, and dissolved into a minimal amount of water. The 
polymers were added to 10,000 MWCO dialysis membranes and allowed to stir for 3 days, 
changing the water periodically. The polymers were filtered through PES syringe filters and 
freeze-dried to yield all the respective quaternary ammonium polymers 5. NMR indicated 
conversion into the desired quaternary ammonium salts. 
6.4.2. FRET PNP formation  
FRET PNPs were generated using the P5 polymer scaffold, labelled either with donor Rhodamine 
Green or acceptor TRITC (Functionalized by incorporating a boc-protected amino monomer 
during the polymerization, followed by purification using a 10,000 MWCO dialysis bag). 
Keeping P5-Rhodamine Green’s concentration constant at ~ 1.6 µM in 2 ml Eppendorf tubes, 
increasing concentrations of P5-TRITC in MQ water was added and the tubes were sonicated for 
one minute and allowed to stand for one hour. The solutions were then transferred to a 96-well 
microplate and the total emission spectrum of both P5 derivatives were recorded on a SpectroMax 
M5 microplate reader (Molecular Device) using 480 nm as the excitation wavelength (480 nm 
was selected so that only P5-Rhodamine Green would be excited). 
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6.4.3. Determination of antimicrobial activities of cationic polymers  
Bacteria were cultured in LB medium at 37 °C and 275 rpm until stationary phase. The cultures 
were then harvested by centrifugation and washed with 0.85% sodium chloride solution for three 
times.54 Concentrations of resuspended bacterial solution were determined by optical density 
measured at 600 nm. M9 medium was used to make dilutions of bacterial solution to a 
concentration of 1 × 106 cfu/mL. A volume of 50 μL of these solutions was added into a 96-well 
plate and mixed with 50 μL of polymer solutions in M9, giving a final bacterial concentration of 
5 × 105 cfu/mL. Polymer concentration varied in half fold per a standard protocol, ranging from 
1024 to 4 nM. A growth control group without polymers and a sterile control group with only 
growth medium were carried out at the same time. Incubation of the polymers with bacteria was 
performed for 16 hours. Cultures were performed in triplicates, and at least two independent 
experiments were repeated on different days. The MIC is defined as the lowest concentration of 
polymer that inhibits visible growth as observed with the unaided eye.52 
6.4.4. Determination of hemolysis of cationic polymers  
We used the previously established protocol to conduct hemolysis assays on Red Blood Cells.36 
Citrate-stabilized human whole blood (pooled, mixed gender) was purchased from 
Bioreclamation LLC, NY and processed as soon as received. 10 mL of phosphate buffered saline 
(PBS) was added to the blood and centrifuged at 5000 r.pm. for 5 minutes. The supernatant was 
carefully discarded and the red blood cells (RBCs) were dispersed in 10 mL of PBS. This step 
was repeated at least five times. The purified RBCs were diluted in 10 mL of PBS and kept on ice 
during the sample preparation. 0.1 mL of RBC solution was added to 0.4 mL of polymer solution 
in PBS in a 1.5 mL centrifuge tube (Fisher) and mixed gently by pipetting. RBCs incubated with 
PBS and water was used as negative and positive controls, respectively. All polymer samples as 
well as controls were prepared in triplicate. The mixture was incubated at 37 ˚C for 30 minutes 
while shaking at 150 r.p.m. After incubation period, the solution was centrifuged at 4000 r.p.m. 
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for 5 minutes and 100 μL of supernatant was transferred to a 96-well plate. The absorbance value 
of the supernatant was measured at 570 nm using a microplate reader (SpectraMax M2, 
Molecular devices) with absorbance at 655 nm as a reference.  
6.4.5. Macrophage cell studies and TNF-alpha secretion  
RAW 264.7 macrophage cell line was purchased from American Type Culture Collection (ATCC, 
Manassas, VA). Roswell Park Memorial Institute media (RPMI 1640) supplemented with 10% 
fetal bovine serum, 1% antibiotics (100 µg/ml penicillin and 100 µg/ml streptomycin) and sodium 
pyruvate, was used for cell culture. The cells were incubated at 37 °C under a humidified 
atmosphere of 5% CO2. The cells were cultured once every four days under the above-mentioned 
conditions.  
6.4.6. Polymer nanoparticles and LPS treatment  
These studies were conducted as per the previously reported protocols.53 Briefly, to evaluate the 
effect of polymer on the immune system, 1.0  105 of RAW 264.7 cells were cultured in a 24-
well plate for 24 h. Then, cells were washed once with cold PBS and treated with different 
concentration of polymer for 3 h or 24h. The macrophage with 100ng/ml of lipopolysaccharide 
were the positive control. At the end of incubation, culture media was collected for TNF-α level 
measurement by ELISA (R&D Systems, MN, USA). Experiments were performed in triplicate. 
6.4.7. Propidium Iodide staining assay  
E. coli CD-2, P. Aeruginosa ATCC19660 and MRSA CD-489 (1 × 108 cfu/mL) were incubated 
with 1 µM P5 PNPs in M9 media at 37 ˚C and 275 rpm for 3 h. The bacteria solutions were then 
mixed with PI (2 μM) and incubated for 30 min in dark. Five microliters of the samples were 
placed on a glass slide with a glass coverslip and observed with a confocal laser scanning 
microscopy, Zeiss 510 (Carl Zeiss, Jena, Germany) using a 543-nm excitation wavelength.  
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6.4.8. Resistance development  
E. coli CD-2 was inoculated in M9 medium with 85 nM (2/3 of 128 nM, MIC) of P5 PNPs at 37 
˚C and 275 rpm for 16 h (~ 64 bacterial generations for 1 serial passage). The culture was then 
harvested and tested for MIC as describe above. E. coli CD-2 was cultured without polymer as 
well every time as a control for comparison of MICs. In the case of P5 PNPs, 20 serial passages 
were performed giving ~ 1,300 generations. 
6.4.9. Biofilm formation and treatment  
Bacteria were inoculated in lysogeny broth (LB) medium at 37 ˚C until stationary phase. The 
cultures were then harvested by centrifugation and washed with 0.85% sodium chloride solution 
three times. Concentrations of resuspended bacterial solution were determined by optical density 
measured at 600 nm. Seeding solutions were then made in M9 medium to reach an OD600 of 0.1. 
A 100 μL amount of the seeding solutions was added to each well of the 96-well microplate. The 
plates were covered and incubated at room temperature under static conditions for 1 day. The 
stock solution of polymers was then diluted to the desired level and incubated with the biofilms 
for 3 hours at 37˚C. Biofilms were washed with phosphate buffer saline (PBS) three times and 
viability was determined using an Alamar Blue assay. Minimal M9 medium without bacteria was 
used as a negative control.54  
Biofilm-3T3 Fibroblast Cell Coculture was performed using the previously reported protocol.54A 
total of 20000 NIH 3T3 (ATCC CRL-1658) cells were cultured in Dulbecco’s modified Eagle 
medium (DMEM; ATCC 30-2002) with 10% bovine calf serum and 1% antibiotics at 37 °C in a 
humidified atmosphere of 5% CO2. Cells were kept for 24 h to reach a confluent monolayer. 
Bacteria (P. aeruginosa) were inoculated and harvested as mentioned above. Afterward, seeding 
solutions 108 cells/mL were inoculated in buffered DMEM supplemented with glucose. Old 
medium was removed from 3T3 cells followed by addition of 100 μL of seeding solution. The 
cocultures were then stored in a box humidified with damp paper towels at 37 °C overnight 
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without shaking. Polymer NPs and other control solutions were diluted in DMEM media prior to 
use to obtain the desired testing concentrations. Old media was removed from coculture, replaced 
with freshly prepared testing solutions, and incubated for 3 h at 37 °C. Cocultures were then 
analyzed using LDH cytotoxicity assay to determine mammalian cell viability using 
manufacturer’s instructions55. To determine the bacteria viability in biofilms, the testing solutions 
were removed and cocultures were washed with PBS. Fresh PBS was then added to disperse 
remaining bacteria from biofilms in coculture by sonication for 20 min and mixing with pipet. 
The solutions containing dispersed bacteria were then plated onto agar plates, and colony forming 
units were counted after incubation at 37 °C overnight. 
6.4.10. Biofilm penetration studies using confocal microscopy  
108 bacterial cells/ml of E2-Crimson (Red Fluorescent Protein) expressing E. coli, supplemented 
with 1 mM of IPTG ((isopropyl β-D-1-thiogalactopyranoside), were seeded (2 ml in M9 media) 
in a confocal dish and were allowed to grow. After 3 days media was replaced by 1000 nM of 
RhodGreen-P5 PNPs and biofilms were incubated for 1 hour, biofilm samples incubated with 
only M9 media were used as control. After 1 h, biofilms were washed with PBS three times and 
were incubated with 100 μM of the substrates for 1 h. The cells were then washed with PBS three 
times. Confocal microscopy images were obtained on a Zeiss LSM 510 Meta microscope by 
using a 63× objective. The settings of the confocal microscope were as follows: green channel: 
λex=488 nm and λem=BP 505-530 nm; red channel: λex=543 nm and λem=LP 650 nm. Emission 
filters: BP=band pass, LP=high pass.  
6.4.11. Mammalian cell viability assay  
A total of 20,000 NIH 3T3 (ATCC CRL-1658) cells were cultured in Dulbecco's modified Eagle 
medium (DMEM; ATCC 30-2002) with 10% bovine calf serum and 1% antibiotics at 37 ºC in a 
humidified atmosphere of 5% CO2 for 48 h.48 Old media was removed, and cells were washed 
one time with phosphate-buffered saline (PBS) before addition of PNPs in the prewarmed 10% 
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serum containing media. Cells were incubated for 24 h at 37 ºC under a humidified atmosphere of 
5% CO2. Cell viability was determined using Alamar blue assay according to the manufacturer's 
protocol (Invitrogen Biosource). After a wash step with PBS three times, cells were treated with 
220 μL of 10% alamar blue in serum containing media and incubated at 37 ºC under a humidified 
atmosphere of 5% CO2 for 3 h. After incubation, 200 μL of solution from each well was 
transferred in a 96-well black microplate. Red fluorescence, resulting from the reduction of 
Alamar blue solution, was quantified (excitation/emission: 560 nm/590 nm) on a SpectroMax M5 
microplate reader (Molecular Device) to determine the cellular viability. Cells without any PNPs 
were considered as 100% viable. Each experiment was performed in triplicate. 
6.4.12. Therapeutic Indices Against Biofilms  
Bacteria were inoculated in lysogeny broth (LB) medium at 37 ˚C until stationary phase. The 
cultures were then harvested by centrifugation and washed with 0.85% sodium chloride solution 
three times. Concentrations of resuspended bacterial solution were determined by optical density 
measured at 600 nm. Seeding solutions were then made in M9 medium to reach an OD600 of 0.1. 
A 100 μL amount of the seeding solutions was added to each well of the 96-well microplate. The 
plates were covered and incubated at room temperature under static conditions for 1 day. The 
stock solution of P5 PNPs was then diluted to the desired level and incubated with the biofilms 
for 3 hours at 37˚C. Biofilms were washed with phosphate buffer saline (PBS) three times and 
viability was determined using an Alamar Blue assay. Minimal M9 medium without bacteria was 
used as a negative control. Concentrations were converted to Log, plotted with bacteria viability, 
and fitted to a curve to determine the minimum biofilm eradication concentration at 90% 
(MBEC90).56 , 57  The therapeutic index with respect to red blood cells was calculated by the 
concentration of P5 PNPs at MBEC90 divided by the hemolysis at 50%. 
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6.4.13. Critical micelle concentration study  
Critical Micelle Concentration of P5 PNP was determined through dilution of Nile Red 
encapsulated PNPs. Briefly, 16.0 mg of Polymer P5 and 2.0 mg of Nile Red was dissolved in 2 
ml of dimethylsulfoxide in a 7ml scintillation vial. While under vigorous stirring, 3 ml of water 
was slowly added over the course of 1 hour and allowed to stir overnight. Afterwards, the vial 
was centrifuged, and the solution decanted to remove precipitated Nile Red that was not 
encapsulated. Followed by filtration through a PES syringe filter, the solution was transferred to a 
3,500 MWCO dialysis bag and allowed to stir in 5L of water for two days, changing the water 
twice each day. Afterwards, the solution was filtered again through a PES syringe filter yielding 
Nile Red encapsulated P5 PNPs. Nile Red’s fluorescence spectrum was monitored (Excitation = 
550nm) as a function of decreasing polymer concentration. it was observed that at 2.5 µM, 
fluorescence decrease became non-linear. Further dilution was not possible due to limitations in 
the amount of Nile Red encapsulated. Therefore, the critical micelle concentration was 
determined to be ~ 2.5 µM and is well within the range of previously reported diblock polymer 
carriers. 
6.5 Supplementary information 
6.5.1. Critical micelle concentration study 
Critical Micelle Concentration of P5 PNP was determined through dilution of Nile Red 
encapsulated PNPs. Briefly, 16.0 mg of Polymer P5 and 2.0 mg of Nile Red was dissolved in 2 
ml of dimethylsulfoxide in a 7ml scintillation vial. While under vigorous stirring, 3 ml of water 
was slowly added over the course of 1 hour and allowed to stir overnight. Afterwards, the vial 
was centrifuged, and the solution decanted to remove precipitated Nile Red that was not 
encapsulated. Followed by filtration through a PES syringe filter, the solution was transferred to a 
3,500 MWCO dialysis bag and allowed to stir in 5L of water for two days, changing the water 
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twice each day. Afterwards, the solution was filtered again through a PES syringe filter yielding 
Nile Red encapsulated P5 PNPs. Nile Red’s fluorescence spectrum was monitored (Excitation = 
550nm) as a function of decreasing polymer concentration. it was observed that at 2.5 µM, 
fluorescence decrease became non-linear. Further dilution was not possible due to limitations in 
the amount of Nile Red encapsulated. Therefore, the critical micelle concentration was 
determined to be ~ 2.5 µM and is well within the range of previously reported diblock polymer 
carriers.  
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Figure 6.6. Critical micelle concentration of P5 PNPs. 
6.5.2. Mammalian cell viability assay  
A total of 20,000 NIH 3T3 (ATCC CRL-1658) cells were cultured in Dulbecco's modified Eagle 
medium (DMEM; ATCC 30-2002) with 10% bovine calf serum and 1% antibiotics at 37 ºC in a 
humidified atmosphere of 5% CO2 for 48 h.48 Old media was removed, and cells were washed 
one time with phosphate-buffered saline (PBS) before addition of PNPs in the prewarmed 10% 
serum containing media. Cells were incubated for 24 h at 37 ºC under a humidified atmosphere of 
5% CO2. Cell viability was determined using Alamar blue assay according to the manufacturer's 
protocol (Invitrogen Biosource). After a wash step with PBS three times, cells were treated with 
220 μL of 10% alamar blue in serum containing media and incubated at 37 ºC under a humidified 
atmosphere of 5% CO2 for 3 h. After incubation, 200 μL of solution from each well was 
transferred in a 96-well black microplate. Red fluorescence, resulting from the reduction of 
Alamar blue solution, was quantified (excitation/emission: 560 nm/590 nm) on a SpectroMax M5 
microplate reader (Molecular Device) to determine the cellular viability. Cells without any PNPs 
were considered as 100% viable. Each experiment was performed in triplicate. 
 
 109 
 
Figure 6.7. Cytotoxicity of PNPs against a. RAW 264.7 cells and b. NIH-3T3 Fibroblast cells. 
6.5.3. Biofilm penetration studies using confocal microscopy 
108 bacterial cells/ml of E2-Crimson (Red Fluorescent Protein) expressing E. coli, supplemented 
with 1 mM of IPTG ((isopropyl β-D-1-thiogalactopyranoside), were seeded (2 ml in M9 media) 
in a confocal dish and were allowed to grow. After 3 days media was replaced by 1000 nM of 
RhodGreen-P5 PNPs and biofilms were incubated for 1 hour, biofilm samples incubated with 
only M9 media were used as control. After 1 h, biofilms were washed with PBS three times and 
were incubated with 100 μM of the substrates for 1 h. The cells were then washed with PBS three 
times. Confocal microscopy images were obtained on a Zeiss LSM 510 Meta microscope by 
using a 63× objective. The settings of the confocal microscope were as follows: green channel: 
λex=488 nm and λem=BP 505-530 nm; red channel: λex=543 nm and λem=LP 650 nm. Emission 
filters: BP=band pass, LP=high pass. 
 
Figure 6.8. Penetration of Rhodamine Green labelled P5 PNPs (RhodGreen PONI-C11-TMA) 
into E2-Crimson expressing E. coli biofilms. The mean fluorescence of each confocal z-stack 
image was calculated using ImageJ software.  
6.5.4. Therapeutic indices against biofilms  
Bacteria were inoculated in lysogeny broth (LB) medium at 37 ˚C until stationary phase. The 
cultures were then harvested by centrifugation and washed with 0.85% sodium chloride solution 
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three times. Concentrations of resuspended bacterial solution were determined by optical density 
measured at 600 nm. Seeding solutions were then made in M9 medium to reach an OD600 of 0.1. 
A 100 μL amount of the seeding solutions was added to each well of the 96-well microplate. The 
plates were covered and incubated at room temperature under static conditions for 1 day. The 
stock solution of P5 PNPs was then diluted to the desired level and incubated with the biofilms 
for 3 hours at 37˚C. Biofilms were washed with phosphate buffer saline (PBS) three times and 
viability was determined using an Alamar Blue assay. Minimal M9 medium without bacteria was 
used as a negative control. Concentrations were converted to Log, plotted with bacteria viability, 
and fitted to a curve to determine the minimum biofilm eradication concentration at 90% 
(MBEC90).56,57 The therapeutic index with respect to red blood cells was calculated by the 
concentration of P5 PNPs at MBEC90 divided by the hemolysis at 50%. 
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Figure 6.9. Therapeutic indices of PNPs against four bacterial biofilms. 
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CHAPTER 7 
FUNCTIONALIZED POLYMERS ENHANCE PERMEABILITY OF 
ANTIBIOITCS IN GRAM-NEGATIVE MDR BACTERIA BIOFILMS FOR 
SYNERGISTIC ANTIMICROBIAL THERAPY 
7.1 Introduction 
Antibiotic-resistant bacteria causes more than 2 million cases of infections and 23,000 
deaths each year in US alone.1 Worldwide annual death toll due to multi-drug resistant (MDR) 
bacteria increases to 700,000 and is expected to reach 10 million by the year 2050. 2  The 
‘ESKAPE’ (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species) pathogens pose 
the biggest threat to global health due to their multi-drug resistance.3,4 In particular, infections 
caused by Gram-negative species of ‘ESKAPE’ pathogens show increased resistance due to an 
additional highly impermeable outer membrane barrier.5 , 6  Threat posed by MDR bacteria is 
further aggravated by their ability to form bacterial biofilms, rendering infections refractory to 
both traditional antimicrobial therapies and host immune response.7 Biofilm-associated infections 
can frequently occur on medical implants, indwelling devices and wounds. 8  Conventional 
strategies to treat these intractable infections involve high dosage treatment with last resort 
antibiotics such as colistin and carbapenems, increasing the risk of neurotoxicity and 
nephrotoxicity.9 Rigorous antibiotic therapy is often followed by surgical debridement of infected 
tissue, resulting in low-patient compliance and excessive healthcare costs. 10 , 11  A significant 
decline in the number of approved antibiotics against MDR bacteria, with no new antibiotic 
developed against Gram-negative bacteria in the last fifty years, has contributed to the urgency 
for developing novel antimicrobial therapies.12  
Antibiotic cocktails targeting multiple pathways in pathogens have demonstrated 
increased antimicrobial efficacy.13,14 However, this strategy is associated with increased risk of 
antibiotic-resistance development. Moreover, antibiotic combination therapies often fail to treat 
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MDR Gram-negative pathogens due to limited penetration of antibiotics inside the cells.15,16 
Combination therapies utilizing antibiotics with membrane-sensitizing adjuvants have shown 
high efficacy in treating planktonic Gram-negative infections.17 However, these small-molecule 
based therapies fail to treat biofilm-associated infections due to their inability to penetrate 
Extracellular Polymeric Substance (EPS) matrix of biofilms.18,19,20  
Synthetic macromolecules such as nanoparticles and polymers have demonstrated ability 
to strongly bind and destabilize the bacterial outer membrane.21,22,23,24 In addition, amphiphilic 
polymers exhibited excellent potential in penetrating biofilm matrix.25,26 We hypothesized that 
combining the membrane-sensitizing and penetration-ability of polymers with the selective 
activity of antibiotics could offer enhanced efficacy in combating MDR bacterial and biofilm 
infections. Here, we report a combination therapy using engineered polymeric nanoparticles 
(PNPs) with colistin against resistant bacterial species. We observed 16- to 32-fold decrease in 
the colistin dosage required to combat planktonic and biofilm bacteria in combination therapy as 
compared to colistin alone. The observed synergy can be attributed to enhanced bacterial 
membrane permeability when the antibiotic was used in combination with PNPs. We further 
determined that antibiotic accumulation increases about 4-fold inside the biofilms in presence of 
PNPs, contributing to the enhanced efficacy.  Overall, this combination therapy illustrates the 
ability of functionalized polymers to enhance the potency of antibiotics against resistant bacterial 
infections, while minimizing the side-effects associated with high dosages of therapeutics. 
7.2 Results and discussion 
We have recently reported that distribution of cationic and hydrophobic moieties on a 
polymer plays a critical role in determining the antimicrobial efficacy of membrane-disrupting 
polymers.25 We have designed a library of polymers by varying the hydrophobicity of the cationic 
headgroups and changing the alkyl chain length bridging the headgroup with polymer backbone, 
to systematically probe the bacterial membrane permeability of the polymers (Figure 7.1 a). We 
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observed that the polymers with an 11-carbon alkyl chain bridge self-assembled to form cationic 
polymeric nanoparticles (PNPs) with a size ~15 nm, as shown by transmission electron 
microscopy (TEM) in Figure 7.1 c. On the other hand, polymers with smaller alkyl chain (2 and 6) 
bridge do not self-assemble into PNPs.  
 
Figure 7.1. a. Molecular structures of oxanorbornene polymer derivatives. Log P represents the 
calculated hydrophobic values of each monomer. b. Membrane permeability induced by different 
polymer derivatives measured as (%) uptake of N-phenyl-1-napthylamine (NPN) plotted vs 
overall hydrophobicity of the polymer derivatives. c. Schematic representation showing self-
assembly of polymer derivatives (n=9) into polymeric nanoparticles. Characterization of polymer 
nanoparticles (P7) using TEM. d. Bar graphs demonstrating membrane disruption as a function of 
polymer nanoparticles with different alkyl chain length bridging polymer backbone and cationic 
headgroup. 
Next, we screened the membrane perturbation ability of polymers (P1-P9) against 
Uropathogenic clinical isolate of E. coli using N-phenyl-1-napthylamine (NPN) uptake 
assays.27,28 We observed that membrane permeation ability of the polymers increases with the 
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increase in the overall hydrophobicity of the structure. However, increasing the length of alkyl 
chain bridging the polymer backbone to cationic headgroup has a stronger effect in membrane-
sensitizing ability of polymers, as compared to increasing the hydrophobicity of the cationic 
headgroup alone (Figure 7.1 d). A strong structure-activity relationship was observed with the 
most hydrophobic polymers (P6-P9) demonstrating highest membrane perturbation activity 
against bacteria (Figure 7.1 b). 
 
Figure 7.2. Checkerboard broth microdilution assays between colistin and polymer derivatives a. 
P7, b. P8 and c. P9 against uropathogenic E. coli (CD-2). Dark cells represent higher bacterial 
cell density. d. Table showing Minimum inhibitory concentrations (MICs) of colistin and 
different polymer derivatives. FIC indices were calculated using checkerboard broth 
microdilution assays as described in the methods section. e. Cell viability of 3T3 fibroblast cells 
after treatment with PNPs.  
After establishing the membrane perturbing ability of the polymers, we tested these 
polymers (P4-P9) for synergistic therapy in combination with colistin antibiotics against bacteria. 
We evaluated the minimal inhibitory concentrations (MIC) for polymers and colistin using broth 
dilution methods as reported in Figure 7.2 d.29,30 Next, we performed checkerboard titrations for 
varied combinations of polymers and colistin and evaluated their FICI (Fractional Inhibitory 
 119 
 
Concentration Index) scores. A FICI score of ≤ 0.5 is defined as a synergistic interaction, whereas 
an additive interaction has FICI score between 0.5 and 4.31,32 Polymers (P7–P9) with higher 
membrane-sensitizing ability exhibited synergistic response in combination with colistin 
antibiotic (FICI scores ranging from 0.375 – 0.5) as shown in Figure 7.2. Moreover, an 8- to 16-
fold reduction in colistin dosage was observed when used in combination with P7-P9 (Table 7.1). 
While polymers (P4-P6) with lesser membrane permeation ability showed additive response (0.5 
< FICI < 1). We further investigated the cytotoxicity of the most potent polymers (P7-P9) by 
performing cytotoxicity assays on human fibroblast cell line.25 We determined the IC50 (half-
maximal inhibitory concentration) of the cells to calculate therapeutic selectivity of polymers 
(ability to kill bacteria while causing minimal toxicity to mammalian cells). Least hydrophobic 
polymer P7 demonstrated an IC50 of ~22 µM, providing a therapeutic selectivity (IC50/MIC) of 
~360. While polymer P8 and P9 demonstrated an IC50 ~ 20 and 2.5 µM, generating a therapeutic 
selectivity of ~160 and ~20, respectively. 
Table 7.1. Fold-increase in antibiotic efficacy obtained for the combination of PNPs and 
antibiotics tested against multiple strains. 
Species (Strain) Polymer Fold-increase in 
antibiotic efficacy 
E. coli (CD-2) P4 0 
E. coli (CD-2) P5 0 
E. coli (CD-2) P6 2 
E. coli (CD-2) P7 8 
E. coli (CD-2) P8 8 
E. coli (CD-2) P9 8 
P. aeruginosa (CD-1006) P7 16 
En. Cloacae (CD-1412) P7 16 
E. coli (CD-549) P7 8 
Acinetobacter species (CD-575) P7 8 
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P. aeruginosa (CD-1006) P8 8 
 
After establishing synergistic interaction between PNPs and colistin antibiotic against E. 
coli, we tested PNP-colistin combination against multiple uropathogenic clinical isolates to 
determine their broad-spectrum applicability. P7 PNPs showed synergistic effect against Gram-
negative clinical isolates of P. aeruginosa, E. cloacae complex, MDR E. coli and Acinetobacter 
species (Figure 7.3), yielding up to 16-fold reduction in colistin dosage to combat the resistant 
bacteria. Similarly, other analogues of PNPs (P8) also demonstrated synergistic response with 
colistin against Gram-negative strains of P. aeruginosa (SI Figure 7.5). On the other hand, PNP-
colistin combination tested against Gram-positive strains (methicillin-resistant S. aureus, B. 
subtilis and S. epidermidis) exhibited additive interactions (Figure 7.6). These results indicate that 
using membrane-sensitizing polymeric nanoparticles can be used as a general strategy to generate 
synergistic antimicrobial therapy against Gram-negative MDR bacteria.  
We hypothesized that PNP-colistin combination disrupted Gram-negative bacterial 
membranes at sub-inhibitory dosages, owing to the strong cationic and hydrophobic nature of the 
PNPs.25 Our claims were supported by staining assays using membrane impermeable crystal 
violet (CV) dye where PNP-colistin combination showed increased CV accumulation inside cells 
as compared to PNPs and colistin alone (Figure 7.3 f).33,34 Additionally, bacterial membrane 
disruption was further monitored by measuring the zeta potential of bacterial surface. Bacteria 
treated with PNP-colistin combination (at sub-lethal dosages) showed sharp shift towards neutral 
charge as compared to the controls, indicating increased membrane disruption and decreased 
bacterial viability (Figure 7.3 g).33,35    
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Figure 7.3. Checkerboard broth microdilution assays between colistin and P7 PNPs against 
uropathogenic a. P. aeruginosa (CD-1006), b. En. cloacae complex (CD-1412), c. MDR E. coli 
(CD-549), d. Acinetobacter species (CD-575). e. Table showing MICs (Minimum Inhibitory 
Concentration) and FICI (Fractional Inhibitory Concentration) scores obtained for PNP-colistin 
combination against different strains of bacteria. Change in bacteria membrane permeability 
assayed by f. crystal violet uptake and g. zeta potential in presence of PNP, colistin and PNP-
colistin combination. 
After establishing the ability of PNP-colistin combination against planktonic “superbugs”, 
we investigated the combination against resistant biofilms. Biofilms are three-dimensional micro-
colonies of bacteria embedded inside an extra polymeric substance (EPS) matrix that prevents the 
penetration of antibiotics inside the biofilms.7,8,9 Limited biofilm penetration plays a major role in 
rendering antibiotics ineffective against biofilm-associated infections. On the other hand, 
amphiphilic PNPs have shown excellent ability to penetrate biofilms. We hypothesized that using 
colistin in combination with PNPs would be able to enhance the penetration and accumulation of 
colistin inside the biofilms, thereby increasing the overall therapeutic effect of the combination 
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therapy.36,37 We treated DsRed-expressing E. coli biofilm with Rhodamine Green-tagged colistin 
in presence and absence of PNPs and examined using confocal microscopy. As shown in Figure 
7.4, antibiotic accumulation inside biofilms increased by ~4-fold in presence of polymers as 
compared to the controls. Furthermore, fluorescent-tagged colistin was homogenously distributed 
throughout the biofilms when used in combination with PNPs, whereas in absence of PNPs 
colistin was confined to the top layer of the biofilm. These results demonstrate that cationic PNPs 
can increase the accumulation of antibiotics inside the biofilms. 
 
Figure. 7.4. a. Representative 3D projection of confocal images stacks of DsRed (Red 
Fluorescent Protein) expressing E. coli DH5α biofilm after 1-hour treatment with Rhodamine 
Green-tagged colistin (1 mg. L-1) in presence and absence of PNP. The panels are projection at 90° 
angle turning along X axis. Scale bars are 30 μm. b. Integrated intensity of Rhodamine Green and 
DsRed biofilm where 0 µm represents the top layer and ~8 um the bottom layer. Checkerboard 
broth microdilution assays between colistin and P7 PNPs against uropathogenic biofilm c. P. 
aeruginosa (CD-1006), d. E. coli (CD-2). e. Table showing MBECs (Minimum Biofilm 
Eradication Concentration) and FICI (Fractional Inhibitory Concentration) scores obtained for 
PNP-colistin combination against biofilms. 
Next, we investigated the therapeutic efficacy of the PNP-colistin combination against 
biofilms. We evaluated minimum biofilm inhibition concentration (MBIC) and minimum biofilm 
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eradication concentration (MBEC) for PNPs and colistin using broth dilution methods as reported 
in Figure 4.38,39,40 We then performed checkerboard titrations using PNP-colistin combination 
against biofilms and evaluated the FICI (Fractional Inhibitory Concentration Index) scores to 
evaluate the efficacy of combinations. FICI scores for PNP-colistin combinations demonstrated 
synergistic effect as compared to the FICI scores for the individual components, with ~32-fold 
decrease in colistin dosage. Similar checkerboard studies performed using colistin with other PNP 
analogues (P8) also showed synergistic effect against biofilms (Figure 7.7). These results further 
indicate that using cationic and hydrophobic PNPs can be used a general strategy to increase the 
accumulation of antibiotics inside the biofilms, thereby increasing their potency. 
7.3. Conclusions 
We have designed bacterial membrane-sensitizing and biofilm penetrating polymeric 
nanoparticles that exhibit synergistic interaction with last-resort antibiotic colistin. The bacterial 
membrane permeability of these polymeric nanoparticles can be regulated by incorporating 
hydrophobic moieties in the polymer structure. PNPs can enhance the potency of colistin up to 
16-fold, owing to the increased susceptibility of bacterial membrane to the polymers. Moreover, 
polymeric nanoparticles enhance the accumulation of antibiotics inside the biofilms, resulting in 
synergistic effect of PNP-colistin combination in eradicating biofilms. PNPs render biofilms 
susceptible to colistin and reduce the antibiotic dosage by 32-fold as compared to antibiotic alone. 
Taken together, strong membrane permeability and biofilm penetration ability of PNPs make 
them promising candidates to enhance the efficacy of standard antibiotic therapies while 
circumventing the concerns associated with high antibiotic dosage. Moreover, combination 
therapies using PNPs have the potential to rejuvenate antibiotics that are rendered ineffective due 
to antibiotic-resistance.    
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7.4 Experimental methods 
7.4.1. Oxanorbornene polymer synthesis 
Oxanorbornene monomers featuring 2,6 and 11 bridging carbon chains were synthesized using 
our own previously reported protocol.41 The oxanorbornene monomers were then polymerized 
through Ring Opening Metathesis Polymerization using Grubbs 3rd generation catalyst as reported 
previously.42 Next, the oxanorbornene polymers were post-functionalized with necessary tertiary 
amines to generate a library of quaternary ammonium poly(oxanorbornene) derivatives using the 
methodology reported previously.41,37,43 Finally, the polymers were added to 10,000 MWCO 
dialysis membranes and allowed to stir for 3 days, changing the water periodically. The polymers 
were filtered through PES syringe filters and freeze-dried to yield all the respective quaternary 
ammonium polymers and characterized using 1H NMR.41 
7.4.2. Synthesis of RhodamineGreen-Colistin  
To a 7ml scintillation vial equipped with a stirbar was added Colistin (0.005 g, 0.004 mmol, 1 eq), 
triethylamine (1.2 µL, 0.0089 mmol, 2.05 eq) and DMF (0.5ml) and allowed to stir. Meanwhile, 
Rhodamine Green™ Carboxylic Acid, Succinimidyl Ester, Hydrochloride (5(6)-CR 110, SE) 
(0.0022 g, 0.004 mmol, 1 eq) was dissolved in 4 ml of DMF. At room temperature, the solution 
of Rhodamine Green was added slowly over the course of 2 hours. Once the addition was 
complete, the reaction mixture was covered with aluminum foil and allowed to stir overnight. 
Afterwards, the reaction mixture was transferred to the appropriately sized round bottom flask 
and rotovaped in the presence of toluene until all DMF was removed. Next, the residue was 
sonicated using THF and DCM and carefully decanted away. With all solvent removed, minimal 
amount of water was added and sonicated to dissolve the residue, filtered through a PES syringe 
filter and lyophilized to yield the RhodamineGreen-Colistin conjugate (red powder). MALDI 
analysis confirmed the M+1 species, 1512 g/mol. 
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7.4.3. Determination of Minimum Inhibitory Concentrations (MICs)  
MIC is defined as the lowest concentration of an antimicrobial agent required to inhibit the 
growth of bacteria overnight as observed from the naked eye.29 Bacteria cell were grown using 
the protocol described above. Next, bacterial solutions with concentrations of 1×106 cells/mL 
were prepared in M9 media. 50 μL of prepared bacteria solution were mixed with 50 µL of 
polymer/antibiotic prepared in M9 media in a 96-well clear plate resulting in final bacterial 
concentration of 5×105 cells/mL.  Polymers were tested with half-fold variations in 
concentrations as per the standard protocols in concentration ranging from 64,000 nM – 4 nM.  A 
sterile control group with no bacterial cells present and growth control group without addition of 
any polymers were carried out at the same time. The prepared 96-well plates were incubated for 
16 hours. The experiments were performed in triplicates with two individual runs performed on 
different days. 
7..4.4. Checkerboard titrations for combination therapy  
We performed two-dimensional checkerboard titrations using micro-dilution method to determine 
the synergy between antibiotics and polymers.31 The concentration of Polymers and colistin were 
varied using 2-fold serial dilutions. The wells without any visual growth were considered as a 
combination that inhibits bacterial growth. For the colistin-polymer combinations, concentrations 
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of the components were varied according to their MIC against the respective bacterial strains. The 
checkerboard titrations were performed in a set of three independent plates and repeated on 
different days.  
Fractional Inhibitory Concentration Index (FICI) for Colistin-polymer combination was 
calculated using FICs of colistin and polymer independently using the following equation: 
FICC = (𝑀𝐼𝐶 𝑜𝑓 𝑐𝑜𝑙𝑖𝑠𝑡𝑖𝑛 𝑎𝑛𝑑 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛) ÷ (𝑀𝐼𝐶 𝑜𝑓 𝑐𝑜𝑙𝑖𝑠𝑡𝑖𝑛 𝑎𝑙𝑜𝑛𝑒) 
FICP = (𝑀𝐼𝐶 𝑜𝑓 𝑐𝑜𝑙𝑖𝑠𝑡𝑖𝑛 𝑎𝑛𝑑 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑐𝑜𝑚𝑏𝑖𝑛𝑎𝑡𝑖𝑜𝑛) ÷ (𝑀𝐼𝐶 𝑜𝑓 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑎𝑙𝑜𝑛𝑒) 
FICI = FICC + FICP 
FICI values ≤ 0.5 corresponds to synergistic combination, whereas  FICI values 
between >0.5 and 4.0 indicates additive effect. FICI values > 4.0 respond to antagonistic effect.31  
7.4.5. Mammalian cell viability assay  
Cell viability studies performed using the previously established protocols.18 Briefly, 20,000 
NIH 3T3 Fibroblast cells (ATCC CRL-1658) were cultured in Dulbecco’s modified Eagle 
medium (DMEM, ATCC 30-2002) with 1% antibiotics and 10% bovine calf serum in a 
humidified atmosphere of 5% CO2 at 37 °C for 48 hours. Media was replaced after 24 hours and 
the cells were washed (one-time) with phosphate-buffered saline (PBS) before incubation with 
polymers. Polymer solution were prepared in 10%serum containing media (pre-warmed) and 
incubated with cells in a 96-well plate for 24 hours in a humidified atmosphere at 37 °C. Alamar 
Blue assays were performed to assess the cell viability as per the established protocol of 
Invitrogen Biosource (manufacturer). Red fluorescence resulting upon the reduction of alamar 
blue agent was quantified using a Spectromax M5 microplate reader (Ex: 560 nm, Em: 590 nm) 
and used to determine cell viability. Cells incubated with no polymers were considered as 100% 
viable. Each experiment was performed in triplicates and repeated on two different days.      
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7.4.6. Membrane penetration using crystal violet assay  
Bacteria cells were cultured, and their concentrations were measured using the methodology 
reported above. Crystal violet assay were performed using the previously reported protocols.33 
Briefly, 0.1 OD bacterial solution was prepared in phosphate-buffered saline (PBS) solution then, 
incubated with the test material for 30 minutes at 37 °C. Untreated cell which served as the 
negative control was prepared similarly without treatment. The cells were harvested by 
centrifugation at 9300×g for 5 minutes at 4 °C followed by redispersion in PBS with 5 μg/mL 
crystal violet. After incubation at 37 °C for 10 minutes, the bacterial cell solution was centrifuged 
at 13,400×g for 15 min. The resulting pellet was resuspended in 80:20 ethanol: acetone and the 
OD of the solution was measured at 590 nm using a Molecular Devices SpectraMax M2. OD 
value from the normal untreated cell was used as blank while the OD value of crystal violet 
solution was considered as 100%. The percentage of crystal violet uptake was expressed as 
follows: 
%CV uptake = 
𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒−𝑂𝐷 𝑏𝑙𝑎𝑛𝑘
𝑂𝐷 𝐶𝑉 𝑜𝑛𝑙𝑦−𝑂𝐷 𝑏𝑙𝑎𝑛𝑘
 𝑥 100 
7.4.7. Monitoring zeta potential of bacterial membrane  
Zeta potential for bacteria membrane was monitored using previously reported protocol.35 
Briefly, bacteria were cultured and harvested as per the above-mentioned protocols. Next, 0.01 
OD of bacteria cells in phosphate buffer (PB) solution (5 mM, pH=7.4) was incubated with the 
test materials (colistin only, polymer only and their combinations) at 37 °C for 15 minutes. The 
cells were harvested by centrifugation (7000×g for 5 minutes, 4 °C), then the resulting pellets 
were resuspended in PB. Solutions were then subjected to zeta potential measurements using 
Zetasizer Nano ZS. Untreated bacteria were used as the negative control.  
7.4.8. Biofilm formation and penetration studies using confocal microscopy  
DsRed-expressing bacteria were inoculated in lysogeny broth (LB) medium at 37 ˚C until 
stationary phase. The cultures were then harvested by centrifugation and washed with 0.85% 
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sodium chloride solution three times. Concentrations of resuspended bacterial solution were 
determined by optical density measured at 600 nm. 108 bacterial cells/mL of DsRed (fluorescent 
protein) expressing E. coli, supplemented with 1 mM of IPTG ((isopropyl β-D-1-
thiogalactopyranoside), were seeded (2 mL in M9 media) in a confocal dish and were allowed to 
grow.18c After 3 days media was replaced by a combination of 1 mg. L-1 of Rhodamine Green-
Colistin and P7 PNPs (150 nM) and incubated for 1 hour. Biofilm samples incubated with only 
Rhodamine Green-Colistin (1 mg. L-1) were used as control. The cells were then washed with 
PBS three times. Confocal microscopy images were obtained on a Zeiss LSM 510 Meta 
microscope by using a 63× objective. The settings of the confocal microscope were as follows: 
green channel: λex=488 nm and λem=BP 505-530 nm; red channel: λex=543 nm and λem=LP 650 
nm. Emission filters: BP=band pass, LP=high pass. 
7.4.9. Determination of minimum biofilm eradication concentration (MBEC)  
MBEC is defined as the minimum concentration of an antimicrobial agent at which there is no 
bacteria (biofilm) growth. We used previously established protocols to determine the MBECs for 
the polymers and antibiotics.38 Briefly, bacterial cells from an overnight culture were diluted to 
1/5th using tryptic soy broth (TSB) and incubated at 275 rpm, 37 °C until they reach mid-log 
phase. 150 μL of bacteria solution was added to each row of a 96-well microtiter plate with 
pegged lid. Biofilms were cultured by incubating the plate for 6 hours in an incubator-shaker at 
37 °C at 50 rpm. Then, the pegged lid was washed with 200 μL PBS for 30 seconds and 
transferred to a plate containing the test material prepared in a separate 96-well plate using M9 
minimal media. The plate was incubated at 37 °C for 24 hours. Then, the biofilms on the peg-lid 
were washed with PBS and transferred to a new plate containing only M9 minimal media. The 
plate was further incubated at 37 °C to determine the Minimum Biofilm Eradication 
Concentration (MBEC).  
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Checkerboard titration for synergy testing for eradication of biofilms: Two-dimensional 
checkerboard titrations similar as described above were used testing synergy against biofilms. 
The concentration of Polymers and colistin were varied using 2-fold serial dilutions and MBEC 
was determined using the above-mentioned protocol.31 The wells without any visual growth 
were considered as a combination that eliminates biofilm formation. For colistin-polymer 
combinations, concentrations of the components were varied according to their MBEC against the 
respective bacterial strains. 
7.5 Supplementary Information 
                          
Figure 7.5. Checkerboard titration between colistin and P8 polymer against P. aeruginosa (CD-
1006). Dark cells represent higher cell density. 
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Figure 7.6. Checkerboard titration between colistin and P7 polymer against a. Bacillus subtills b. 
S. epidermidis and c. methicillin-resistant S. aureus (CD-489). Dark cells represent higher cell 
density. The combinations did not show any significant increase in the efficacy of the antibiotics.  
                               
Figure 7.7. Checkerboard broth microdilution assays between colistin and P8 PNPs against 
uropathogenic biofilm E. Coli (CD-2). The combination shows upto 16-fold increase in the 
efficacy of colistin at sub-MBEC dosage of P8 PNPs. 
7.6 References
 
1. B. Li, T. J. Webster, J. Orthop. Res. 2018, 36, 22. 
2. C. Willyard, Nature 2017, 543, 15. 
3. H. Kunishima, Nihon Naika Gakkai Zasshi 2014, 102, 2839. 
4. L. B. Rice, Infect. Control Hosp. Epidemiol. 2010, 31, S7. 
5. P. D. Leeson, B. Springthorpe, Nat. Rev. Drug Discov. 2007, 6, 881. 
6. H. I. Zgurskaya, C. A. López, S. Gnanakaran, ACS Infect. Dis. 2016, 1, 512. 
7. C. A. Fux, J. W. Costerton, P. S. Stewart, P. Stoodley, Trends Microbiol. 2005, 13, 34. 
8. R. M. Donlan, Emerg. Infect. Dis. 2001, 7, 277. 
9. H. Spapen, R. Jacobs, V. Van Gorp, J. Troubleyn, P. M. Honoré, Ann. Intensive Care 2011, 1, 
14. 
10. P. G. Bowler, B. I. Duerden, D. G. Armstrong, Clin. Microbiol. Rev. 2001, 14, 244. 
11. B. Parsons, E. Strauss, Am. J. Surg. 2004, 188, 57. 
12. B. Spellberg, J. H. Powers, E. P. Brass, L. G. Miller, J. E. Edwards, Clin. Infect. Dis. 2004, 38, 
1279. 
13. T. Tängdén, Ups. J. Med. Sci. 2014, 119, 149. 
 131 
 
 
14. P. D. Tamma, S. E. Cosgrove, L. L. Maragakis, Clin. Microbiol. Rev. 2012, 25, 450. 
15. E. D. Brown, G. D. Wright, Nature 2016, 529, 336. 
16. A. H. Delcour, Biochim. Biophys. Acta 2009, 1794, 808. 
17. J. M. Stokes, C. R. Macnair, B. Ilyas, S. French, J. P. Côté, C. Bouwman, M. A. Farha, A. O. 
Sieron, C. Whitfield, B. K. Coombes, E. D. Brown, Nat. Microbiol. 2017, 2, 17028.  
18. P. S. Stewart, J. W. Costerton, Lancet (London, England) 2001, 358, 135.  
19. J. N. Anderl, M. J. Franklin, P. S. Stewart, Antimicrob. Agents Chemother. 2000, 44, 1818. 
20. A. Gupta, R. Das, G. Yesilbag Tonga, T. Mizuhara, V. M. Rotello, ACS Nano 2018, 12, 89. 
21. A. Gupta, S. Mumtaz, C. H. Li, I. Hussain, V. M. Rotello, Chem. Soc. Rev. 2019, 48, 415. 
22. G. N. Tew, R. W. Scott, M. L. Klein, W. F. Degrado, Acc. Chem. Res. 2010, 43, 30. 
23. A. Jain, L. S. Duvvuri, S. Farah, N. Beyth, A. J. Domb, W. Khan, Adv. Healthc. Mater. 2014, 
3, 1969. 
24. M. J. Hajipour, K. M. Fromm, A. Akbar Ashkarran, D. Jimenez de Aberasturi, I. R. de 
Larramendi, T. Rojo, V. Serpooshan, W. J. Parak, M. Mahmoudi, Trends Biotechnol. 2012, 30, 
499. 
25. H. Takahashi, E. T. Nadres, K. Kuroda, Biomacromolecules 2017, 18, 257. 
26. A. Gupta, R. F. Landis, C. H. Li, M. Schnurr, R. Das, Y. W. Lee, M. Yazdani, Y. Liu, A. 
Kozlova, V. M. Rotello, J. Am. Chem. Soc. 2018, 140, 12137. 
27. C. R. MacNair, J. M. Stokes, L. A. Carfrae, A. A. Fiebig-Comyn, B. K. Coombes, M. R. 
Mulvey, E. D. Brown, Nat. Commun. 2018, 9, 458. 
28. I. M. Helander, T. Mattila-Sandholm, J. Appl. Microbiol. 2000, 88, 213. 
29. I. Wiegand, K. Hilpert, R. E. W. Hancock, Nat. Protoc. 2008, 3, 163. 
30. X. Li, S. M. Robinson, A. Gupta, K. Saha, Z. Jiang, D. F. Moyano, A. Sahar, M. A. Riley, V. 
M. Rotello, ACS Nano 2014, 8, 10682. 
31. F. C. Odds, J. Antimicrob. Chemother. 2003, 52, 1. 
32. A. Gupta, N. M. Saleh, R. Das, R. F. Landis, A. Bigdeli, K. Motamedchaboki, A. R. Campos, 
K. Pomeroy, M. Mahmoudi, V. M. Rotello, Nano Futur. 2017, 1, 015004. 
33. S. Halder, K. K. Yadav, R. Sarkar, S. Mukherjee, P. Saha, S. Haldar, S. Karmakar, T. Sen, 
Springerplus 2015, 4, 672. 
34. P. Plesiat, H. Nikaido, Mol. Microbiol. 1992, 6, 1323. 
 132 
 
 
35. H. Bai, H. Yuan, C. Nie, B. Wang, F. Lv, L. Liu, S. Wang, Angew. Chemie - Int. Ed. 2015, 54, 
13208. 
36. A. Gupta, R. F. Landis, V. M. Rotello, F1000Research 2016, 5, 364. 
37. R. F. Landis, C. H. Li, A. Gupta, Y. W. Lee, M. Yazdani, N. Ngernyuang, I. Altinbasak, S. 
Mansoor, M. A. S. Khichi, A. Sanyal, V. M. Rotello, J. Am. Chem. Soc. 2018, 140, 6176. 
38. H. Ceri, M. E. Olson, C. Stremick, R. R. Read, D. Morck, A. Buret, J. Clin. Microbiol. 1999, 
37, 1771. 
39. J. J. Harrison, C. A. Stremick, R. J. Turner, N. D. Allan, M. E. Olson, H. Ceri, Nat. Protoc. 
2010, 5, 1236. 
40. J. Li, K. Zhang, L. Ruan, S. F. Chin, N. Wickramasinghe, H. Liu, V. Ravikumar, J. Ren, H. 
Duan, L. Yang, M. B. Chan-Park, Nano Lett. 2018, 18, 4180. 
41. A. Gupta, R. F. Landis, C. H. Li, M. Schnurr, R. Das, Y. W. Lee, M. Yazdani, Y. Liu, A. 
Kozlova and V. M. Rotello, J. Am. Chem. Soc., 2018, 140, 12137–12143. 
42. Madkour, A. E.; Koch, A. H. R.; Lienkamp, K.; Tew, G. N. Macromolecules 2010, 43 (10), 
4557. 
43. W. J. Peveler, R. F. Landis, M. Yazdani, J. W. Day, R. Modi, C. J. Carmalt, W. M. Rosenberg, 
V. M. Rotello, Adv. Mater. 2018, 30, 1800634. 
 133 
 
CHAPTER 8 
CROSSLINKED POLMER-STABILIZED NANOCOMPOSITES FOR THE 
TREATMENT OF BACTERIAL BIOFILMS 
8.1 Introduction 
MDR bacterial infections are an emerging threat to human health.1 According to a recent 
report, MDR bacterial infections are responsible for 700,000 deaths each year all over the world 
and by 2050 this number is expected to increase to more than 10 million.2 In particular, wounds 
and indwelling systems such as catheters,3 joint prosthesis,4 and other medical implants5 are often 
infected by biofilms, micro-colonization of bacteria.6 Biofilms secrete extracellular polymeric 
substances7 (EPS) which acts as a protective barrier against antibiotics, limiting the efficacy of 
drugs including vancomycin, 8  teicoplanin, 9  and colistin 10  deemed as, “drugs of last resort”. 
Excising infected tissues/implants 11  and long-term antibiotic therapy 12  is currently the best 
treatment for combatting biofilm-based infections. This “gold standard” treatment however has 
obvious limitations, including incurring extensive health care costs 13  and leaving patients 
bedridden with concomitant suffering. 
Phytochemicals,14,15 extracts from plants inherently responsible for their self-defense,16 
have emerged as promising tools to combat MDR bacteria.17 These essential oils are of particular 
interest as “green” antimicrobial agents 18  due to their low cost, 19  biocompatibility, 20 , 21  and 
potential anti-biofilm properties.22 Previous studies have demonstrated that numerous essential 
oils are severely cytotoxic towards pathogenic bacteria, 23 , 24  however, poor solubility 25  and 
stability26 in aqueous media has substantially limited their therapeutic application. Essential oils 
can be encapsulated into surfactant-stabilized colloidal delivery vehicles to enhance their aqueous 
stability and antimicrobial activity against bacteria. 27  However, these carriers have not been 
shown to be stable in serum, restricting their use in relevant biological conditions. Furthermore, 
surfactant stabilized emulsions are susceptible to Ostwald ripening, 28  significantly impairing 
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long-term shelf life and practical use.  It is critical to develop essential oil delivery vehicles that 
provide good shelf life, maintain stability in complex biofluids, and effectively treat MDR 
biofilms. 
Previously, we have designed a self-assembled micron-sized essential oil-in-water 
Pickering emulsion with the use of silica nanoparticles which could effectively eradicate bacterial 
biofilms.29 We hypothesized that using a polymer-stabilized essential oil platform would enable 
us to generate nano-sized emulsions to improve the delivery of the payload30 and increase its 
stability31 by incorporating crosslinking strategies. Herein, we report an essential oil-in-water 
crosslinked polymer nanocomposite (X-NC). The nanocomposite exhibits long-term shelf life 
high stability in serum media, and could readily penetrate throughout biofilms as evidenced by 
confocal experiments. X-NCs showed efficient killing of multiple pathogenic biofilms including 
methicillin-resistant Staphylococcus aureus (MRSA). Furthermore, their ability to treat wound 
biofilms was tested in a fibroblast-biofilm co-culture model, which showed effective eradication 
of biofilms while maintaining high fibroblast cell viability. Taken together, our X-NC is shown to 
be an excellent candidate to treat wounds and indwelling systems contaminated with pathogenic 
bacteria/biofilms. 
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Figure 8.1. Schematic depiction of the strategy used to generate antimicrobial composites a. 
Carvacrol oil with dissolved p-MA-alt-OD is emulsified with an aqueous solution containing the 
PONI-GAT polymer. The anhydride units on p-MA-alt-OD react with the amines on PONI-GAT. 
This crosslinking reaction simultaneously pulls the polymer into the oil phase as the polymer 
becomes more hydrophobic, generating an oil-containing nanocomposite structure. b. Composites 
release their payload disrupting the biofilm, eliminating the bacteria. 
8.2 Results and discussion 
Poly(oxanorbornene imide) polymers (PONIs) were chosen to stabilize the essential oil 
nanocomposites as they are well-controlled, 32  easily modulated, 33  and scalable. 34  To ensure 
effective crosslinking to stabilize the oil, we dissolved the commercially available poly(maleic 
anhydride-alt-1-octadecene) (p-MA-alt-OD) at different weight percentages within the oil. 
Incorporating amine functionalities within PONI would enable fast crosslinking with the maleic 
anhydride units.35 Guanidine functionality was added onto PONIs for charge neutralization with 
the released carboxylates from the anhydride,36 enabling PONIs to partition further into the oil 
phase for further amidation reactions. In addition, tetraethylene glycol monomethyl ether (TEG-
ME) functionality can impart extra amphiphilicity so that PONIs are water-soluble yet can 
partition into the oil. Therefore, we synthesized copolymer PONIs bearing guanidine, amino, and 
TEG-ME units (PONI-GAT) at a 35-35-30 monomer ratio respectively (Supporting Information – 
Synthesis of PONI-GAT).  
Antimicrobial nanocomposites were generated using an oil emulsion template as shown 
in Figure 8.1. Nanocomposites were created by emulsifying carvacrol oil loaded with p-MA-alt-
OD or carvacrol only (non-crosslinked control) into Milli-Q H2O adjusted to a pH of 10 
containing PONI-GAT (The pH was adjusted to ensure nucleophilicity of the amines on PONI-
GAT). Upon emulsification, PONI-GAT partitions to the oil-water interface to initially stabilize 
the carvacrol oil droplets and with p-MA-alt-OD present, crosslinking further stabilizes the oil. 
Optimization, such as varying the amount of PONI-GAT and p-MA-alt-OD was performed to 
determine the smallest, yet most stable formulation. With a final PONI-GAT concentration of 6 
µM and 10 wt% of p-MA-alt-OD, nanocomposites with a size of ~250 nm were generated.  
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Figure 8.2. Confocal micrograph of a. X-NCs. PONI-GAT was partially labeled with TRITC 
(red fluorescence) and the oil core is loaded with DiO (green fluorescence). Scale bars are 1 μm. 
b. Percentage of amines remaining on PONI-GAT after X-NCs formation. 
We hypothesize that reacting PONI-GAT with p-MA-alt-OD would change its inherent 
hydrophobicity and enhance partitioning within the oil. To test this hypothesis, 
tetramethylrhodamine-5-isothiocyanate (TRITC, red fluorescence) was conjugated to PONI-GAT 
while 3,3-Dioctadecyloxacarbocyanine (DiO, green fluorescence) was loaded within the oil. In 
addition, the formulation was modulated to generate micron-sized emulsions so that confocal 
experiments could be performed. As shown in Figure 8.2 a, both green and red fluorescence was 
co-localized within the oil, indicating a composite morphology. 
Theoretically, a crosslinking reaction between amines and anhydrides at the oil-water 
interface would yield carboxylates, imparting negative charge. We examined the surface charge 
of the nanocomposite and found the surface to be negatively charged regardless of the amount of 
p-MA-alt-OD added. Furthermore, attenuated total reflectance Fourier transform infrared 
spectroscopy (ATR-FTIR) indicated complete loss of anhydrides and formation of 
amides/carboxylates after formation of the nanocomposite. To further explore the crosslinking, a 
fluorescamine assay37 (Figure 8.2 b) was performed to identify the progression of the reaction 
between amines on PONI-GAT and the anhydrides on p-MA-alt-OD. PONI-GAT was used to 
generate a calibration curve relating to the polymer concentration and the respective fluorescence 
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generated from the assay. The fluorescamine assay is a valuable tool to monitor primary amines 
by generating fluorescence.38 We expected that as the p-MA-alt-OD wt% increases within the oil, 
more amines will react, and the overall fluorescence generated from fluorescamine will decrease. 
The results show that a substantial reduction in remaining amines on PONI-GAT occurs as p-
MA-alt-OD increases, showing almost complete reaction at 10 wt%. Taken together, the 
experiments described above support the stabilization of the oil via crosslinking between the 
amines on PONI-GAT and the anhydrides on p-MA-alt-OD, possessing a composite morphology. 
 
Figure 8.3. a. Stability of 10 wt% X-NCs after two days. b. Fluorescence spectra of loaded DiO 
in 10 wt% X-NCs and non-crosslinked analog. Excitation of DiO = 490nm. 
Nanoemulsion stability in biological media is a challenge as biological stresses (protein 
adsorption/corona formation)39 may induce destabilization and aggregation.40 In particular, serum 
stability is critical when considering bacteria/biofilm treatment both topically 41  and 
systemically.42 Negatively charged serum proteins can bind onto delivery vehicles, forming a 
corona. This corona can significantly alter the delivery vehicles size, interfacial composition, and 
ultimately its biological identity. 43  Our crosslinked nanocomposite vehicle which bears a 
negatively charged surface should be resistant to serum protein adsorption. To determine the 
compatibility of our X-NCs in serum conditions, we incubated X-NCs with 10% serum media for 
two days and analyzed the stability of the composites using dynamic light scattering (DLS). As 
shown in Figure 8.3 a, 10 wt% X-NCs showed complete stability with no evidence of 
destabilization/aggregation. As a control, non-crosslinked analogs using the same formulation 
minus p-MA-alt-OD showed no stability in serum. In addition, DiO was loaded into both 
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crosslinked nanocomposites and non-crosslinked analogs and incubated in serum for one hour. 
Destabilization of the non-crosslinked analog would result in leakage and quenched fluorescence 
of the loaded dye.44 Figure 8.3 b shows that DiO maintains its fluorescence within the X-NCs 
while its non-crosslinked analog shows no fluorescence, further supporting the stability of X-NCs 
in serum conditions. Taken together, our crosslinking strategy provides stability in serum 
containing media. 
Having established a composite morphology with successful crosslinking to impart 
stability, we probed the ability of X-NCs to penetrate into biofilms. X-NCs loaded with DiO 
within the oil were used to track the delivery of nanocomposites in the biofilms formed by Red 
Fluorescent Protein (RFP) expressing Escherichia coli. As shown in Figure 8.4, the X-NCs 
diffuse into the biofilm matrix and efficiently disperse throughout the biofilm, co-localizing with 
the bacteria. This data supports X-NCs deliver their payload and that the oil core and 
nanocomposite fabrication strategy are operative for effective delivery. 
 
Figure 8.4. Confocal image stacks of 1 day-old E. coli DH5α biofilm after 3 h treatment with 10 
wt% X-NCs. Scale bars are 30 µm. 
Next, we investigated the therapeutic efficacy of the X-NCs against multiple pathogenic 
biofilms. Four pathogenic bacterial strains of clinical isolates, Pseudomonas aeruginosa (CD-
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1006), Staphylococcus aureus (CD-489, a methicillin-resistant strain), Escherichia coli (CD-2), 
and Enterobacter cloacae (E. cloacae, CD-1412) complex were chosen to test our system. As 
shown in Figure 8.5, X-NCs were able to effectively kill bacterial cells in all four biofilms within 
three hours. The isolated components used to generate the nanocomposites, carvacrol oil and 
PONI-GAT, were ineffective at eradicating the biofilms, indicating that the combination of all the 
components to generate X-NCs is critical for maximum therapeutic efficiency. Notably, X-NCs 
are able to effectively treat both Gram negative (E. coli, P. aeruginosa, and E. cloacae complex) 
and Gram positive (S. aureus) bacteria, supporting the broad spectrum activity of X-NCs as a 
viable platform treatment complementary to traditional antibiotics. 
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Figure 8.5. Viability of 1 day-old a. E. coli (CD-2), b. S. aureus (CD-489), c. P. aeruginosa 
(CD-1006), and d. E. cloacae complex (CD-1412) biofilms after 3 h treatment with 10 wt% X-
NCs, carvacrol oil, and PONI-GAT at different emulsion concentrations (v/v % of emulsion). The 
data are average of triplicates, and the error bars indicate the standard deviations. 
Biofilm infections associated with wounds and indwelling implants interfere with the 
host’s ability to regenerate damaged tissue.45 In particular, fibroblasts play a key role during 
wound healing processes by aiding to close the area and redevelop necessary extracellular matrix 
within the skin.46 We used an in vitro co-culture model comprised of mammalian fibroblasts cells 
with bacterial biofilm grown over them. P. aeruginosa bacteria were seeded with a confluent NIH 
3T3 fibroblast cell monolayer overnight to generate biofilms prior to X-NCs treatment. The 
cocultures were treated with X-NCs for three hours, washed, and the viabilities of both bacteria 
and fibroblasts were determined.  As shown in Figure 8.6, X-NCs effectively treated the biofilm 
infection while 3T3 fibroblast viability was largely unaffected. It was observed that 15 v/v % of 
generated emulsion solution was sufficient to eradicate 99.5% of the bacteria within the biofilm. 
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Figure 8.6. Viability of 3T3 fibroblast cells and P. aeruginosa biofilms in the coculture model 
after 3 h treatment with 10 wt% X-NCs at different emulsion concentrations (v/v % of emulsion). 
Scatters and lines represent 3T3 fibroblast cell viability. Bars represent log10 of colony forming 
units in biofilms. The data are average of triplicates and the error bars indicate the standard 
deviations. 
8.3 Conclusions 
In summary, we report the fabrication of a polymer-stabilized oil-in-water nanocomposite 
which demonstrates high therapeutic activity towards pathogenic biofilms. These nanocomposites 
show high stability in serum and can effectively penetrate throughout biofilms. Furthermore, 
effective elimination of a biofilm infection while maintaining fibroblast viability in an in vitro 
coculture was observed. We envision these nanocomposites as a valuable treatment option for 
topical wounds by loading them onto various medical devices. Future studies will probe 
composite performance in combatting topical in vivo biofilms along with assays to determine if 
bacteria acquire resistance towards the essential oil payload. Furthermore, bio-degradable analogs 
are currently being formulated and evaluated; expanding our arsenal. The polymer-based 
crosslinked emulsion strategy we present provides a promising platform to create effective 
delivery vehicles to combat the ever-increasing danger of MDR bacterial biofilms. 
8.4 Experimental methods 
8.4.1. Synthesis of PONI-GAT. Synthesis of PONI-GAT 
Br
NH3
Br
O
O O
O
O
DCM, Et3N, r.t 
overnight
Br
H
N
O
O
1  
Synthesis of 1. To a 500ml round bottom flask equipped with a stirbar was added 150ml of 
dichloromethane (DCM). Next, 3-Bromopropylamine hydrobromide (10.0g, 45.7mmol, 1.0eq) 
was added to the DCM solution. Then, triethylamine (Et3N) (25.5ml, 182.7mmol, 4.0eq) was 
added to the reaction mixture. Finally Di-tert-butyl dicarbonate (12.6ml, 54.8mmol, 1.2eq) was 
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added dropwise. After addition of di-tert-butyl dicarbonate, the reaction was stirred overnight at 
room temperature (r.t.). Afterwards, the DCM was rotovaped, diluted with 100ml of diethyl ether, 
and extracted with 1M HCL (1x 20ml), saturated sodium bicarbonate (2x 20ml), and brine (1x 
20ml). The organic layer was dried with sodium sulfate, filtered, and rotovaped to yield 1 as a 
clear liquid. 1 was purified using column chromatography and silica gel as the stationary phase. 
1H NMR (400MHz, CDCL3) 4.6 (br, 1H) 3.43 (t, 2H), 3.26 (br, 2H), 2.04 (t, 2H), 1.43 (s, 9H). 
O
NH
O
O
Et2O, 100
o C 
overnight 
Pressure Tube
O
OO N
H
2  
Synthesis of 2. In a pressure tube, furan (4.5ml, 61.7mmol, 1.5eq) and maleimide (4.0g, 
41.1mmol, 1.0eq) were added in addition to 5ml of diethyl ether. The tube was sealed and heated 
at 100oC overnight. Afterwards, the pressure tube was cooled to r.t. and the formed solid was 
removed, filtered, and washed with copious amounts of diethyl ether to isolate 2 as a white solid 
and was used without further purification. 1H NMR (400MHz, MeOD) 11.14 (s, 1H), 6.52 (s, 2H), 
5.12 (s, 2H), 2.85 (s, 2H). 
O
OO N
H
2
1
K2CO3, KI, DMF 
50oC overnight
O
OO N
HN
O
O
3  
Synthesis of 3. To a 100ml round bottom flask equipped with a stirbar was added 30ml of 
dimethylformamide (DMF). Next, 2 (2.36g, 14.3mmol, 1.0eq) was added along with potassium 
carbonate (7.9g, 57.2mmol, 4.0eq). The reaction mixture was heated at 50oC for five minutes. 
Finally, potassium iodide (0.05g, 0.30mmol, 0.02eq) and 1 (3.47g, 14.6mmol, 1.02eq) were 
added and stirred at 50oC overnight. Afterwards, the reaction mixture was cooled to room 
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temperature, diluted to 150ml with ethyl acetate and washed with water (7x, 50ml) and brine (1x, 
50ml). The organic layer was dried with sodium sulfate, filtered, and rotovaped to yield 3 as a 
white solid. 3 was purified using column chromatography and silica gel as the stationary phase. 
1H NMR (400MHz, CDCL3) 6.51 (s, 2H), 5.26 (s, 2H), 5.03 (br, 1H), 3.56 (t, 2H), 3.05 (q, 2H), 
2.86 (s, 2H), 1.73 (quint, 2H) 1.45 (s, 9H). 
O
OO N
HN
O
O
TFA, DCM (1:1)
r.t. 2 h
O
OO N
H3NO
O
F
F F
3
4
 
Synthesis of 4. To a 50ml round bottom flask equipped with a stirbar was added 3 (2.0g, 6.2mmol, 
1.0eq). Nitrogen was bubbled through DCM for five minutes and 5ml was added to the flask 
which was purged with nitrogen. 5ml of trifluoroacetic acid (TFA, excess) was added and the 
reaction was stirred for two hours. Afterwards, excess TFA was removed by rotovaping with 
DCM (3x) yielding 4. 4 was isolated as a white solid by washing with diethyl ether (3x, 10ml) 
and used without further purification and directly used in the next reaction (Ninhydrin test 
confirms free primary amine). 
O
OO N
H3NO
O
F
F F
N
N
NN
H
O
O
O
O
Et3N, MeCN/H2O (9:1) 
r.t. overnight
O
OO N
HN
N
HN
O
O
O
O
4
5  
Synthesis of 5. To a 100ml round bottom flask equipped with a stirbar was added 4 (1.2g, 
3.6mmol, 1.0eq), 45ml acetonitrile (MeCN), and 5ml of water. Triethylamine (4.7ml, 33.5mmol, 
9.2eq) was added and finally N,N′-Di-Boc-1H-pyrazole-1-carboxamidine (1.7g, 5.5mmol, 1.5eq) 
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in portions. The reaction was allowed to stir at r.t. overnight. Afterwards, the solution was diluted 
with 100ml of ethyl acetate and extracted with water (2x, 50ml) and brine (2x, 50ml). The 
organic layer was dried with sodium sulfate, filtered, and rotovaped to yield 5. 5 was purified 
using column chromatography and silica gel as the stationary phase to yield a white solid. 1H 
NMR (400MHz, CDCL3) 8.49 (t, 1H), 6.49 (s, 2H), 5.25 (s, 2H), 3.53 (t, 2H), 3.47 (q, 2H), 2.83 
(s, 2H), 1.82 (quint, 2H), 1.49 (s, 18H). 
 
O
O
O
O
OH
CBr4, PPh3
MeCN, 0oC - 5min 
r.t. - overnight
O
O
O
O
Br
6
 
Synthesis of 6. To a 250ml round bottom flask was added Tetraethyleneglycol monomethyl ether 
(4.2ml, 20.9mmol, 1.0eq) and 80ml of MeCN. The reaction was cooled to 0oC and 
tetrabromomethane (8.4g, 25.1mmol, 1.2eq) was added. Finally, triphenylphosphine (6.6g, 
25.3mmol, 1.2eq) was added in portions and allowed to stir for five minutes at 0oC. After five 
minutes, the reaction was warmed to room temperature and stirred overnight. Afterwards, the 
reaction was concentrated by rotovaping and purified using column chromatography and silica 
gel as the stationary phase to yield 6 as a clear oil (Potassium permanganate was used to visualize 
6). 1H NMR (400MHz, CDCL3) 3.75 (t, 2H), 3.6 (br, 10H), 3.49 (t, 2H), 3.41 (t, 2H), 3.32 (s, 3H). 
O
O
O
O
Br
6
2
K2CO3, KI, DMF 
50oC overnight
O
OO N
O
O
O
O
7
 
 
Synthesis of 7. To a 100ml round bottom flask equipped with a stirbar was added 30ml of DMF. 
Next, 2 (2.84g, 17.2mmol, 1.0eq) was added along with potassium carbonate (9.48g, 68.7mmol, 
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4.0eq). The reaction mixture was heated at 50oC for five minutes. Finally, potassium iodide 
(0.05g, 0.30mmol, 0.02eq) and 6 (4.9g, 18.0mmol, 1.05eq) were added and stirred at 50oC 
overnight. Afterwards, the reaction mixture was cooled to room temperature, diluted to 150ml 
with ethyl acetate and washed with water (7x, 50ml) and brine (1x, 50ml). The organic layer was 
dried with sodium sulfate, filtered, and rotovaped to yield 7. 7 was isolated as a clear oil using 
column chromatography and silica gel as the stationary phase. 1H NMR (400MHz, CDCL3) 6.49 
(s, 2H), 5.23 (s, 2H), 3.66 (t, 2H), 3.6 (br, 8H), 3.58 (br, 4H), 3.51 (t, 2H), 3.35 (s, 3H), 2.83 (s, 
2H). 
O
OO N
HN
N
HN
O
O
O
O
O
OO N
O
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+
1) DCM, 12 min, r.t.
2) Ethyl Vinyl Ether
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Synthesis of Polymer 8. To a 10ml pear-shaped flask equipped with a stirbar was added 5 (457mg, 
0.98mmol, 1.0eq), 3 (317mg, 0.98mmol, 1.0eq) and 7 (300mg, 0.84mmol, 0.85eq) along with 
5ml of DCM. In a separate 10ml pear-shaped flask equipped with a stirbar was added Grubbs 
Catalyst 3rd Generation (38.4mg, 0.043mmol, 0.04eq) along with 1ml of DCM. Both flasks 
underwent freeze-pump thaw three times, warmed to room temperature and the catalyst 
transferred to the reaction mixture. After 12 minutes, ethyl vinyl ether (200µl, excess) was 
quickly added and stirring continued for 15 minutes. The polymer was precipitated using 200ml 
of 1:1 hexane:ethyl ether. The polymer was collected by filtration, dissolved in a minimal amount 
of DCM and precipitated again in the same hexane:ethyl ether solution yielding 8 as a gray solid. 
MW = 31,736 (MW was determined through gel permeation chromatography (tetrahydrofuran) 
with a polystyrene calibration curve). 1H NMR (400MHz, CDCL3) 11.4 (s, 1H), 8.39 (br, 1H), 
6.01 (s, 2H), 5.72 (br, 2H), 4.95 (br, 2H), 4.41 (br, 2H), 3.55 (br, 11H), 3.32 (br, 2H), 3.30 (s, 2H), 
3.29 (br, 2H), 3.01 (br, 1H), 1.82 (br, 1H), 1.7 (br, 3H), 1.42 (s, 12H), 1.35 (s, 6H). 
 146 
 
 
 
Synthesis of Polymer 9 – PONI-GAT. To a 50ml round bottom flask equipped with a stirbar was 
added Polymer 8 (400mg). Dichloromethane was purged with nitrogen for five minutes and 12ml 
was added to the flask, sealed with a septum and purged with nitrogen for five minutes. The main 
nitrogen line was left in the septum and the nitrogen pressure was reduced to a steady stream. 
12ml of trifluoroacetic acid (excess) was added and the reaction was allowed to stir for two hours. 
Afterwards, excess TFA was removed by rotovaping with DCM (3x). The reaction residue was 
dissolved in a minimal amount of water, filtered through a polyethersulfone (PES) syringe filter 
and lyophilized to yield 9 as an off-white solid which readily dissolves in water. MW ~ 23,486. 
1H NMR (400MHz, D2O) 6.1 (br, 2H), 5.91 (br, 2H), 5.2 (br, 2H), 4.64 (br, 2H), 3.65 (br, 19H), 
3.39 (s, 2H), 3.21 (br, 2H), 3.01 (br, 2H), 1.99 (br, 2H), 1.89 (br, 2H) (1H NMR confirms 
complete loss of all Boc protecting groups). 
8.4.2. Preparation of Nanocomposites  
Stock nanocomposite solutions were prepared in 0.6 ml Eppendorf tubes. To prepare the stock X-
NC emulsions, 3 µL of carvacrol oil (containing 10 wt% p-MA-alt-OD) was added to 497 µL of 
Milli-Q H2O (previously adjusted to a pH of 10) containing 6 µM of PONI-GAT and emulsified 
in an amalgamator for 50 s. The non-crosslinked analogs were done in the same fashion however 
without p-MA-alt-OD dissolved in carvacrol. The emulsions were allowed to rest overnight prior 
to use. 
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Fluorescamine Assay - The fluorescamine calibration curve was generated by mixing various 
concentrations of PONI-GAT with fluorescamine (dissolved in acetonitrile – 2.5 mg/ml, 50 µL 
aliquots) in phosphate buffer (PB – 5mM, pH = 7.4). The solutions were sonicated in the dark for 
5 min, diluted with ethanol and their emission maxima at 470 nm analyzed. The percentage of 
amines remaining on PONI-GAT at different wt% of p-MA-alt-OD after emulsification was 
performed by diluting the stock emulsion solution by half. Afterwards, 450 µL of PB was added 
along with 50 µL of fluorescamine. The solutions were sonicated in the dark for 5 min, diluted 
with ethanol and their emission maxima at 470 nm analyzed. 
8.4.3. Biofilm Formation  
Bacteria were inoculated in LB broth at 37°C until stationary phase. The cultures were then 
harvested by centrifugation and washed with 0.85% sodium chloride solution three times. 
Concentrations of resuspended bacterial solution were determined by optical density measured at 
600 nm. Seeding solutions were then made in M9 to reach OD600 of 0.1. 100 μL of the seeding 
solutions were added to each well of the microplate. M9 medium without bacteria was used as a 
negative control. The plates were covered and incubated at room temperature under static 
conditions for a desired period. Planktonic bacteria were removed by washing with PB saline 
three times. Varied v/v % of X-NCs, made in M9 medium, were incubated with the biofilms for 3 
h. Biofilms were washed with phosphate buffer saline (PBS) three times and viability was 
determined using an Alamar Blue assay. M9 medium without bacteria was used as a negative 
control. 
Biofilm – 3T3 Fibroblast Cell Coculture. A total of 20,000 NIH 3T3 (ATCC CRL-1658) cells 
were cultured in Dulbecco's modified Eagle medium (DMEM; ATCC 30-2002) with 10% bovine 
calf serum and 1% antibiotics at 37oC in a humidified atmosphere of 5% CO2. Cells were kept for 
24 hours to reach a confluent monolayer. Bacteria (P. aeruginosa) were inoculated and harvested. 
Afterwards, seeding solutions were made in buffered DMEM supplemented with glucose to reach 
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an OD600 of 0.1. Old medium was removed from 3T3 cells followed by addition of 100 μL of 
seeding solution. The cocultures were then stored in a box with damp paper towels at 37oC 
overnight without shaking. Testing solutions at different concentrations were made by diluting 
nanocomposites into DMEM prior to use.  Media was removed from coculture, replaced with 
testing solutions, and incubated for 3 hours at 37oC. Cocultures were then analyzed using a LDH 
cytotoxicity assay to determine mammalian cell viability.  To determine the bacteria viability in 
biofilms, the testing solutions were removed and cocultures were washed with PBS. Fresh PBS 
was then added to disperse remaining bacteria from biofilms in coculture by sonication for 20 
min and mixing with pipet. The solutions containing dispersed bacteria were then plated onto 
agar plates and colony forming units were counted after incubation at 37oC overnight. 
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